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Chronic inflammation of the central nervous system (CNS) is a large contributing 
factor to neurodegeneration. Neuroinflammation is mediated by cellular communication 
between microglia, astrocytes, neurons and invading leukocytes from the periphery in 
response to neuronal injury. The second most common neurodegenerative disorder, 
Parkinson’s disease (PD), is characterized by progressive loss of dopaminergic (DA) 
neurons from the substantia nigra (SN) and sustained neuroinflammatory activation of 
glial cells in the vicinity of these neurons. One master regulator of glial cell activation is 
transcription factor, NF-kB. NF-kB is ubiquitously expressed throughout the CNS and 
when activated, positively regulates neuroinflammatory genes in glia and induces 
prosurvival/synaptic plasticity genes in neurons. Therefore, targeting cell-specific NF-kB 
is critical for a desirable outcome when intervening with PD pathology. In the present 
studies, we utilized several experimental strategies to target neuroinflammation in 
multiple animal models of parkinsonism. The first utilized an astrocyte-specific NF-kB 
knock-out (KO) mouse model. We showed that KO animals were protected from 
neurotoxin-induced PD pathology and associated behavior, thus supporting the 
importance of astrocyte- NF-kB activation in parkinsonism. The second experimental 
strategy utilized small molecular compound, C-DIM12, which has agonistic properties with 
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orphan nuclear receptor Nurr1 (NR4A2). Nurr1 activation indirectly suppresses NF-kB 
regulated gene expression in glial cells and also positively regulates genes associated 
with the production/release of DA in neurons. Through counter-regulation of NF-kB by 
Nurr1 activation with orally delivered C-DIM12, a neuroprotective effect was conveyed to 
the SN in a similar experimental mouse model of PD. Lastly, an alternative approach to 
modulating neuroinflammation utilized adeno-associated viruses (AAVs) to target specific 
cells of the CNS for transgene expression. Data revealed multiple AAV serotypes differed 
in transduction capacity and by comparison, an optimal serotype was identified for 
astrocyte targeting. Using AAV technology, transgene Nurr1 was overexpressed in 
astrocytes in vitro and in vivo. The preliminary results with AAV-Nurr1 display a protective 
effect against neurotoxicity and a promising direction for future studies. In conclusion, 
these studies investigate the role of neuroinflammation in relation to DA neuronal injury 
and provide disease modification strategies by cell-specifically targeting NF-kB and Nurr1 
signaling pathways.
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1.1 PARKINSON’S DISEASE 
 
In 1817, Dr. James Parkinson documented the first report of a malady described 
as ‘paralysis agitans’ in his monograph entitled: An Essay on the Shaking Palsy. The 
study patients were male, between the ages of 55-72 years old, and each suffering from 
an analogous manifestation of motor impairment that was easily noticeable while walking 
down the streets of London. Over time, the malady seemed to progressively worsen and 
cause a shaking palsy or an uncontrollable resting tremor, which made the disorder 
distinguishable from other diseases (Parkinson 1817). This disease is now commonly 
recognized as Parkinson’s disease (PD). 
 Two centuries after the Dr. Parkinson’s discovery, the direct etiology of the disease 
is still unknown. However, research suggests that PD development/progression is heavily 
affected by genetic predisposition, environmental stimuli and ultimate effects of 
senescence. Each of these factors cause PD neuropathology in animals and human 
subjects (Shastry, 2001; Hirsch et al., 2012). The pathology is commonly characterized 
as progressive degeneration of dopamine (DA) neurons residing in the ventral midbrain 
area or substantia nigra pars compacta (SNpc) and the dorsolateral striatum (ST). 
Damage to DA neurons cause an imbalance of thalamic-cortical output, resulting in 
movement symptoms such as bradykinesia, loss of balance and resting tremors. Non-
motor symptoms known as depression/anxiety, loss of smell and GI tract issues also 
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highlight the complexities of PD diagnoses. However, investigating the underlying effects 
of genetic mutations, neurotoxic exposure, and age could uncover new treatments for 
PD.  
1.1.1 GENETIC 
The risk for PD development due to familial history is only 10%, as majority of 
cases are sporadic (C Klein and Westenberger, 2012). Thus far, a library of eight rare 
gene mutations are associated with familial PD. These genes have nomenclature PARK1-
PARK8, although this classification can be misleading to the true function and effect of 
the normal gene. Therefore, specific gene names and function of a select few will be 
described for brevity. 
 The most common coding variant to cause familial form of PD is mutations of 
leucine-rich kinase 2 (LRRK2; PARK8). LRRK2 phosphorylation is associated with crucial 
pathways for neuronal health such as, apoptosis, autophagy and mitochondrial function 
(A Price et al., 2018). Additionally, recent studies associate LRRK2 mutations with 
Crohn’s disease, which could link enteric nervous system pathology to PD (Hui et al., 
2018). Another autosomal-dominant mutation is alpha-synuclein (SNCA; PARK1). 
Normal SNCA function mediates vesicular protein transport from the endoplasmic 
reticulum to the Golgi in neurons (AA Cooper et al., 2006). However, SNCA protein is 
prone to aggregate in the form of fibrils and oligomers which produce neurotoxic 
intracellular protein inclusions known as Lewy bodies (Zhou et al., 2008). Progressive 
seeding and spread of Lewy bodies (LB) throughout the CNS is a hallmark of PD 
pathology (Braak et al., 2004). Mutated form of DJ-1(PARK-7) is an autosomal-recessive 
mutation associated with early-onset of PD. Basal levels of normal DJ-1 provides anti-
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oxidant function by regulating the expression of detoxifying enzyme glutathione (GSH). 
Interestingly, DJ-1 overexpression can remove toxic alpha-synuclein aggregates from 
destressed neurons (Zhou et al., 2011). These described genes are just a few examples 
of how loss of the normal function through hereditary effects can predispose an individual 
to developing PD later in life. Yet, focusing on only one of these genes for monotherapy 
is perhaps a wrong direction due to the low percentage of PD patients whom possess 
these mutations.   
 1.1.2 ENVIRONMENT 
Since the majority of PD patients suffer from sporadic form, environmental 
exposure is suggested to be a primary cause. The discovery of exposures that increase 
the risk or produce neurotoxicity have generated enormous breakthroughs in 
understanding the progression of neurodegeneration. Effects of neurotoxic pesticides, 
heavy metals, traumatic brain injury (TBI), viral and bacterial infection on DA neurons 
have been heavily investigated, since these cues can be easily controlled and tested in a 
laboratory setting.  
 A valuable PD research tool for approximately thirty-five years is 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP). Dr. William Langston discovered MPTP by 
treating patients whom intravenously injected the chemical mistaken for synthetic  heroin 
and quickly developed severe forms of parkinsonism (Langston et al., 1983). The 
metabolite of MPTP, MPP+, causes specific degeneration of DA neurons within the SNpc 
by inhibition of mitochondrial electron transfer at the NADH dehydrogenase-ubiquinone 
junction (complex I) (Ramsay et al., 1991). Due to the consistency of DA neuronal loss 
and induction of PD neuropathology, MPTP is a staple model in mice and non-human 
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primates for pre-clinical drug testing. Other complex I mitochondrial inhibitors used in 
animal models are pesticides paraquat and rotenone. These chemicals can cause SNCA 
formation of fibrils, a precursor to LBs, in rodents (Manning-Bog et al., 2002; Sherer et 
al., 2003) (Uversky et al., 2001).  
 Studies also identify exposures from various heavy metals, such as copper, iron 
and manganese (Mn) predispose individuals to acquire PD. Metal ions are necessary for 
multiple cellular functions and enzymatic processes, however in high levels of exposure, 
metals are neurotoxic. Elevated levels of copper and iron are associated with multiple 
neurological disorders (Lan et al., 2016). Specifically, in PD, increased levels of iron are 
found in degenerating DA neurons of the SNpc (Zhu et al., 2007). Manganese toxicity is 
also evident in occupational work settings, such as welding or mining (Racette et al., 
2017). Severe cases of Mn exposure result in the PD-like disorder, manganism, which 
manifests neurological symptoms such as dystonia, bradykinesia, rigidity, and 
depression. Interestingly, manganese crosses the blood brain barrier (BBB) by iron 
transporter, transferrin, where it accumulates in non-neuronal cells, known as astrocytes 
(Peres et al., 2016).  The specific role of astrocytes in PD and mediating Mn toxicity will 
be discussed later in the dissertation.  
 The brain is considered an “immune-privileged” organ due to formation of the BBB, 
consisting of tight junctions between astrocytes and endothelial cells, which creates a 
selective passage for peripheral cells to the CNS. However, ongoing research suggests 
a sophisticated innate immune system persists within the brain, causing 
neuroinflammation. Neuroinflammation is mediated between the resident immune cells, 
microglia, astrocytes, neurons and invading leukocytes from the periphery in response to 
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infectious pathogens. Interestingly, gram-negative bacteria molecules have been found 
in post-mortem brain tissue from Alzheimer’s patients (AD) (Zhan et al., 2016). Endotoxin 
lipopolysaccharide (LPS) derived from gram-negative bacteria is mainly recognized by 
toll-life receptor 4 (TLR 4) which is expressed on the surface of glial cells and can induce 
a cascade of neurotoxic glial activation and neuronal death (Glass et al., 2010). Viral 
infection is also a potential concern which increases susceptibility to develop PD, as 
studies show peripheral H1N1 influenza virus infection synergizes neurodegenerative 
effects of MPTP and increases microglia activation in mice (Sadasivan et al., 2017). 
Additionally, acute trauma, or TBI acquired by at risk activities such as heavy contact 
sports is an environmental risk factor for developing PD. Initially, TBI causes mechanical 
damage of parenchymal cells and blood vessels following a secondary  injury resulting in 
a buildup of oxidative stress and chronic neuroinflammation that damages neurons over 
time (Impellizzeri et al., 2016; Mettang et al., 2017).  
1.1.3 AGING  
Since the average age of PD diagnosis is over the age of 60 years old, cellular 
aging is another primary factor. Studies show over time, mitochondria lose the capacity 
for necessary adenosine triphosphate (ATP) production which causes large, energy-
dependent DA neurons to die. DA neurons are highly energy dependent upon oxidative 
phosphorylation for ATP production, rather than glycolysis, increasing the demand for 
functional healthy mitochondria (Surmeier et al., 2017). Additionally, the sheer size of DA 
neuron arborizations and travel from SNpc to the striatum (ST), require supplemental 
mitochondrial bioenergetics that only deteriorate with age (Pacelli et al., 2015). 
Mitochondrial dysfunction also overproduce radical oxidative species (ROS) present in 
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the microenvironment (Patel, 2016). ROS and reactive nitrogen species (RNS) increase 
to levels beyond anti-oxidant repair, as result of aging (Dong et al., 2014). DA neurons 
are especially vulnerable to intracellular oxidative stress due to the formation of DA-
quinones during the synthesis of DA. The buildup of DA-quinones is hypothesized to 
cause downstream signaling to reactive glial cells which further accelerates 
neurodegeneration (Kuhn et al., 2006). 
1.2  NEUROINFLAMMATION IN PARKINSON’S DISEASE 
The topic of neuroinflammation has caused speculation over if it could be a 
preceding cause to DA neuronal death or merely a result of brain injury. However, 
depending on the context, more recent evidence points to the former, as we further 
understand the cell specific roles that mediate neuroinflammation. This section will 
explore the immune functions of microglia, astrocytes, and neurons in relation to PD 
pathogenesis. 
1.2.1 MICROGLIA 
Microglia are the resident immune cell of the brain that constantly scan the CNS 
for invading pathogens. Upon encountering a recognized pathogen, microglia change 
from a ramified, resting morphology, to an amoeboid shape for phagocytosis of invaders, 
also known as microglia activation (Glass et al., 2010). Additionally, activated microglia 
provide neurotropic properties, as phagocytic function is necessary for pruning synapses 
of neurons for healthy neurotransmission (Schartz, Wyatt-Johnson, LR Price, Colin, and 
Brewster, 2018b). Therefore, microglia activation could be beneficial or detrimental to the 
host. Microglia derive from myeloid lineage, which polarize into two unique macrophage 
subtypes that determine the level of neuroinflammatory response present in the 
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microenvironment. M1 is a neurotoxic subtype, which express a neuroinflammatory profile 
of cytokines, chemokines, and ROS. M1 microglia release factors such as, tumor necrosis 
factor a (TNFa) interleukins, and chemokine ligands (CCL 2 and 3) that communicate 
with surrounding astrocytes and neurons leading to  neurotoxicity (Hirsch and SP Hunot, 
2009). M2 is a subtype associated with neurotropism, tissue repair and as previously 
mentioned, synaptic pruning (Kirkley et al., 2017; Schartz, Wyatt-Johnson, LR Price, 
Colin, and Brewster, 2018a). Evidence suggests microglia also communicate with 
peripheral infiltrating T-cells at site of lesion. Major histocompatibility complex (MHC) 
class II molecules, identified on microglia from MPTP treated mice, have been shown to 
present endocytosed antigens to CD4+ T-cells (Kurkowska-Jastrzebska et al., 1999). 
Since activated microglia exist as a heterogeneous population, usage of the term 
“activation” is diverse in context to the ultimate outcome. However, for the purpose of the 
dissertation, the term will suggest neurotoxic M1 microglia are investigated.  
1.2.2 ASTROCYTES 
Astrocytes are the most abundant cell type in the mammalian CNS, constituting 
approximately 30% of all cells. Astrocyte metabolism production of energy and amino 
acids is crucial for normal neuronal function. Neurons do not produce pyruvate 
carboxylase, so are dependent on astrocytes for the production of glutamate (Glu) 
(Sidoryk-Wegrzynowicz and Aschner, 2013). Astrocyte-derived Glu is crucial for neuronal 
homeostasis and neurotransmitter production for neural signaling. Additionally, neurons 
rely on astrocytes for normal concentrations of intracellular GSH. GSH activity detoxifies 
a large number of protein-thiols and ROS to protect the neuron from oxidative damage 
(Dringen et al., 1999).   
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Astrocytes also have immune function. As the first line of defense from foreign 
invaders, astrocytic endfeet (glia limitans) create the BBB, excluding peripheral cells that 
produce cytokines and ROS (Liddelow and Ben A Barres, 2017). Also, like microglia, 
astrocytes respond to a multitude of different CNS insults. Astrocytes proliferate to the 
site of lesioning, noticeable by increased numbers of glial fibrillary acidic protein (GFAP+) 
cells, forming a “glial scar” (Wanner et al., 2013; Hammond 2018). GFAP is the most 
common marker for measuring gliosis, however, recent transcriptomic analysis revealed 
new markers for identifying reactive astrocyte phenotypes (Liddelow et al., 2017). Similar 
to the classification of microglia, a heterogeneous population of activated astrocytes 
exists. Liddlelow et al. identified subtypes A1, neurotoxic, or A2, neuroprotective, 
phenotypes by single-cell transcriptional profiling. Upon ischemic stroke in mice, 
astrocytes transformed to a A2 reactive phenotype which repaired and protected neurons 
from further damage. In contrast, LPS injection in mice induced an A1 reactive phenotype, 
which exacerbated neurotoxicity. These studies suggest complement protein, C3, is an 
ideal marker for A1 neurotoxic astrocytes (Liddelow et al., 2017). C3 was originally 
investigated as an essential immune regulator in the peripheral system, by mediating a 
signal cascade for the formation of membrane attack complexes on the surface of 
pathogens (Lian et al., 2016). Interestingly, astrocytes also express C3 in response to 
Interleukin 1, alpha (ILa), TNFa, and complement component subunit 1 q (C1q) which are 
released from activated microglia (Liddelow et al., 2017). This classical complement 
pathway between microglia, astrocytes and neurons may be a new candidate mechanism 
for controlling neuroinflammation (Schartz et al. 2018). Studies also show astrocytes 
communicate with peripheral infiltrating monocytes through a CCL2-CCR2 signaling 
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mechanism in response to MPTP lesioning in mice (Parillaud et al., 2017). Together, 
these findings suggest a crucial astrocyte-driven immune-regulatory system exists in 
neurodegenerative disease.  
1.2.3 NEURONS 
Neuroinflammation and immunity is controlled by neurons as well. MHC class I 
molecules are expressed on the surface of neurons to communicate with invading 
cytotoxic T-cells upon neurotropic viral infection (Chevalier et al., 2011). Neurons express 
pattern recognition receptor TLR3, which binds viral double-stranded RNA and relays 
innate immune responses. Other neuronal cell surface receptors, CCLR and C3aR, 
mediate chemokine and complement protein signaling, respectively, and dictate whether 
neurons will be engulfed by glia cells or repair itself in response to injury (Parillaud et al., 
2017; Schartz et al., 2018). In MPTP mice models, cell surface DA transporters recognize 
MPP+ ions, which downstream induce intracellular oxidative stress and production of 
nitric oxide (NO). NO reacts with super oxide (O2-) forming peroxynitrite and has high 
binding affinity to amino acid tyrosine causing nitro-tyrosine adducts and neuronal 
dysfunction (Moreno, Streifel, et al., 2009). Neurons can also release NO to the 
extracellular matrix which exacerbates glia activation, resulting in a cyclic loop of neuronal 
damage (Glass et al., 2010). However, the direct link between oxidative stress and 
neuroinflammatory reaction is still not fully understood (McElroy et al., 2017). 
Consequently, by investigating select genes with cell specific transcriptional roles that 
mediate neuroinflammation in the CNS we can under cover their functions in microglia, 
astrocytes and neurons. 
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1.3 CANDIDATE GENES FOR DISEASE MODIFICATION 
To date, prescribed PD drugs only treat the symptoms and do not slow the 
progressive loss of DA neurons. Dopamine replacement therapy, known as levo-dopa (L-
DOPA), improve movement deficits. Yet, a side effect of L-DOPA is dyskinesia, due to an 
overproduction of DA. Transplantation of fetal DA stem cells into the ST is another viable 
DA replacement. Transplantation has shown to improve motor symptoms, but only to the 
same degree as L-DOPA administration (Freed et al., 2011).  Since these treatments do 
not slow the progression of PD and patients still worsen over time, new disease 
modification therapies are necessary. In the following section, two candidate gene 
pathways highly expressed in the CNS that halt neurodegeneration in animal models will 
be discussed in detail.  
1.3.1 NF-kB SIGNALING 
NF-kB transcriptional and posttranslational activity is ubiquitously expressed in 
multiple cell types. There are five mammalian NF-kB nuclear subunits that homo- or 
heterodimerize for transcription: p50, p52, p65 (Rel-A), c-Rel, and Rel B (Kaltschmidt et 
al., 2006).  NF-kB signaling was initially identified as the link between the transcription of 
immunoglobulin light chain genes in the response to LPS treatment in B-cells (Baltimore, 
2009). Currently, studies show NF-kB activation is upregulated in PD (Hirsch and SP 
Hunot, 2009), Huntington’s disease (HD) (Hsiao et al., 2013), and AD (Kaltschmidt et al., 
1997). NF-kB is the master transcriptional regulator of multiple proinflammatory amplifiers 
(e.g IL-1b, TNFa, interleukin-6; IL-6, C3, C1q) in both astrocytes and microglia (Glass et 
al., 2010; Liddelow and Ben A Barres, 2017). Inflammatory insult, such as LPS treatment 
on microglia, induces NF-kB nuclear subunits p65 and p50 to translocate from the 
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cytoplasm to the nucleus and bind to upstream promotor regions of proinflammatory 
genes (De Miranda et al., 2015). Proinflammatory cytokines and chemokines released 
from microglia activate astrocytes which amplify the inflammatory response further back 
to microglia between glia-glia crosstalk (Kirkley et al., 2017). Augmentation of released 
inflammatory mediators are recognized by neurons resulting in induction of apoptosis 
(Hirsch and SP Hunot, 2009).  NF-kB is also a primary regulator of nitric oxide synthase 
2 (NOS2), in both astrocytes and microglia. Upon the induction of NOS2, NO and other 
ROS mediators, are released from glia cells and taken up by DA neurons inducing 
nitrosative stress, apoptosis or necrosis (Moreno et al., 2011). Interestingly, recent 
evidence suggests NF-kB regulates C3 expression primarily in A1, “neurotoxic” 
astrocytes (Lian et al., 2016).  
Despite negative proinflammatory effects regulated by NF-kB in glial cells under 
pathological conditions, NF-kB activation is necessary for synapse formation, neural 
plasticity, and expression of pro-survival genes in neurons (Lian et al., 2016; Liddelow 
and Ben A Barres, 2017). Inhibition of NF-kB in neurons  decreases synaptic plasticity, 
by lack of CREB phosphorylation, resulting in loss of spatial memory in mice (Kaltschmidt 
et al., 2006). Furthermore, loss of subunit p50 in neurons results in enhanced 
susceptibility to hippocampal brain injury (Kassed et al., 2002). Taken together these 
findings, global inhibition of NF-kB in the CNS may be beneficial for alleviating 
neuroinflammation regulated by glia cells, except it may be detrimental by suppression of 
synaptogenesis and regeneration in neurons during PD progression. Therefore, targeting 
NF-kB indirectly through counter regulation could lead to a more cell-specific effect in 
CNS for disease modification. 
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1.3.2 NURR1 SIGNALING 
Nurr1 is predominantly expressed in the ventral midbrain, down regulated in PD 
patients, and critical for DA neuronal development/homeostasis. High cellular energy 
demand makes neurons more susceptible to decreased ATP production by mitochondrial 
failure, which can result from Nurr1-down regulation (Kadkhodaei et al. 2013). There are 
no known endogenous ligands for Nurr1, but the nature of its interactions with DNA 
suggests several modes of dimerization with retinoic acid receptors (RXR) to the 
consensus nerve growth factor binding recognition element (NBRE) (García-Yagüe et al. 
2013; Saijo et al. 2009). The NBRE sequences is recognized in promoter regions of the 
rate-limiting enzyme for DA production, tyrosine hydroxylase (TH), aromatic amino acid 
decarboxylase (AADC) and transporter proteins: vesicular monoamine transporter 2 
(VMAT2) and transmembrane dopamine transporter (DAT) in neurons (Zetterström et al., 
1996; Smits et al. 2003; Sakurada et al. 1999). Recently, our group confirmed that upon 
Nurr1 activation, a dopaminergic phenotype is up regulated by induction of Nurr1 
regulated genes, TH and VMAT2 in neurons. Also, we observed Nurr1 activation provides 
neuroprotection from 6-hydroxydopamine (6-OHDA)-induced neurotoxicity in DA 
neuronal cultures (Hammond, 2015). Current experimental models using transgenic mice 
allow for only Nurr1 (+/-) expression, as Nurr1 null mice lack TH expression and die 24 
hours after birth, implicative of Nurr1 significance in DA differentiation (Jiang et al. 2005). 
These studies demonstrate Nurr1 (+/-) DA neurons in mice are more vulnerable to MPTP 
(Le et al. 1999).  
Nurr1 also provides anti-inflammatory effects in glial cells. Constitutive Nurr1 binds 
to nuclear subunits of NF-kB at inflammatory promoter sequences, recruiting co-
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repressor proteins and histone deacetylase (HDAC) responsible for suppression of 
neurotoxic gene expression in both microglia and astrocytes. ROS and NOS produced by 
glial cells are suggested to be under control of the Nurr1-transrepression pathway (Saijo 
et al. 2009). This transcriptional transrepression through Nurr1 activation results in 
counter regulation of NF-kB through an indirect pathway. Additional studies have shown, 
upon Nurr1 overexpression, there is a decrease of mitochondrial pro-apoptotic factors, 
such as Bax proteins (Zhang et al. 2009). Targeting the cell specific functions of Nurr1 
activation that indirectly inhibits NF-kB in glia cells and upregulates dopaminergic gene 
expression in neurons by pharmacologic or gene therapeutics may be a novel approach 
in halting the progression of PD. 
1.4 EXPERIMENTAL STRATEGIES FOR DISEASE MODIFICATION 
1.4.1 TRANSGENIC MOUSE MODELS 
Current in vivo models for genetic modifications in mice include the introduction of 
plasmid genes in utero or neonatal electroporation, intrauterine viral transduction, germ 
line modifications with Cre-directed to lox-mediated recombination, and recently, CRSPR-
Cas9 genome editing with guide RNAs (De Vry et al. 2010; Hashimoto and Mikoshiba 
2003; Zong et al. 2005; Nemudryi et al. 2014). Since a murine genome is approximately 
97.5% similar to human, mice are desirable models for studying human disease. By 
increasing normal WT gene expression, inducing expression of a mutant gene, or 
decreasing WT gene expression, we can further understand the complexities of 
neurodegeneration. In PD research, transgenic mice can replicate the pathology by toxic 
gain of function or loss of neuroprotective function. Two examples of toxic gain of function 
mouse models are the Y39C and A53T mice. Tyrosine-to-cysteine mutant form of human 
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SNCA protein (Y39C) displayed abnormal SNCA aggregation and motor deficits similar 
to PD patients (Zhou et al., 2008). Mutated form of human SNCA, alanine-to-threonine 
mutant (A53T) in mice also developed LB formation similarly seen in PD patients, which 
resulted in paralysis and death (Giasson et al., 2002). However, loss of DA neurons was 
not evident in both of these animal models (Giasson et al., 2002; Zhou et al., 2008). Lack 
of severe PD-like pathology in the midbrain DA neurons could explain a species 
difference between human and mouse or conceivably SNCA overexpression is not the 
only cause of DA neurodegeneration. Loss of neuroprotective function in Nurr1 +/- 
deficient mice can recapitulate PD neurobehavior, have fewer DA neurons in the SNpc, 
and are more susceptible to MPTP induced neurotoxicity. Although, these mice do not 
exhibit pathological hallmark of LB formation (Zetterström et al., 1997). In summary, no 
mouse model is flawless in recapitulating PD pathology, which limits the progress in 
therapeutic development. 
The above mentioned are mouse models heavily focused on neuronal 
mechanisms. As discussed earlier, non-neuronal cells mediate PD neurotoxicity as well, 
which requires investigation of cell-specific genetic modifications in mice. One strategy is 
the Cre-loxP recombination system. Cre-recombinase is a genome-editing enzyme that 
was originally identified in bacteriophage and targets small palindromic sequences known 
as loxP sites (Gorman and Bullock 2000). A gene of interest is flanked by the loxP sites 
on both the 5’ and 3’ ends of the gene. loxP expressing mice are crossed with chimeric 
Cre-expressing mice. Through homologous recombination, Cre excises and deletes the 
gene of interest by targeting the flanking loxP sites. Specific promoters can be inserted 5’ 
of the Cre gene to drive cell specific gene deletion.  Interestingly, an astrocyte-specific, 
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NF-kB hyperactivated transgenic mouse model was generated by Lian et al. 2015. This 
group crossed hGFAP-Cre and loxP-IkBa-loxP mice to specifically knock-out IkBa in 
GFAP+ astrocytes. IkBa is the protein necessary for sequestering the nuclear subunits of 
NF-kB in the cytoplasm. Thereby loss of IkBa induces translocation of the nuclear 
subunits, and constitutive activation of NF-kB in astrocytes. The hyperactivation of 
astrocyte specific-NF-kB exacerbated neurodegeneration and further supports the 
importance of targeting glial-mediated neuroinflammation in PD research (Lian et al., 
2015). In contrast, recently in our work, we generated a knock-out mouse that inactivated 
NF-kB in astrocytes and will be further explained in chapter 2.  
1.4.2 PRE-CLINICAL PHARMACOLOGY 
To halt neurodegeneration, a drug must penetrate to the CNS for site of action. 
Small lipophilic molecular compounds (<400 Da) can cross the BBB by lipid-mediated 
diffusion (Pardridge, 2012). Upon BBB penetration, the drug should target a specific cell 
and pathway in PD pathogenesis. Mechanistic properties are tested pre-clinically in 
animal models and cellular assays. Therefore, the model must closely mimic PD. For 
instance, the anti-inflammatory drug, minocycline, delivered promising results in a 
amyotropic lateral scelerosis (ALS) transgenic mouse model, but worsened ALS patients 
in a phase III clinical trials. The mouse model tested was later suggested to poorly 
recapitulate ALS pathology which caused misleading results (Gordon et al., 2007). 
Additionally, potential drugs must be deemed clinically safe without severe on or off-target 
toxicity. On target toxicity occurs when interaction between drug and molecular target 
creates a toxic effect at the dose necessary for the therapeutic result. Changing the 
disease target may be necessary since the effect is specific to the target and not of the 
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drug itself. In contrast, off-target toxicity can occur if the drug causes undesirable effects 
by interacting with an alternative target or region of tissue (Guengerich, 2011). Therefore, 
altering the derivative or class of compound may be necessary. Drugs that target innate 
immune function also must not suppress normal immune response which increases 
susceptibility to sporadic infections (Glass et al., 2010). The need for specificity in 
targeting neuroinflammation in PD suggests a cell specific delivery system is necessary 
for controlled pharmacologic response. Interestingly, we have demonstrated that a novel 
class of compounds, p-substituted-diindoylymethane (C-DIM) analogs, have high brain 
bioavailability, are considered therapeutically safe in mice and canines and can provide 
anti-inflammatory effects in mouse models of PD (De Miranda et al., 2013; 2014; 
Hammond 2018; Safety data unpublished). Supporting in vitro and in vivo data are 
detailed in chapters 3 and 4, respectively. 
1.4.3 VIRAL MEDIATED GENE THERAPEUTICS 
Gene therapy targeting neurodegeneration is theoretically self-explainable. A gene 
of interest is delivered into a specific region of the brain that should provide some 
therapeutic benefit to the neurons affected by the disease. The first step to consider is 
which vector to use. Genes can be delivered by adenovirus, lentivirus, adeno-associated 
virus (AAV), and transfection or electroporation of nucleic acids (NA) alone. Each vector 
has its advantages and flaws. Adenoviruses package a large cloning capacity and 
transduce neural cells, but lasting expression and cytotoxicity is a concern. Lentiviruses 
also transduce neural cells and integrate into the host genome. However, safety concerns 
persist due to the potential of insertional mutagenesis which causes cancer (Hacein-Bey-
Abina et al., 2003). Nucleic acids delivered by transfection or electroporation have 
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endless cloning capacity, except limited on the delivery efficiency and are diluted by cell 
division. AAVs transduce neural cells and are non-pathogenic in humans and animals, 
although restrictive concerns are also DNA dilution due to the lack of chromosomal 
integration (Manfredsson et al. 2016).  
Regardless of the limiting factors, AAVs are the most commonly used vector for 
gene delivery to the CNS.AAVs are small (20nm), contain a single-stranded DNA genome 
and are a member of the Parvoviridae family within the Dependovirus genus (Kotterman 
and Schaffer, 2014) (Daya and Berns, 2008). Several attempts to treat PD patients with 
AAVs have been made. Safety/feasibility in clinical phases has shown potential gene 
therapy with AAV2- Glial Derived Neurotrophic Factor (GDNF/neurturin) (Kirik et al., 2000; 
Bartus et al., 2013). However, results from a phase 2 randomized trial declared there was 
no significant therapeutic benefit and 3 patients developed tumors (Marks et al., 2010; 
Merienne et al., 2013). Another failed attempt tested AAV2- aromatic L-amino acid 
decarboxylase (AADC) in PD patients, but suggested a new trial was needed to confirm 
efficacy (Mittermeyer et al., 2012). Current clinical trials have predominately only used 
neurotropic serotype AAV2, which do not target astrocytes. Drinkut et al., confirmed 
injection of AAV5-hGFAP(2.2 kb) for astrocyte-specific GDNF overexpression in the 
mouse provided the same neuroprotective efficacy as neuron-derived GDNF, and 
suggests more AAV based therapies should be targeted towards astrocytes (Drinkut et 
al., 2012). A large data set that characterizes specific AAVs which transduce astrocytes 
will be further explored in chapter 6.  
In summary, multiple factors contribute to PD pathogenesis that are not well 
understood and are even less comprehendible when these factors are considered for 
 18 
combinatorial effects. Therefore, a study that investigates the role of astrocyte-NF-kB 








JUVENILE MANGANESE EXPOSURE EXACERBATES NEURODEGENERATION IN 
A MPTP “TWO-HIT” ANIMAL MODEL AND IS DEPENDENT ON ASTROCYTE-





Manganese (Mn) is an essential trace element necessary for multiple enzymatic 
processes in the central nervous system (CNS) that accumulates in astrocytes during 
overexposure in adults and children. Transport of Mn into astrocytes occurs 
predominately through divalent metal transporters such as DMT1, ZIP and SLC39A3, 
where it is a required co-factor for glutamine synthetase (GS), the key enzyme regulating 
glutamate-glutamine metabolic shuttling between astrocytes and neurons (Erikson and 
Aschner, 2003; 2006). Mn is also a critical cofactor for superoxide dismutase (Mn-SOD), 
which protects neurons from the damaging effects of oxidative stress (Zidenberg-Cherr 
1983).  
However, abnormally high exposure to Mn is neurotoxic. Epidemiological studies 
correlate elevated levels of Mn in the brain to cognitive and behavioral impairment, to 
which children appear to be particularly sensitive (Rugless et al., 2014; Takser 2003; He 
1994). In more severe cases, Mn exposures from occupational work settings in adults 
(e.g. mining, welding), can cause classical ‘manganism' (RODIER, 1955; Wang et al., 
1989; Racette et al., 2017). The neurological sequelae of manganism consist of cognitive 
and motor deficits similar to Parkinson’s disease (PD), including bradykinesia, dystonia, 
rigidity and depression (RODIER, 1955; Wang et al., 1989; Mergler and Baldwin, 1997; 
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Racette et al., 2017). Although, patients with manganism do not display severe nigro-
striatal dysfunction or resting tremors and are typically non-responsive to levodopa (L-
DOPA) therapy (Guilarte et al., 2006;Peres et al., 2016; Racette et al., 2017). These 
differences are likely due to distinct patterns of neuropathology compared to idiopathic 
PD, causing toxicity primarily in more glial rich regions, such as the globus pallidus (Gp), 
subthalamic nuclei(Sth) and substantia nigra pars reticulata (SNpr) (Guilarte et al., 2006; 
Peres et al., 2016). Whereas PD is characterized by preferential loss of dopamine (DA) 
neurons in the substantia nigra pars compacta (SNpc) and long axonal projections to the 
striatum (ST). Despite these findings, the mechanism by which Mn exposure accelerates 
PD pathogenesis, is largely undefined. 
We previously demonstrated that Mn-induced neurotoxicity results in profound 
activation of astrocytes and microglia and expression of a large number of 
neuroinflammatory genes that potentiate neuronal injury (Moreno et al., 2011; Kirkley et 
al., 2017). Furthermore, we reported that mice pre-exposed to Mn during juvenile 
development had higher levels of gliosis and neuronal dysfunction than mice exposed to 
Mn only as adults (Moreno, Yeomans, et al., 2009). These neurotoxic levels of glial 
activation and neuroinflammation resulting from Mn exposure are heavily controlled by 
the transcription factor, nuclear factor kappa B (NF-kB), a master regulator of innate 
immune responses in lymphoid and myeloid cells, as well as microglia and astrocytes 
(Glass et al., 2010; Kirkley et al., 2017). In vitro, Mn directly activates microglia, which 
release cytokines and signaling molecules that chronically activate astrocytes through a 
NF-kB-dependent mechanism  (Kirkley et al., 2017). NF-kB can be stimulated by 
numerous intra- and intercellular stressors, including reactive oxygen species (ROS), 
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inflammatory cytokines and chemokines, as well as Mn accumulation (Moreno et al. 
2011). NF-kB has distinct functions within different cell types of the CNS, including 
regulation of inflammatory gene expression in glia and induction of pro-survival genes in 
neurons including IAP’s, Bcl2, Bcl-XL and surivin. (Glass et al., 2010).  
To determine the role of NF-kB in regulating the neuroinflammatory effects of Mn, 
we recently developed a novel transgenic model with astrocyte-specific deletion of the 
NF-kB signaling pathway (Kirkley 2018). Mice expressing cre-recombinase under control 
of the human glial fibrillary acidic protein promoter (hGFAP) were crossed with I kappa B 
kinase 2 (IKK2)-loxP mice. Selective deletion of IKK2 in astrocytes provided almost 
complete protection against loss of DA neurons caused by the neurotoxin, 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) (Kirkley 2018). The active metabolite of MPTP, 
MPP+, inhibits mitochondrial complex I and causes severe nigrostriatal dysfunction and 
behavioral deficits in mice similar to those in PD (Jackson-Lewis and Przedborski, 2007). 
Lack of NF-kB function in astrocytes also decreased reactive gliosis by suppressing the 
expression of NOS2 and TNFa, resulting in prevention of MPTP-induced neuronal 
apoptosis (Kirkley 2018). However, it is unknown whether exposure to Mn can exacerbate 
the effects of other dopaminergic neurotoxins such as MPTP by modulating glial reactivity 
and subsequent inflammatory neuronal injury.  
 In the present study, we postulated that Mn exposure during development would 
stimulate NF-κB-dependent intercellular signaling between microglia and astrocytes, 
resulting in ongoing neuroinflammation that enhances susceptibility to neurological 
dysfunction during aging. To test this hypothesis, we used a two-hit neurodegenerative 
model by administering Mn in drinking water to hGFAP-cre+/-/IKK2fl/fl (KO) or hGFAP-cre-
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/-/IKK2fl/fl (WT) mice during juvenile development, followed by exposure to MPTPp (MPTP 
+ probenecid) four-five months later during adulthood. Neurobehavioral analysis was 
conducted during the two-week MPTPp dosing regimen to detect locomotor deficits 
associated with injury to the basal ganglia. Brain tissue from multiple regions was 
collected for determination of Mn, catecholamines, stereological assessment of neuronal 
numbers, glial activation and expression of proteins regulating DA function. In addition, 
we identified high levels of the complement protein, C3, in activated astrocytes that was 
dramatically reduced in KO mice. We also detected a similar pattern of glial activation 
and C3 expression in human brain tissue from individuals highly exposed to Mn in an 
occupational setting. These studies indicate that early exposure to Mn exacerbates glial 
activation and neuronal loss following challenge with a second dopaminergic 
neurotoxicant through neuroinflammatory activation of NF-kB in astrocytes.  
2.2 MATERIALS AND METHODS 
Animals and treatment regimen 
All animals were housed on a 12 hr light/dark cycle in a temperature-controlled room 
(maintained at 22-24°C) and access to standard chow/water ad libitum. Procedures were 
approved by Colorado State University Institutional Animal Care and Use Committee 
(IACUC) and were conducted in compliance of National Institute of Health guidelines. 
hGFAP-cre+/- (Cat#: 004600; Jackson Laboratories) mice were backcrossed on a 
C57/BlJ6 background for twelve generations before crossbreeding with IKK-loxP+/+ 
(acquired from the Karin lab at UC Davis) mice. Four generations of crossbreeding were 
conducted to acquire hGFAP-cre+/-/IKK2fl/fl (KO) or hGFAP-cre-/-/IKK2fl/fl (WT) animals for 
the study. At day P21, mice were administered MnCl2 (50mg/kg/day; Sigma) by 
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monitoring water intake and weight gain for thirty days following. After P51, mice were 
placed back on normal drinking water for a period of three-four months for aging and 
susceptibility to MPTP-HCl solubilized in saline (0.9% NaCl2) by subcutaneous injection 
(s.c.; 20mg/kg; MedchemExpress; Monmouth Junction, NJ) and probenecid by 
intraperitoneal injection (i.p.; 100mg/kg; Sigma) every other day for one week (4 dosages 
total), per our previously published protocol (Hammond 2018). Treated mice were aged 
an additional week before tissue collection. 
Behavioral analysis  
Two weeks before initial behavioral testing, all mice were acclimated to stress handling 
by methods closely adapted to previously established protocols (Gouveia and Hurst, 
2013; Stuart and Robinson, 2015). Open field testing (OFT) was monitored with 
Versamax System (Omnitech Electronics, Inc; Columbus Ohio) as previously described 
by Hammond et al. 2018 (Hammond 2018). Gait measurements of stride length, rate and 
paw intensity were detected by our custom-made in house real-time video gait analysis 
system. Video recordings of mouse gait were conducted as previously reported 
(Hammond 2018).  All behavioral testing was performed before mice were treated on 
days 0, 7 and 14 (no treatment) of the MPTPp dosing regimen. All parameter values were 
subtracted from day 0 for change from baseline measurements. 
Tissue processing 
For immunohistochemical analysis: mice were anaesthetized under deep isoflourane and 
transcardially perfused with 0.1M phosphate buffered saline (PBS)-cacodylate/heparin 
(10 U/ml) and 3% paraformaldehyde/PBS. Following decapitation, whole brains were 
dissected and stored in 3% paraformaldehyde/PBS overnight at 4°C. The next day, 
 24 
samples were transferred to a gradient of 15-30% sucrose/PBS prior to cryosectioning 
and storage in cryoprotectant at -20°C until processed for tissue staining. For 
neurochemical detection of Mn2+ and catecholamines: mice were similarly anaesthetized 
with isoflourane and then rapidly decapitated. Whole brains were dissected and placed 
on a 1 mm brain block for separation of ST, SN, hypothalamus (Hyp), and cortex (Cx). 
Specific brain regions were snap frozen in liquid nitrogen and then stored at -80°C until 
processed for HPLC and ICP-MS. Trunk blood was also collected from decapitated 
animals and centrifuged at (1,500 rpm at 4°C /15 minutes) for plasma fractionation and 
transferred to a fresh tube before storage at -80°C.  
Western Blotting  
ST tissue used for western blotting was homogenized and lysed in RIPA in presence of 
protease inhibitors. Protein concentrations were determined by BCA protein assay 
(ThermoScientific, Pierce Rockford, Il). 23ug/well of protein was separated on 12% SDS-
PAGE gel and transferred to PVDF membranes. Blots were incubated with Anti-TH 
(1:1000; Millipore AB152), anti-VMAT2 (1:750; gift from Dr. Gary Miller’s Laboratory, 
Emory University), anti-DARPP32 (1:1000; Millipore AB10518), anti-pDARPP32-Thr34 
(1:1000; Millipore AB9206), anti-DARPP32-Thr75 (1:1000; Millipore AB9208), and anti-
Beta Actin (1:2000; Sigma A1978) diluted into 5% milk/tris-buffered saline with tween 
(0.1%) blocking buffer. Secondary antibodies used were: anti-Rabbit (Cell signaling 
7076S) or anti-Mouse (Cell Signaling 7074S) diluted in blocking buffer. Chemiluminescent 
imaging was conducted with on a BioRad ChemiDoc MP and raw TIFF files were 
analyzed for mean optical band density with ImageJ analysis software (Schneider et al., 
2012). 
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Immunostaining and automated stereological cell counting for fixed mouse brain 
tissue  
For stereological determination of TH+ neurons within the SN: the entire SNpc was serially 
cryosectioned from the subthalamic nucleus (rostral) to the retrorubal field(caudal) 
regions. Every sixth free-floating section (8 total) was selected from each animal and 
immunostained for anti-TH (1:500; Millipore AB152) and anti-Neuronal Nuclei (NeuN; 
1:250, Millipore; MAB377) by our previously reported protocol (Hammond et al. 2018) 
(Miller et al., 2011). SNpc neurons were automatically quantitated from 10x-objective 
montage images of each immunostained section using a Hammatsu ORCA-Flash4.0 
digital CMOS camera, ProScan III stage controller (Prior, Rockland, MA USA) and 
CellSens Dimension software (version 1.12, Olympus, Center Valley, PA, USA).  For 
automated relative counts of GFAP+, IBA-1+, NeuN+ cells, two sections/animal were 
selected from the same anatomical regions of SN and ST. Primary antibodies for glia 
labeling were anti-GFAP (1:500; DAKO Z0334), anti-IBA1 (1:250; WAKO 016-20001) and 
anti-TH (Abcam 76442) to demarcate the SNpc and SNr nuclei. Region of interest was 
highlighted based on Allen Brain Atlas for reference, following application of an adaptive 
threshold with shape factor and area (m2) object filters for automatic cell detection. 
Detected cell number was divided over the area (µm2) of region. The investigator was 
blinded from all experimental groups during imaging and cell quantitation.  
Immunostaining for post-mortem human brain tissue 
Formalin-fixed paraffin embedded (FFPE) human brain sections mounted on glass slides 
were donated by Dr. Brad Racette at Washington University, St. Louis. All section labeling 
was coded for an unbiased processing/analysis of all experimental groups. 
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Immunofluorescence processing was conducted as follows: 1) slides were incubated at 
55 °C (15 min), 2) cooled to room temperature (15 min), 3) deparaffinization of sections 
by 2X-xylene (5 min); 2X-100% ethanol (EtOH); 1X-95% EtOH (5 min);1X- 70% EtOH (5 
min); 1X-TBS containing 2% Triton X (5 min), 4) antigen retrieval by submersion in 75% 
methanol (10 min) and .01M Na Citrate (20 min), 5) blocked sections in 1% donkey and 
1% goat serum (1 hr), 6) primary antibodies: anti-GFAP (1:100; DAKO Z0334), anti-IBA1 
(1:50; WAKO) and anti-C3 (1:50; Abcam 11871) were diluted in TBS (2% Triton) for 48 
hours at 4°C, 7) sections were washed-4X (10 min), secondary anti-Rabbit alexa flour 
555-IBA1, anti-Rabbit alexa flour 488-GFAP and anti-mouse alexa flour 555-C3 were 
diluted in TBS (2% Triton) at 1:200 (2 hr), 8) tissue sections were washed 2X (5min) and 
1X (5min) with (2% Triton) containing DAPI, 9) sections were mounted with medium with 
glass coverslips and stored at 4°C until imaged.  
Image analysis of microglia morphology and reactive astrocytes 
For detection of microglia morphology, the same sections immunostained for anti-
IBA1/TH as mentioned for automated counting were reimaged on a Zeiss Axiovert 200M 
inverted fluorescent microscope equipped and a Hammatsu ORCA-ER-cooled charge 
coupled device camera using a 10x and 40x air objective with Slidebook imaging software 
(version 5.0, Intelligent Imaging Innovations, Denver CO). Optical fractionator method 
employed counting frame size (150 X 150 μm) and frame spacing (for SN; 250 X 250 μm, 
for ST; 550 X 550 μm). 40x z-stack images of IBA+ cells from the SNpc, and Gp were 
acquired and converted to max projection, following a binary transformation and then 
rendered to a skeletonized image in ImageJ, as previously described in Morrison and 
Filosa et al. 2013(Schneider et al., 2012; Morrison and Filosa, 2013).  To detect C3+ and 
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S100b+ co-localizing cells, same optical fractionator method was applied for imaging. 
Cells were manually quantitated per z-stack images. The investigator was blinded from 
all experimental groups during cell counting. 
High-performance liquid chromatography 
Samples of striatum were processed for high performance liquid chromatography (HPLC) 
coupled with electrochemical detection to quantitate levels of DA, 3, 4-
dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), serotonin (5-HT) and 
metabolite 5-hydroxindoleacetic acid (5-HIAA). The Neurochemistry Core Laboratory at 
Vanderbilt University’s Center for Molecular Neuroscience Research group (Nashville, 
TN) processed all tissue samples from each experimental group with coded labeling for 
unbiased analysis. 
Statistical Analysis 
All data was presented as mean +/- SEM, unless otherwise noted. Experimental values 
from each mean were analyzed with a Grubb’s (α=0.05) test for exclusion of significant 
outliers. Differences between each experimental group were analyzed by a one-way 
ANOVA following a Tukey post hoc multiple comparisons test.  Significance was identified 
as ++P < 0.01, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. All statistical analysis 
was conducted using Prism (version 6.0; Graph Pad Software, San Diego, CA). 
2.3 RESULTS 
 
Developmental weights and water consumption over MnCl2 treatment 
At post-natal day (PND) 7 mice were tail clipped for DNA purification and 
identification of KO and WT progeny per our previously published PCR genotyping 
protocol (Kirkley et al. 2018). At PND 21, mice were placed on a 30-day MnCl2 
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(50mg/kg/per day) drinking water regimen during juvenile development following MPTPp-
induced parkinsonism as depicted in Figure 1A. Based on statistical analysis of MnCl2 
water consumption, WT consumption increased 2.19 ± 0.44 (mL) and KO consumption 
increased 2.63 ± 0.78 (mL) from 21-51 PND (n=4-5; no significance difference between 
groups) (Fig 1B). For accurate dosing of MnCl2 and detection in change of body weight, 
mice were weighed every day for the first week of treatment. From 21-27 PND, KO and 
WT animals significantly increased in weight by 10.65 ± 0.97 and 10.86 ± 0.83 (g), 
respectively (n=8/group; ****P < 0.0001). No significant difference in body weight was 
detected between groups treated with MnCl2 (Fig 1C). 
Inhibited astrocyte-NF-kB protects DA neurons from MPTP-induced toxicity in the 
SNpc, but MnCl2 does not exacerbate neuronal loss 
To assess the severity of lesion present in all six experimental groups, SN tissue 
was serially cryosectioned and systematically immunolabeled with anti-TH (greyscale) for 
DA neuronal soma (Fig 2A-F). Estimated mean of total TH+ neurons within the SNpc were 
quantitated for each experimental animal group as follows: WT no treatment (8,024 ± 
637.1), WT with MnCl2 (8,779 ± 777.0), WT with MPTPp (3,759 ± 503.7), WT with MPTPp/ 
MnCl2 (3,867 ± 222.1), KO with MPTPp (7,421 ± 537.2), KO with MPTPp/MnCl2 (6,957 ± 
1,049). Both WT with MPTPp and with MPTPp/MnCl2 displayed a significant ~51-53% 
loss of TH+ neurons compared to control. KO with MPTPp and MPTPp/MnCl2 endured 
only a ~7.5-13.3 loss of TH+ neurons (Fig 2G). For total neuronal nuclei of the SNpc, 
sections were co-labeled with anti-NeuN. Mean estimate of total neuronal nuclei within 
the SNpc were quantitated as follows: WT no treatment (14,034 ± 631.2), WT with MnCl2 
(15,162 ± 609.8), WT with MPTPp (9,778 ± 379.3), WT with MPTPp/MnCl2 (9,636 ± 
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159.0), KO with MPTPp (12,932 ± 1,167), KO with MPTP/MnCl2 (11,695 ± 1,152). 
Comparably, WT with MPTPp and MPTPp/MnCl2 displayed a significant ~30-31% loss of 
total neurons neurons compared to control. KO with MPTPp and MPTPp/MnCl2 only 
sustained a 7.8-16.7% loss of NeuN+ cells which was not significantly different from 
control (Fig 2H) (n=6 animals/per group; **P < 0.01, ***P < 0.001). 
MnCl2/MPTPp induces neuronal death in the globus pallidus and striatum by an 
astrocyte-NF-kB dependent mechanism 
In order to evaluate level of neuronal dysfunction in other areas of the brain, 
anatomically identical cyro-sections of the basal ganglia were selected for quantitation of 
total NeuN+ neurons in the globus pallidus and caudate putamen nuclei. Representative 
10x-objective montage images of sections immunolabeled with anti-NeuN (green) shows 
level of resolution for measurement (Fig 3A). The globus pallidus (Fig 3B) and caudate 
putamen (Fig 3C) were highlighted as a region of interest (ROI) for accurate detection of 
total NeuN+ per area (µm2), notice blue objects dictate individual cell bodies within the 
ROI. Based on quantitation of total NeuN+/µm2, there was an apparent decrease of 
neurons in WT animals treated with only MPTPp or MnCl2 but was not statistically different 
from control. In constrast, WT animals treated with MPTPp/MnCl2 had a ~44.1% loss of 
NeuN+ neurons within the globus pallidus. In contrast, KO animals with dual treatment 
were protected from loss of neurons, with no differences in neuronal numbers detected 
from WT control animals (Fig 3E). Quantitation of NeuN+ cells/µm2 within the caudate-
putamen showed a similar trend as the globus pallidus, however no groups were 
statistically different (Fig 3F). To measure integrity of TH+ presynaptic terminals of the 
caudate-putamen, sections were also co-immunolabeled with anti-TH (red) as depicted 
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in representative image (Fig 3D). A decrease in TH intensity was apparent in WT animals 
treated with MnCl2 or MPTPp individually but were not significantly different from control. 
Dual treatment with both MnCl2 and MPTPp in WT mice increased loss of DA terminals 
to ~62.5% of control animals, whereas KO animals with dual treatment only had a ~20.7% 
loss of terminals compared to control WT mice (Fig 3G) (n=6-7 animals/group; *P < 0.05, 
**P < 0.01, ***P < 0.001). For detection of apoptosis, striatal tissue was collected from 
WT and KO animals treated with MPTPp and immunoblotted for cleaved caspase-3. 
Representative blot of three individual experiments shows an intense band detected in 
WT treated with MPTPp treatment and a suppression of c-caspase 3 protein was evident 
in KO with MPTPp treatment (Fig 3H). 
IKK2 knockout mice are protected against behavioral and neurochemical deficits 
caused by exposure to Mn and MPTPp 
Spontaneous locomotor activity was detected by open field test (OFT) for each 
experimental group. MnCl2-only treatment seemed to only decrease the total distance 
traveled, as all other parameters did not change from baseline (Fig 4A). Whereas dual 
treated WT (with MnCl2/MPTPp) animals displayed hyperactive behavior in multiple 
parameters of OFT analysis. Dual treatment significantly increased levels of margin time 
(Fig 4B), center time (Fig 4C), horizontal movement (Fig 4E), stereotypy movement (Fig 
4F), and ambulatory movement (Fig 4G) compared to MPTPp-only treatment. 
Interestingly, treated KO animals did not display hyperactive behavior and were no 
different from WT control animal behavior as depicted in representative images of total 
trace and pseudocolored time plots of activity over a 5 min interval (Fig 4D) (n=7-10 
animals/group; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001). 
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Quantitative analysis of stride length from each experimental animal was 
conducted using a real-time video gait analysis system. WT animals treated with MPTPp 
and MnCl2/MPTPp exhibited an apparent decrease of stride length compared to WT 
control but was not statistically different. However, dual treated KO animals had a 
significantly longer stride length compared to treated WT animals during the course of the 
study (Fig 4H) (n=5-6 animals/group; *P < 0.05). Levels of striatal catecholamines and 
metabolites were detected with HPLC analysis. All MPTPp treated animals with or without 
MnCl2 exhibited a drastic loss of DA and DOPAC. Additionally, a slight increase of DA 
levels was apparent in MnCl2-only treated WT animals but was not statistically different 
from control (Fig 4I, J). Dual treated WT animals also displayed a significantly higher ratio 
of DOPAC/DA compared to control (Fig 4K). Assessment of DA metabolite, HVA, also 
displays MPTPp treatment significantly decreased HVA levels, independent of MnCl2 
treatment and genotype (Fig 4L). Serotonin (5H-T) content showed no statistical 
difference between experimental groups (Fig 4M). However, analysis of the serotonin 
metabolite (5-HIAA) showed a significant increase in both WT and KO dual treated 
animals compared to MPTPp-only treatment (Fig 4N) (n=5-9 animals/group; *P < 0.05, 
**P < 0.01, ***P < 0.001). 
Dual MnCl2/MPTPp treatment intensifies microglia activation in the globus pallidus 
and is suppressed by the intercellular effects of astrocyte NF-kB inhibition 
Relative number of microglia within basal ganglia was detected by immunolabeling 
with anti-IBA1 (green) as depicted in representative images of the Gp and Cp (Fig 5A-
C). Both MPTPp and MPTPp/MnCl2 treatments in WT animals increased number of IBA-
1+ cells/µm2 within the caudate putamen and treated KO animals displayed significantly 
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less as depicted in Figure 5D. Dual treated WT animals also exhibited the most IBA-1+ 
cells/µm2 within the globus pallidus and similarly, KO animals had significantly less (Fig 
5E). There was a significant increase of IBA-1+ cells/µm2 in the SNpc of MPTPp treated 
WT animals and slightly fewer in KO animals, but was not statically different from WT (Fig 
5F) (n=5-6 animals/group; **P < 0.01, ***P < 0.001, ****P < 0.0001). A similar trend of 
IBA-1+ cells/µm2 in the SNpr was apparent, although not statically different between 
groups (Fig 5F). For assessment of microglia morphology, 40x-objective IBA-1 
(greyscale) images of the Cp and Gp were skeletonized to detect for number of branches 
as depicted in representative images in Figure 5H. WT dual treated animals exhibited 
significantly less branches/cell in the Cp (Fig 5I), Gp (Fig 5J), and less junctions/cell in 
the Cp (Fig 5K), and Gp (Fig 5K) compared to dual treated KO animals (n=7 
animals/group; *P < 0.05). 
Dual MnCl2/MPTPp-induced astrocyte proliferation is regulated by NF-kB in the 
basal ganglia 
Expression of IKK2 was determined in hGFAP-cre+/-/IKK2fl/fl mice by co-
immunolabeling with anti-GFAP (red) and anti-IKK2 (green), as depicted in representative 
100x-objective images from the globus pallidus in WT control (Fig 6A), WT dual treated 
(Fig 6B) and KO dual treated (Fig 6C) mice. For assessment of the relative number of 
GFAP+ cells present in multiple nuclei of each experimental group, anatomically 
consistent cyrosections of ST and SN were selected for automated counting of 
GFAP+/µm2. As depicted in representative 10x-objective montage images of the Gp and 
Cp, dual treated WT animals exhibited an amplified proliferation of GFAP+ in both nuclei 
(Fig 6F). Dual treatment significantly increased GFAP+/µm2 over MPTPp-only treatment 
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in WT animals in Gp and KO animals exhibited significantly less independent of treatment 
(Fig 6 D-G). Similarly, increased GFAP+/µm2 was evident in dual treated WT animals in 
the Cp but was not statistically different from MPTPp-only WT treated animals for this 
region (Fig 6H). Comparably, dual treated WT animals exhibited the most amount of 
GFAP+ immunoreactivity in the SNpc and KO animals significantly suppressed 
GFAP+/µm2 to control levels (Fig 6I-L). We also observed an apparent trend of 
GFAP+/µm2 in the SNpr of each experimental group but was not statistically significant 
(Fig 6M) (n=6; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.001). 
Complement protein-C3 is highly expressed in reactive astrocytes following 
treatment with MnCl2/MPTPp and down regulated in IKK2 KO mice  
To quantitate number of neurotoxic astrocytes present, anti- complement protein 
C3 (red) was utilized for an additional measurement of astrocyte activation in regions of 
the basal ganglia. Anti-S100b (green) was used to detect total amount of astrocyte cell 
bodies. By randomized sampling of each nuclei and quantitation of astrocytes co-
expressing C3+S100b+ over total number of S100b+ cells, dual MnCl2/MPTPp treated WT 
animals exhibited significantly more neurotoxic astrocytes in the Gp (Fig 7B, D, F), Cp 
(Fig 7B, F, H), SNpc (Fig 7J, L, N), and SNpr (Fig 7J, N, P). Inhibition of astrocyte NF-
kB with same treatment suppressed the number of C3+ present in each region, as 
depicted in representative images in Figures 7C, G, K, O (n=7 animals/group; *P < 0.05, 
**P < 0.01, ***P < 0.001). Immunostaining on test human brain tissue shows expression 
of GFAP (green) and IBA1 (yellow) appear to be specific for glia cells. Anti-C3 (red) was 
also tested for antibody efficiency, which appears to be primarily only expressed in 
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peripheral leukocytes as C3+ cells only in arterioles of control human tissue (Fig 8A-C) 
(images represent replicates of three sections/antibody).  
2.4 DISCUSSION AND CONCLUSIONS 
 Almost two hundred years ago, James Couper described the first case of 
manganism from inhalation of Mn oxide ore dusts in workers who developed gait 
disorders similar to Parkinson’s disease (Couper 1837). Today, the pathological 
mechanisms underlying irreversible neurological damage from Mn exposure are still not 
completely understood. However, neuroinflammatory activation of glial cells is a common 
mechanism underpinning the neurotoxicity of Mn in both humans and in animal models 
of the disease, as we have previously reported (Kirkley et al. 2017; Moreno et al. 2011). 
Accordingly, we demonstrated that PND 20-34 juvenile mice were particularly susceptible 
to Mn-induced neuroinflammation (Moreno et al 2009), potentially due to a critical period 
of striatal development in rodents (Soiza-Reilly and Azcurra, 2009). Recently, we 
characterized a novel astrocyte-IKK2 transgenic animal that prevented the production of 
proinflammatory factors NOS2 and TNFa  and was neuroprotective in a MPTPp animal 
model of PD (Kirkley et al. 2018). The present study expanded on this work and elucidated 
the role of astrocyte activation induced by juvenile Mn intake, which resulted in neuronal 
loss from the globus pallidus, behavioral abnormalities and drastic differences in glia cell 
proliferation. 
 Combined developmental/adult exposure to Mn and MPTPp caused considerably 
different OFT performance compared to the other experimental groups. Spontaneous 
locomotor activity was increased in multiple parameters of total distance (Fig 4A), margin 
time (Fig 4B), center time (Fig 4C), horizontal count (Fig 4E), stereotypy count (Fig 4F), 
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and ambulatory count (Fig 4G), representing an overall hyperactive phenotype. CNS 
activity aberrations such as abnormal neuromuscular function and fine motor deficits have 
been documented in rat models ranging from low (4.8mg/kg) subchronic to high 
(50mg/kg) chronic MnCl2 administration (Witholt et al., 2000) (Beaudin et al., 2016). This 
implies as to which neurotransmitter systems are dysregulated by dual treatment of 
MnCl2/MPTPp to the presented hyperactivity. Pre-synaptic DA neurotransmission is not 
a major system effected since dual MnCl2/MPTPp treatment did not exacerbate DA 
neuronal loss in the SNpc (Fig 2G) or striatal dopamine production (Fig 4H). Or maybe a 
threshold loss of DA and neuronal bodies was exceeded by MPTPp treatment alone 
because there was still a significant loss of TH+ immunoreactivity in the Cp of dual treated 
WT animals compared to control and MPTPp-only treatment (Fig 3G). Low subchronic 
dose of MnCl2 for 5-weeks also demonstrated no further depletion of nigro-striatal DA 
depletion due to MnCl2 treatment (Gwiazda et al., 2002). In contrast, Beudin et al. showed 
chronic administration of 50mg/kg/day from PND 20-460 significantly depleted DA 
(Beaudin et al., 2016). Therefore, if treatment of MnCl2 was extended longer than 30 days 
with the same dose (50mg/kg/day) prior to MPTPp treatment, more severe effects could 
have been observed on DA neurons in the current study. 
 Thus, we investigated MnCl2 effects on Gp neurons, which receive and relay 
primarily inhibitory gamma butyric acid (GABA)-ergic innervation. By quantitation of total 
neuron marker (NeuN), there was an apparent decrease of NeuN+/µm2 in both MnCl2-
only and MPTPp-only treated groups.  Significant depletion was only detected in dual 
MnCl2/MPTPp treated WT animals compared to controls, demonstrative of amplified loss 
neurons in the Gp (Fig 3E). Investigations of Mn-induced neurotransmitter dysregulation 
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in the Gp are variably dependent on the model and dose regimen. For example, chronic 
exposure (10 mg/kg) in non-human primates depleted expression of GS in the Gp, but no 
effect on GABAergic or glutamatergic systems (Burton et al., 2009). Other investigations 
with rats treated with 6 mg/kg/per day led to significant increase of Mn brain levels and 
decrease in GABA (Lai et al 1984). Conversely, another study demonstrated that 20 
mg/kg/day treatments in rats led to a significant increase of both Mn and GABA 
concentrations in the brain (Lipe et al 1999).  
It is interesting to speculate that the observed hyperactive locomotor responses 
observed in Mn-treated mice repesent loss of neurons in the Gp, which would cause less 
GABAergic output to the Sth and therefore increased Glu excitation to the SNpc and 
increased firing of DA neurons to the ST (Erikson and Aschner, 2003). This theory of 
increased DA firing could explain the modest increases in the number of TH+ neurons 
observed in the SNpc (Fig 2G), as well as increases in DA content (Fig 4G), TH 
immunoreactivity in the ST (data not shown) and hyperphosphorylation of the post-
synaptic DA protein DARPP32 (data not shown) in Mn-treated WT animals. Serotonergic 
neurotransmission is also a possible target of juvenile Mn toxicity. Modulation of 
monoamine serotonin (5-HT) cause abnormalities in many physiologic functions, such as 
food intake, motor activity and sleep; which are also symptoms of manganism (Lesch et 
al., 1996). There was significant increase of the 5-HT metabolite (5-HIAA) of the ST from 
both dual treated animal groups, but no differences for 5-HT (Fig 4M). This is coherent to 
a previous report where we observed only juvenile mice treated with MnCl2 exhibited high 
levels of 5-HIAA compared to adult MnCl2 treated animals (Moreno, Yeomans, et al., 
2009). 
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 Irrespective of which neurotransmitter system is most affected by dual treatment, 
neuronal death was controlled by neurotoxic astrocyte activation regulated by NFkB. 
Inhibition of astrocyte-NFkB protected DA neurons from both MPTPp and MnCl2/MPTPp-
induced toxicity by ~90% compared to control within the SNpc (Fig 2G). KO animals also 
did not sustain any loss of neurons in the Gp, terminals of the Cp and were protected 
from apoptotic mechanisms such as activation of cleaved-caspase 3 (Fig 3E-G). Prior 
studies report constitutively active astrocyte-NFkB increased cytokine production in a 
MPTP mouse model of PD and increased amyloid burden and gliosis in a mouse model 
of AD (Oeckl et al., 2012; Lian et al., 2016).  Knock-out of IKK2 in all CNS cells 
demonstrated protection in an auto-immune encephalitis mouse model (van Loo et al., 
2006). However, IKK2/NF-kB signaling in neurons is also necessary for protection against 
traumatic brain injury and synaptic plasticity for memory formation (Mettang et al., 2017; 
Kaltschmidt et al., 2006). Therefore, targeting NF-kB pro-inflammatory function 
specifically in glia cells may be necessary for a desirable outcome. In the current study, 
we are the first to report inhibition of astrocyte-IKK2 protected the CNS from gliosis and 
neuronal death induced by both MnCl2 and MPTPp treatment.   
The astrocyte-specific genotype caused intercellular effects by triggering fewer 
activated microglia to the Gp (Fig 5E, J, L) and Cp (Fig 5D, I, K). Inhibition of microglia 
activation in the Gp of KO animals directly correlated with the preservation of NeuN+ cells 
with dual treatment (Fig 5E, 3E). However, no significant suppression was observed in 
the SNpc or SNr, consistent with the initial characterization of hGFAP-cre+/-/IKK2fl/fl treated 
with MPTPp (Fig 5F-G) (Kirkley 2018). These studies confirmed purified primary 
astrocytes isolated from KO mice exhibited 70% knockdown of IKK2 which was 
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consistently observed in vivo as depicted in representative images of IKK2/GFAP co-
localization in Figure 6A-C. Quantitation of GFAP+/µm2 confirmed that the most affected 
nucleus in WT mice exposed to Mn/MPTPp was the Gp (Fig 6D, F). Interestingly, KO 
animals exhibited significantly less GFAP+/µm2 in the Gp, Cp, SNpc. Albeit no groups 
were different in the SNpr, potentially due to high basal levels present in each 
experimental group prior to treatment (Fig 6D-M). 
Studies of MPTP neurotoxicity demonstrate that astrocytes remain chronically 
activated long after activation of microglia subsides subsequent to DA neuronal death 
(Hirsch and SP Hunot, 2009; Huang et al., 2018). Therefore, we expected that MnCl2 
exposure would prime astrocytes to an activated state which was further enhanced to a 
neurotoxic state by MPTP administration months later through an NF-kB dependent 
mechanism. To specifically detect neurotoxic astrocytes expressing a reactive A1 
phenotype, we immunolabeled for complement protein-C3 in regions that we saw 
induction of gliosis and neuronal death (Fig 7). C3 has been known for decades as a 
major convergent factor of the classical complement pathway that mediates a peripheral 
innate immune response in the presence of pathogens (Ricklin et al., 2016). The 
expression of C3 in the CNS has more recently been identified in astrocytes from patients 
with PD, AD, ALS and even HIV infection (Liddelow et al., 2017; Nitkiewicz et al., 2017). 
Several of these studies demonstrate that astrocyte-C3 expression is regulated through 
NF-kB (Lian et al., 2016; Nitkiewicz et al., 2017). Lian et al. reported that constitutively 
active NF-kB driven by hGFAP in astrocytes promoted an increase of C3 expression in a 
mouse model of AD. Inversely, the present study, the KO animals had significantly less 
C3++S100b+/S100b+ expressing astrocytes in regions lesioned with dual MnCl2/MPTPp 
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treatment compared to the WT animals (Fig 7D, H, L, P). These data suggest that 
astrocyte-NF-kB regulated C3 expression may be a novel mechanism to attract reactive 
microglia, maintain a chronically neurotoxic state of astrocytes and drive 
neurodegeneration at the site of lesion, such as the Gp in this model.  
To determine whether glial activation and expression of C3 in astrocytes was a 
feature of human manganism, we assessed reactive gliosis and C3 expression in post-
mortem human brain tissue isolated from South African miners known to be highly 
exposed to Mn throughout their lifetime. Immunofluorescence staining for anti-GFAP (Fig 
8A), anti-C3 (Fig 8B), and anti-IBA1 (Fig 8C) were performed on control human brain 
tissue to optimize staining efficiency. C3 expression was only expressed in blood cells 
present in the vessels of brain tissue, which is expected since the antibody was purified 
against plasma C3 protein (Fig 8B). However, we predict to see the bulk of C3 expression 
shift to GFAP+ astrocytes when we analyze/process the Mn exposed brains in the final 
data set. If the data we analyzed from mouse tissue is translatable to human samples, 
more C3+-GFAP+/GFAP+ and IBA-1+ cells should be evident in Gp, Cp, and SN from the 
miner brains as compared to control brain tissue (data not shown).  
In conclusion, we have elucidated a novel neuroinflammatory mechanism 
associated with juvenile MnCl2 exposure that exacerbated neurodegeneration from 
MPTPp treatment during adulthood in a transgenic mouse model. Our results reveal that 
the Gp is the most affected basal ganglion nuclei by dual treatment and 
neurodegeneration can be blocked by inhibition of astrocyte-NF-kB. Additionally, we 
provide evidence that MnCl2/MPTPp treatments in mice increase the presence of 
neurotoxic C3+ astrocytes and is highly regulated by astrocyte-NF-kB activation. Ongoing 
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research that targets cell-specific NF-kB in astrocytes could lead to a novel therapeutic 






Figure 2.5.1 Two-hit neurodegenerative dosing schematic and monitoring of MnCl2 
intake (A) Depicted dosing schematic applied to both wild-type and knock animals 
Consumption of water containing MnCl2 was monitored over the juvenile development 
period for accurate administration of Mn/50mg/kg/per day (B). Weight measurements 
were also conducted to monitor significant increases of body mass during juvenile 
development (C) (****P < 0.0001; data represented as N=4-5 animals/genotype).  
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Figure 2.5.2 Stereological cell counting for total DA neurons of SNpc Nigral DA 
neurons were immunolabeled with anti-TH (black) and imaged for entire SN region as 
depicted in 10x-objective images of WT control (A), WT + MnCl2 (B), WT + MPTPp (C), 
WT + MnCl2/MPTPp (D), KO + MPTPp (E), KO + MnCl2/MPTPp (F). (G) Quantitative 
assessment of TH+ neurons in the SNpc. (H) Quantitative assessment of total NeuN+ 




Figure 2.5.3 MnCl2/MPTPp induces neuronal loss in Gp by astrocyte-NF-kB 
dependent mechanism (A) Automated total neuronal quantitation of specific brain 
regions were detected with anti-NeuN (green) immunolabeling as depicted in 10x-
objective montage and zoomed in inset of Gp. The Gp (B) and Cp (C) were identified as 
ROIs for automated cell detection (blue). Co-labeling with anti-TH (red) depicts DA pre-
synaptic terminals in the Cp (D). Total NeuN+/µm2 were quantitated for the Gp (E) and Cp 
(F). (G) Mean intensity of TH+ immunoreactivity was also measured for detection of DA 
innervation in the Cp (*P < 0.05, **P < 0.01, ***P < 0.001; N=6-7 animals/group). 
Representative western blot image depicts level of cleaved-caspase 3 protein expression 
from ST tissue isolated from KO and WT animals treated with MPTPp (blot is a 




Figure 2.5.4. MnCl2/MPTPp induces a hyperactive behavioral phenotype dependent 
on astrocyte-NF-kB Open field test was conducted to detect for change of total distance 
(A), margin time (B), and center time (C) compared to day 0. (D) Representative trace 
plots (top) and pseudocoloring of total time spent (bottom) in position of chamber of 5 min 
intervals are depicted for WT-control, WT + MnCl2/MPTPp and KO + MnCl2/MPTPp 
treated animals. (E) Change in horizontal count, (F) stereotypy count, and ambulatory 
count(G) values were also subtracted from day 0 (*P < 0.05, **P < 0.01, ***P < 0.001, 
****P < 0.0001; N=7-10 animals/group). (H) Real-time video gait analysis was utilized to 
quantitate change of stride length from day 0 (*P < 0.05; N=5-6 animals/group). HPLC 
analysis for detection of DA (I), metabolite DOPAC (J), DOPAC/DA (K), homovanillic acid 
(HVA) (L), serotonin (5-HT) (M), and metabolite 5-HIAA were analyzed for 
neurotransmitter content from ST tissue (*P < 0.05, **P < 0.01, ***P < 0.001; N=5-9 
animals/group).   
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Figure 2.5.5 MnCl2/MPTPp treatment increases microglia activation and by an 
astrocyte-NF-kB dependent mechanism Microglia cell bodies were detected by 
automated quantitation of tissue stained for anti-IBA1 (green) as depicted in 10x-objective 
images of WT-control (A), WT + MnCl2/MPTPp (B), and KO + WT + MnCl2/MPTPp (C) 
treated animals. Total IBA1+/µm2 for the Cp (D), Gp (E), SNpc (F), and SNpr (G) were 
quantitated for all experimental groups (**P < 0.01, ***P < 0.001, ****P < 0.0001; N=5-6 
animals/group).. (H) Image skeletonization of IBA1+(black) cell morphology are depicted 
in representative images of WT-control, WT + MnCl2/MPTPp, and KO + WT + 
MnCl2/MPTPp. Three experimental groups were quantitated for #branches/cell in Cp/Gp 




Figure 2.5.6 MnCl2/MPTPp treatment increases astrocyte activation and by an 
astrocyte-NF-kB dependent mechanism 100x-objective representative images of anti-
IKK2 (green), anti-GFAP (red) colocalizing cells (arrowheads) from WT-control (A), WT + 
MnCl2/MPTPp (B), and KO + MnCl2/MPTPp (C) treated animals. Total GFAP+/µm2 were 
quantitated from the Gp (D) and Cp (H) in all experimental groups, as depicted in 10x-
objective montage images of ST with anti-GFAP (red) in three groups (E-G). SNpc and 
SNr was also immunostained for GFAP as depicted in representative 10x-objective 
images in (I-K). Analysis of GFAP+/µm2 in SNpc (L) and SNpr (M) (*P < 0.05, **P < 0.01, 
***P < 0.001, ****P < 0.001; N=6). 
 46 
 
Figure 2.5.7 MnCl2/MPTPp treatment induces neurotoxic astrocyte-C3 expression 
and is controlled by NF-kB Representative 10x-objective montage images of Gp/Cp co-
immunostained for anti-C3 (red), dapi (blue) and S100b (green) from WT-control (A,E), 
WT + MnCl2/MPTPp (B,F), and KO + MnCl2/MPTPp (C,G) treated animals. Bottom inset 
displays 20x-magnification of outlined region with merged channels (E-G). Quantitation 
of C3+S100b+/S100b+ in the Gp (D) and Cp (E), were conducted for three experimental 
groups. Similarly, SNpc/SNpr 10x-objective images of C3 with dapi (I-K) and S100b with 
C3 (M-O) and quantitation of C3+S100b+/S100b+ in SNpc (L) and SNpr (P) (*P < 0.05, 




Figure 2.5.8 Preliminary data depicting immunostaining in post-mortem human 
tissue (A) GFAP (green) in astrocytes, (B) C3 (red) in arteriole walls, and (C) IBA1 








A NOVEL SYNTHETIC ACTIVATOR OF NURR1 INDUCES DOPAMINERGIC GENE 
EXPRESSION AND PROTECTS AGAINST 6-HYDROXYDOPAMINE 






Parkinson’s disease (PD) is the second most common neurodegenerative disorder 
worldwide. There are no disease-modifying therapies for PD and patients become 
resistant to current symptomatic treatments as loss of dopaminergic neurons progresses 
(Shastry, 2001). There is considerable interest in the nuclear receptor, NR4A2 (Nurr1), 
as a promising target for control of PD progression. Nurr1 is a member of the 
steroid/thyroid hormone nuclear receptor transcription factor superfamily (Jankovic et al., 
2005) and regulates DA metabolism by inducing expression of tyrosine hydroxylase (TH), 
vesicular monoamine transporter (VMAT2), and aromatic amino acid decarboxylase 
(AADC) (Kadkhodaei et al., 2009; García-Yagüe et al., 2013).  Additionally, Nurr1 is 
important for development of DA neurons and can inhibit expression of 
neuroinflammatory genes in glial cells, suggesting a cell-specific context for the 
transcriptional regulatory effects of the receptor (Zetterström et al., 1997; Saijo et al., 
2009). Ablation of Nurr1 in mature DA neurons recapitulates the progressive pathology 
of PD, with reduced striatal DA, impaired motor behaviors and dystrophic axon/dendrites 
(Kadkhodaei et al., 2013). The endogenous ligand for Nurr1 is unknown but selected 
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synthetic lipophilic molecules can enhance the transcriptional activity of Nurr1 in vitro (X 
Li et al., 2012; Smith et al., 2015).  
 We previously demonstrated that one such molecule, 1,1-bis(3’-indolyl)-1-(p-
chlorophenyl)methane (C-DIM12), has neuroprotective efficacy in the subacute 1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of PD (Inamoto et al., 2008; De 
Miranda et al., 2014). C-DIM12 activates Nurr1 in pancreatic cancer and keratinocyte 
epidermal cells (X Li et al., 2012) and also enhances expression of Nurr1 in DA neurons 
in vivo, along with the Nurr1-regulated proteins, tyrosine hydroxylase (TH) and the 
dopamine transporter (DAT) (De Miranda et al., 2014). In the present study, we 
investigated the capacity of C-DIM12 to regulate expression of Nurr1 and Nurr1-regulated 
genes in cultured dopaminergic neuronal cell lines and in primary dopaminergic neurons. 
We found C-DIM12 induced expression of Nurr1-regulated genes in multiple neuronal cell 
lines and increased Nurr1 expression in TH expressing primary neurons. RNAi studies 
show these effects were dependent upon expression of Nurr1. Treatment with C-DIM12 
also preserved cell viability following exposure to the neurotoxin, 6-hydroxydopamine (6-
OHDA). These findings suggest that C-DIM12 is a direct transcriptional activator of Nurr1 
in DA neurons. 
3.2 MATERIALS AND METHODS 
 
Cell culture and Reagents 
Neuro-2a cells (N2A) and MN9D cells were cultured as previously described (García-
Yagüe et al., 2013; W Li et al., 2015). N27 cells were cultured in RPMI1640 medium (Life 
Technologies, Carlsbad, CA) supplemented with 10% FBS and 1X-PSN. Primary 
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dopaminergic neurons were isolated at E18 and cultured as previously described (W Li 
et al., 2015).   
Quantitative PCR and transfections 
qPCR was performed as previously described (De Miranda, Popichak, Hammond, 
Jorgensen, et al., 2015) and total RNA was quantified relative to hypoxanthine-guanine 
phosphoribosyltransferase (N2A) or b-actin (N2A).  The sequences of qPCR primers are 
listed in Supplementary Table 1. Transfections with DsiRNA oligonucletodes or 
expression plasmids was performed as previously described (De Miranda, Popichak, 
Hammond, Jorgensen, et al., 2015). 
Immunoblotting and immunofluorescence  
Immunoblots were performed as described (De Miranda et al., 2014) using the following 
antibodies: rabbit anti-Nurr1 (1:500; Santa Cruz, Dallas, TX), anti-Rabbit HRP (1:5,000; 
Cell Signaling), mouse anti-Beta Actin (1:1,000; Sigma, St. Louis, MO) and anti-mouse 
HRP (1:5,000; Cell Signaling, Danvers, MA). For immunofluorescence staining, N2A cells 
and primary neurons fixed and stained as previously described (W Li et al., 2015). Primary 
antibodies used: rabbit polyclonal anti-Nurr1 (1:250; Santa Cruz, Dallas, TX), chicken 
polyclonal anti-Tyrosine Hydroxylase (1:500; Abcam, Cambridge, MA), rabbit polyclonal 
anti-Flag (1:500; Sigma F-7425). Secondary antibodies used: Alexafluor647 (1:500; 
Invitrogen, Carlsbad, CA) and Alexafluor488 (1:500; Invitrogen). All imaging was 





Cell Viability Assays 
MN9D and N2A cells were grown on 96-well plates for 24 hrs before treatment with 6-
OHDA and C-DIM12. After 24 hrs, cells were imaged using the PrestoBlue Cell viability 
reagent (Life Technologies, Carlsbad, CA) per the manufacturers protocol.  
Statistical Analysis 
All data are presented as mean +/- SEM. Analyses of multiple experimental groups was 
performed using a one-way ANOVA with a Tukey post hoc test or Dunnett’s multiple 
comparison test. With two group comparisons, an unpaired t-test Welch’s correction and 
two-sided P-value with 95 % comparison interval was used. Statistical significance is 
represented by p < 0.05 (*), p < 0.001 (**), p < 0.001(***), and p < 0.0001 (****). 
Statistical analyses were performed using Prism software (version 6.0; Graph Pad 
Software, San Diego, CA). 
RESULTS 3.3 
Time-dependent expression of Nurr1, TH and VMAT2 was determined in N2A and 
N27 cells (Figure 1). Treatment with 10 μM C-DIM12 increased expression of Nurr1 in 
N2A cells that was maximal at 8 hr (Fig 1A) and remained relatively constant up to 24 
hrs, whereas mRNA expression of TH and VMAT2 in N2A cells was maximal at 4 and 8 
hr, respectively (Fig 1A). In N27 cells, Nurr1 mRNA level was induced at 8 hr, TH was 
increased at 8 and 24 hrs and VMAT2 mRNA levels were significantly elevated at 4 hrs 
(Fig 1B). Dose-dependent expression of Nurr1, TH and VMAT2 was examined in N2A 
(Fig 1C) and N27 (Fig 1D) cells following treatment with 5 – 10 μM C-DIM12. Treatment 
with 10 µM C-DIM12 increased expression of Nurr1, TH and VMAT2 in N2A cells (Fig
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1C), whereas mRNA levels for Nurr1 and VMAT2 were maximally induced by 5 µM C-
DIM12 in N27 cells and TH levels were increased by 10 µM C-DIM12 in N27 cells (Fig 
1D). 
 To determine whether C-DIM12-induced expression of TH and VMAT2 requires 
Nurr1, expression of Nurr1 was knocked down using RNA interference with Dicer 
substrate duplex RNA (DsiRNA) oligonucleotides (Figure 1E-G). Consistent knockdown 
was observed by immunoblotting in siNurr1-transfected cells compared to siScr-
transfected cells (Fig 1E). Cell morphology was unaffected by transfection with RNAi 
oligonucleotides (Fig 1F), as determined by differential interface contrast (DIC) imaging. 
In N2A cells transfected with siScr control RNA oligonucleotides, C-DIM12 significantly 
induced expression of Nurr1 and VMAT2 (Fig 1G). Levels of mRNA for Nurr1, TH and 
VMAT2 were reduced relative to siScr controls in N2A cells transfected with siNurr1 
oligonucleotides. Likewise, Nurr1 RNAi largely abolished the capacity of C-DIM12 to 
increase expression of Nurr1, TH and VMAT2 in N2A cells. A slight increase in C-DIM12-
induced expression of VMAT2 was still observed following Nurr1 RNAi in N2A cells, 
although the overall level of expression VMAT2 was decreased relative to control cells 
transfected with scrambled RNAi oligonucleotides (Fig 1G). 
 To determine the capacity of C-DIM12 to enhance levels of exogenously 
expressed Nurr1, N2A cells were transfected with a plasmid containing FLAG-tagged full 
length human Nurr1 or Gal4 control vector and treated with C-DIM12 for 24 hrs (Figure 2 
A-D). Expression of FLAG was evident 24 hrs after transfection and was localized to the 
nucleus of N2A cells (Fig 2A), identical to the pattern of Nurr1 expression (Fig 2B). 
Treatment with C-DIM12 (10 μM) increased nuclear fluorescence of FLAG (Fig 2C, 
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p<0.05) and Nurr1 (Fig 2D, p<0.0001) relative to DMSO (0.1%) treated controls. No 
expression of FLAG was detected in N2A cells transfected with Gal4 control vector.  
The effect of C-DIM12 on expression of Nurr1 in primary dopaminergic neurons 
was examined in Figure 2, E-G. Neurons were cultured for 1 week until morphologically 
mature and then treated with C-DIM12 (10 µM) or DMSO (0.1%) vehicle control for 24 
hrs. Dopaminergic neurons were identified by expression of TH and Nurr1 expression 
was determined in TH-positive neurons by immunofluorescence (Figure 2E). C-DIM12 
increased expression of both Nurr1 (Fig 2F, p<0.001) and TH (Fig 2G, p<0.0001) 
compared to control cells treated with DMSO (0.1%, vehicle control).  
 To examine the neuroprotective effects of C-DIM12 in both functionally mature 
neurons and undifferentiated neuronal cells, we compared the response of differentiated 
MN9D dopaminergic neurons cells to that of N2A cells following exposure to 6-
hydroxydopamine (6-OHDA) (Figure 3). After five days of differentiation with sodium 
butyrate, MN9D neurons responded to a depolarizing K+ stimulus with robust intracellular 
Ca2+ transients (Fig 3A,B). Relative changes in intracellular Ca2+ were determined by live 
cell imaging using Fluo-4-AM and compared to the baseline image prior to stimulation 
with K+ (F/F0). We next exposed N2A and differentiated MN9D cells to increasing 
concentrations of the neurotoxin, 6-hydroxydopamine (6-OHDA), for 24 hrs and 
determined viability by measuring cellular reducing potential. Treatment with 0.1 – 100 
µM 6-OHDA caused dose-dependent cell death in MN9D and N2A cells, with LD50 values 
of 100 and 10 µM, respectively (Fig 3C,E). Exposure to 6-OHDA for 24 hrs in the presence 
of C-DIM12 (10 µM) significantly increased viability in both cell lines (p<0.01, MN9D; 
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p<0.05, N2A. Fig 3D,F). The protective effect was greater in differentiated MN9D cells 
than in undifferentiated N2A cells. 
3.4 DISCUSSION AND CONCLUSIONS 
Nurr1 DNA binding sequences regulate the transcriptional activity of genes 
necessary for DA production and transport, such as TH, the synaptic dopamine 
transporter (DAT) and the vesicular monoamine transporter (VMAT2) (Sakurada et al., 
1999; Sacchetti et al., 1999). Nurr1 knockout mice fail to develop midbrain dopaminergic 
neurons and die soon after birth, whereas conditional Nurr1 knock-out mice exhibit 
deprecations in the nigro-striatal dopamine system and are more susceptible to alpha-
synuclein toxicity (Zetterström et al., 1997) (Decressac et al., 2012).  Thus, Nurr1 is 
thought to regulate both the development and maintenance of DA neurons, as well as 
protecting DA neurons from neurotoxic insults. Interestingly, transcriptional responses to 
Nurr1 appear to depend both on cell type and on the constitutive level of Nurr1 expression 
(Johnson et al., 2011). For example, Nurr1 strongly induces TH expression in rodent 
neural precursor and differentiated cells, but the inductive effects on TH in human neural 
precursor cells are more modest (Romano et al., 2005) and can even be repressive in 
human neural stem cells (TE Kim et al., 2013). Such varying transcriptional responses to 
Nurr1 may depend on the constitutive level of protein expression. In studies that 
generated a number of neuronal cell lines with graded expression of Nurr1, bioinformatics 
analysis indicated that many transcripts that were induced at low levels of Nurr1 protein 
expression were suppressed at high levels of Nurr1 and vice versa (Johnson et al., 2011). 
Thus, cell- and concentration-specific effects of Nurr1 likely influence the biological 
outcome in a different cell type.  
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In the current study, we noticed differences in the pattern of expression of 
dopaminergic genes between the different neuronal cell lines evaluated, indicated by 
variance in the timeand magnitude of mRNA expression across the time points and 
concentrations of C-DIM12 evaluated in N2A and N27 cells (Figure 1). C-DIM12 treatment 
increased expression of Nurr1 and VMAT2 after 8 hrs of treatment in N2A cells, whereas 
expression of TH maximal at 4hrs, prior to the peak of induction of Nurr1 mRNA  (Figure 
1A), suggesting that expression of TH and VMAT2 depend on the concentration of Nurr1 
or other regulatory factors needed for TH gene transcription. In N27 cells, Nurr1 mRNA 
levels also were moderately induced by C-DIM12 at 8hrs, whereas VMAT2 mRNA was 
significantly increased at 4hrs (1B). These temporal patterns in gene induction in 
response to C-DIM12 could also reflect saturation of Nurr1 binding by the compound. 
Although differences in mRNA responses were evident between cell lines, C-DIM12-
induced expression of the Nurr1-regulated genes TH and VMAT2 was conserved across 
mouse and rat cells, suggesting a common mechanism of regulation. C-DIM12 directly 
activates Nurr1, based on transcriptional reporter assays in bladder cancer cells and 
protein induction studies in epidermal keratinocytes(Inamoto et al., 2008) (Boakye et al., 
2013) and we recently reported that C-DIM12 induced Nurr1 nuclear translocation and 
increased protein expression in dopaminergic neurons in the MPTP/probenecid model of 
PD(De Miranda et al., 2014). Although Nurr1 appears to lack a classic ligand binding 
pocket, a separate region of the LBD site is thought to possess ligand binding affinity at 
the co-activator binding site (Z Wang et al., 2003). Computational modeling and binding 
studies indicated that other C-DIM compounds bind the co-activator binding site of NR4A1 
(Nur77), which is highly homologous to Nurr1 (S-O Lee et al., 2014).  Further studies are 
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now being conducted to investigate whether C-DIM compounds have direct binding 
affinity for Nurr1 at a similar site in the LBD. To test the hypothesis that C-DIM12 requires 
Nurr1 to induce expression of dopaminergic genes in neuronal cultures, the expression 
of Nurr1 was ablated using RNAi in N2A cells (Figure 1E-G). Loss of Nurr1 expression 
prevented the capacity of C-DIM12 to induce expression of the Nurr1-mediated 
mechanism (Figure 1E-G), indicating that Nurr1 is required for the transcriptional 
activation of these genes by C-DIM12. Even in the absence of C-DIM12, expression of 
VMAT2 and TH significantly decreased in Nurr1 siRNA cells compared to siRNA control 
cells, indicating direct regulation of these genes by Nurr1 in N2A cells (Figure 1G). Our 
current findings support the hypothesis that C-DIM12 directly regulates dopaminergic 
gene expression of TH and VMAT2 in N2A cells through a Nurr1-dependent mechanism. 
Nurr1 is down-regulated in patients with PD and polymorphisms in Nurr1 increase the risk 
for a rare familial form of the late onset disease (Liu et al., 2012). Therefore, preservation 
or increased expression of Nurr1 in neurons is a therapeutically desirable outcome in PD 
and related neurodegenerative disorders. In this regard, AAV-mediated gene delivery of 
Nurr1 and the forkhead transcription factor, Foxa2, preserved TH-positive neurons in a 
mouse model of PD (Oh et al., 2015). When we expressed full length human Nurr1 in 
N2A cells (Fig 2A-D), C-DIM12 treatment increased expression of the Flag-tagged 
protein, as determined by immunofluorescence labeling for both Flag and Nurr1. Similarly, 
C-DIM12 increased expression of Nurr1 and TH in primary mouse dopaminergic neurons 
isolated from the ventral midbrain at E18 (Fig 2E-G). The capacity of C-DIM12 to increase 
protein levels of both exogenously expression human Nurr1 as well as to enhance 
expression of native Nurr1 protein in primary DA neurons suggests that C-DIM12 is a 
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direct regulator of Nurr1 in neurons. To the examine the direct neuroprotective effect of 
C-DIM12 in functionally mature neurons compared to undifferentiated neuronal cells, we 
exposed differentiated MN9D cells and undifferentiated N2A cells to increasing 
concentrations of 6-OHDA in the presence and absence of C-DIM12. Differentiated 
MN9D neurons were less sensitive to 6-OHDA than undifferentiated N2A cells, with an 
LD50 of 100 μM 6-OHDA, compared to 10 μM 6-OHDA in N2A cells (Figure 3C,E). This is 
consistent with other studies of 6-OHDA in MN9D cells and with similar studies comparing 
the response of differentiated and undifferentiated neuronal cells to mitochondrial 
toxicants (Polunas et al., 2011). Moreover, undifferentiated N2A cells may share 
phenotypic similarity with other immortalized cell lines, which may render them less 
sensitive to the protective effects of C-DIM12 (X Li et al., 2012). Concurrent treatment of 
MN9D and N2A cells with C-DIM12 and 6-OHDA at the LD50  for each cell type 
significantly increased cell viability, particularly in differentiated MN9D neurons (Figure 
3D,F), indicating that C-DIM12 provides direct neuroprotective benefit, although the 
underlying mechanisms require further investigation. Functionally mature MN9D neurons 
are also more similar to dopamine neurons than undifferentiated N2A cells and may 
therefore be more responsive to the neuroprotective effects of C-DIM12, similar to the 
perseveration of DA neurons we reported in the MPTP/probenecid model of PD, where 
levels of Nurr1 were strongly induced in TH-positive soma in the substantia nigra pars 








Figure 3.5.1 C-DIM12 induces expression of Nurr1-regulated genes in dopaminergic 
cell lines by Nurr1 dependent mechanism. Levels of mRNA for Nurr1, VMAT2 and TH 
were measured by qPCR in N2A (A) and N27 cells (B) following treatment with C-DIM12 
(10 µM) for 4, 8 and 24 hrs. Dose-dependent changes in mRNA for Nurr1, VMAT2 and 
TH were measured by qPCR in N2A (C) and N27 cells (D) following treatment with vehicle 
control (DMSO) or C-DIM12 (5 and 10 µM) for 4, 8 and 24 hrs. *p<0.05, **p<0.01, 
****p<0.0001, n=3-4 biological replicates across 3 independent experiments. (E) Protein 
samples collected from N2A cells transfected with scrambled control sequence (siScr) 
and Nurr1 siRNA (siNurr1) were examined for expression of Nurr1 and β-actin as a 
loading control. (F) Morphology of N2A cells was determined following transfection with 
siScr and siNurr1 using differential interference contrast (DIC) imaging. Nuclei were 
counterstained with DAPI and visualized by fluorescence microscopy. Scale bar = 10 μm. 
(G) mRNA levels of Nurr1, TH and VMAT2 were measured by qPCR in N2A cells 
transfected with siScr or siNurr1 in the presence or absence of C-DIM12 for 24 hrs. 




Figure 3.5.2 C-DIM12 induces expression of tranfected human Nurr1 in N2A cells 
and induces expression of TH in primary dopaminergic neurons. (A, B) N2A cells 
were transfected with FLAG-Nurr1 or vector control and treated with C-DIM12 or DMSO 
for 24 hrs. Fixed cells were stained with anti-FLAG (yellow) and anti-Nurr1 (green) 
counterstained with DAPI (blue) and imaged using DIC and fluorescence microscopy. (C, 
D) Quantification of FLAG and Nurr1 fluorescence intensity in transfected N2A cells 
(arbitrary units, AU). *p<0.05, ****p<0.0001. n=100-200 cells from three biological 
replicates across 3 independent experiments.  (E) Primary mouse dopaminergic neurons 
were treated for 24 hrs with 10 µM C-DIM12 or 0.1% DMSO (vehicle control) and 
immunostained for Nurr1 (cyan), Tyrosine Hydroxylase (TH, green) or MAP2 (red) and 
couterstained with DAPI (blue). Fluorescence images were acquired using a 40X air 
Planapochromat objective with a 1.6X optivar lens (64X total magnification, scale bar = 
10 µm). (F) Nurr1 and (G) TH protein levels were quantified based on fluorescence 
intensity in TH+ cells. ***p<0.001, ****p<0.0001 n=100 – 200 cells per group from three 
biological replicates across 3 independent experiments. 
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Figure 3.5.3 Treatment with C-DIM12 is neuroprotective against 6-
hydroxydopamine in MN9D and N2A cells. (A) Pseudocolor images of Ca2+ influx pre-
treatment (0 seconds) and upon administration of 25mM, 56mM and 75mM KCl (24 
seconds) in live differentiated MN9D cells. 20X objective, Scale bars=10 μm. (B) Trace 
plots of dose dependent KCl induced Ca2+ influx over time, 8-16 cells from n=3 biological 
replicates. Arrow=KCl administration. (C, E) ½ log dosage of 6-OHDA administered to 
differentiated MN9D and undifferentiated N2A cells for LD50 curve, n=6 biological 
replicates. (D, F) Cell viability of differentiated MN9D and N2A cells treated +/- 6-OHDA 







THE NURR1 LIGAND, 1,1-BIS(3’-INDOLYL)-1-(P-CHLOROPHENYL)METHANE, 







Gene expression necessary for the synthesis and regulation of the dopamine (DA) 
in neurons of the substantia nigra pars compacta (SNpc) is controlled by the orphan 
nuclear receptor related 1 (Nurr1 or NR4A2) protein (Zetterström et al., 1996; Sakurada 
et al., 1999). Nurr1 is highly expressed in the ventral midbrain and is down-regulated in 
Parkinson’s disease (PD) patients(Kadkhodaei et al., 2013; Montarolo et al., 2016). The 
homeostatic function of Nurr1 in DA neurons is mediated by nuclear binding to the nerve 
growth factor binding recognition element (NBRE) as monomers, homodimers or 
heterodimers with the co-activator protein retinoic acid receptor (RXR) (Saijo et al., 2009; 
García-Yagüe et al., 2013). NBRE sequences are recognized in the upstream promoter 
regions of DA genes such as tyrosine hydroxylase (TH), vesicular monoamine transporter 
2 (VMAT2), dopamine transporter (DAT) and aromatic amino acid decarboxylase (AADC) 
(Smits et al., 2003). Thus, Nurr1 activity is crucial for DA neuronal differentiation during 
development to maintenance throughout adulthood(Sakurada et al., 1999; Jankovic et 
al., 2005).  
 Homozygous Nurr1 (-/-) mice do not survive past 1 day postnatal and Nurr1 (+/-) 
mice are more susceptible to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)- 
induced neurotoxicity (Saucedo-Cardenas et al., 1998; Le et al., 1999).  Inhibition of 
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mitochondrial complex 1 by the active metabolite of MPTP, MPP+, causes loss of 
dopamine neurons in the nigro-striatal system and is accompanied by significant glial 
activation and neuroinflammation that is thought to exacerbate neuronal injury (Wu et al., 
2003; Glass et al., 2010; Parillaud et al., 2017). Nurr1 is now recognized as a critical 
regulator of inflammatory gene expression in glial cells, where it acts as a tonic regulator 
of NF-κB-regulated inflammatory genes by stabilizing nuclear co-repressor proteins at 
p65/p50 cis-acting promoter elements, thereby limiting expression of inflammatory genes 
(Saijo et al., 2009).  
Despite the known transcriptional regulatory functions of Nurr1 (NR4A2), an 
endogenous ligand for this receptor is yet to be identified. Therefore, like Nur77 (NR4A1) 
and Nor1 (NR4A3), Nurr1 is classified as an orphan nuclear receptor (Safe et al., 2015). 
However, multiple studies have demonstrated modulation of Nurr1 transcriptional activity 
using synthetic compounds (Ordentlich, 2003; X Li et al., 2012; Smith et al., 2015). Our 
previous studies using several phenyl-substituted diindolylmethane (C-DIM) compounds 
demonstrated that selected analogs are structure-dependent activators of NR4A orphan 
nuclear receptors (Inamoto et al., 2008; Safe et al., 2008). One compound from this series 
with high specific activity toward Nurr1, 1,1-bis(3′-indolyl)-1-(p-chlorophenyl)methane (C-
DIM12) activates Nurr1 and induces antineoplastic effects in cancer cells (X Li et al., 
2012). We also reported that C-DIM12 inhibits expression of NF-κB-regulated genes in 
glial cells and induces a dopaminergic phenotype in neuronal cell lines (De Miranda, 
Popichak, Hammond, Jorgensen, et al., 2015; Hammond et al., 2015). RNAi knockdown 
of Nurr1 in both glia and neurons ablated the effects of C-DIM12 in each cell type, 
demonstrating that in neural cells C-DIM12 acts through a Nurr1. In vivo, C-DIM12 
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displayed favorable pharmacokinetics and neuroprotective efficacy with oral dosing, 
including high bioavailability and distribution to the CNS, as well as protection against 
loss of dopamine neurons in the SNpc in the MPTP/probenecid (MPTPp) model of PD  
(De Miranda et al., 2013; 2014). These studies demonstrating that C-DIM12 inhibits 
neuroinflammatory activation of microglia and astrocytes and protects against loss of 
dopamine neurons. However, it remains to be determined whether lower doses of C-
DIM12 will have similar pharmacodynamic efficacy during concurrent lesioning with 
MPTPp will provide a similar degree of protection against an ongoing neurotoxic insult 
mimicking the complex I deficits in PD. 
Based on the demonstrated neuroprotective and anti-neuroinflammatory effects of 
C-DIM12, we postulated that this Nurr1 activator would protect against loss of 
dopaminergic neurons during lesioning with MPTPp, despite the neurotoxic stress of 
mitochondrial complex 1 inhibition. To test this hypothesis, C57BL/6 mice were dosed 
with MPTPp twice weekly for two weeks and concurrently given C-DIM12 (25 mg/Kg daily, 
p.o.) once daily throughout the treatment period. Neurobehavioral analysis was 
conducted during the study to detect motor deficits consistent with deprecations in nigro-
striatal dopamine. Brain tissue (SN and ST) was collected to determine pharmacokinetic 
parameters of C-DIM12 at this dose, as well as stereological determination of dopamine 
neuron numbers, glial activation and qPCR array measurement of gene expression for 
inflammatory and cell death pathways. In addition, we conducted transactivation reporter 
studies in neural cell lines, as well as in silico modeling to identify putative binding sites 
for C-DIM12 within the ligand binding domain of human Nurr1. These findings 
demonstrate that C-DIM12 is an activating ligand of Nurr1 that induces an anti-
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inflammatory phenotype in glial cells and preserves dopaminergic soma even during 
concurrent lesioning with MPTPp.  
4.2 MATERIALS AND METHODS 
Chemicals and Reagents  
C-DIM12 was synthesized and obtained by Dr. Stephen Safe’s laboratory at Texas A&M. 
Working concentrations of C-DIM12 were diluted in corn oil and sonicated in hot water 
bath until solubilized. MPTP (Sigma, St. Louis MO) was solubilized at final working 
concentration in saline (0.9% NaCl2). Probenecid (Sigma, St. Louis MO) was prepared in 
5% sodium bicarbonate/MilliQ water to final working concentration (pH 7.5). All additional 
reagents were obtained by Sigma Aldrich (St. Louis MO), unless stated otherwise.  
Animals and Treatment Regimen 
Inbred C57/Bl6 male mice (~24 weeks of age; 25-30 grams in weight) were acquired by 
Charles River Laboratories (Wilmington, MA) and housed on 12-hour light/dark cycles in 
a temperature-controlled room (maintained at 22-24°C) with access to standard chow and 
water ad libitum. Mice were administered C-DIM12 (25mg/kg) or corn oil (vehicle control) 
by oral gavage. Mice were dosed with MPTPp twice weekly for two weeks, with each dose 
delivered 2 days apart. On the day of dosing, probenecid was delivered in the morning 
by intraperitoneal injection (100 mg/kg) and then MPTP (20 mg/kg) or saline (0.9%NaCl) 
was administered 4 hrs later by subcutaneous injection, per our previously published 
protocol (De Miranda et al. 2014). C-DIM12 or corn oil was administered daily by 
intragastric gavage (14 doses total) throughout the treatment period. At the conclusion of 
the study, mice were anesthetized under deep isoflurane anesthesia and transcardially 
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perfused with 0.1M phosphate buffered saline (PBS)-cacodylate/heparin (10 U/mL) and 
3% paraformaldehyde/PBS. Post perfusion, brains 
were dissected and stored in paraformaldehyde at 4 °C overnight, and then stored in 
sodium-cacodlyate-PBS (pH 7.2) containing 15-30% sucrose at 4°C until processed for 
cryo-sectioning.  For neurochemical sample collection, animals were also administered 
deep isoflurane before rapid removal of striatum and ventral midbrain for flash freezing in 
liquid nitrogen. Brain samples were then transferred to -80°C storage until processed for 
RNA, protein and HPLC analysis. 
Real-time video gait analysis and open field behavioral testing. Changes in gait were 
determined by analysis of unrestricted movement along a fixed trackway using a video-
based system constructed in our laboratory. Briefly, mice were allowed to walk along a 2 
m long glass trackway with fixed sides and top that was illuminated with green LED lights 
such that paw placement results in total internal reflection of light downward toward a high 
speed video camera for digital recording. Animals were backlit from above with low power 
red LED lights to distinguish the silhouetted form of the mouse (black) from paw prints 
(green) for digital analysis. Incentive to traverse the trackway was provided by placement 
of the animal’s home cage at the end of the trackway, thereby permitting reliable detection 
of unrestricted gait and motion. Mice were habituated to the trackway once daily for two 
days prior to the onset of the treatment period and a baseline of gait was recorded on the 
first day of the study prior to dosing with MPTPp. Video recording of mouse gait was 
filmed using a GoPro Hero3+ camera at 60 fps, 1080 dpi (GoPro; San Mateo, California) 
and analysis code was written in Matlab (Mathworks; Natick, MA) in conjunction with the 
Department of Electrical and Computer Engineering at Colorado State University.Open 
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field activity parameters were acquired with Versamax System (Omnitech Electronics, 
Inc; Columbus Ohio). Mice were allowed to acclimate to OFT behavioral chambers for 
two days prior to study for measurement of x-, y- and z-planes of activity for a monitoring 
period of 5 minutes under white noise and ambient light. OFT activity was then monitored 
for animals on day 0, 7, and 14 of study. Parameters were analyzed utilizing Fusion 
(Omnitech Electronics, Inc; Columbus Ohio) software for detection of total margin and 
center time activity. All Values were normalized for the difference from day 0 baseline. 
Three-dimensional design-based stereology of neuronal cell bodies and 
assessment of striatal terminal density. Stereological determination for the number of 
neurons in the substantia nigra pars compacta was performed using a 3D design-based 
stereology method as we previously reported (De Miranda et al., 2014). The entire SNpc 
was serially sectioned from rostral to caudal, which was demarcated by the subthalamic 
nucleus to the retrorubal field, respectively.  Every fifth free-floating section (10 total) was 
selected from each animal and immunostained with antibodies against tyrosine 
hydroxylase (TH; Abcam) and MAP2 (Abcam). Stereological counting of both cell markers 
was performed using Slidebook software (version 5.0, Intelligent Imaging Innovations, 
Denver CO). The SNpc boundary was marked on a 10x-objective montage image of 
entire section. Optical fractionator method was employed with randomized 40x-objective 
z-stack image sampling setup frame size (100 X 100μm), frame spacing (200 X 200 μm), 
dissector height (30 μm), and upper guard distance (2 μm). Each z-stack image was 
blindly quantitated for TH+ and MAP2+ cells to calculate a total estimate of neuronal cell 
bodies within the SNpc of each animal. For measurement of TH+ striatal terminals, two 
striatum sections/per animal with similar anatomical landmarks were selected and 
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immunostained for TH. 10x-objective montage images were generated for a masked 
outline of the caudate putamen. Each masked region was normalized for background 
subtraction and quantified for mean intensity fluorescence of TH. 
Immunofluorescence staining  
All brain tissue processed for IF was frozen with OCT on microtome stage and 
sectioned/collected for ST (25 μm in thickness) and SN (40 μm in thickness) regions. 
Tissue sections were stored in cryoprotectant (30% sucrose, 30% ethylene glycol, 0.5M 
phosphate buffer; pH 7.2) at 20°C until selected for immunostaining. IF staining was 
conducted as previously described by Miller et al. 2011, and all antibody dilutions were 
1:500, unless stated otherwise (Miller et al., 2011). For stereology, SN sections were 
immunostained with anti-tyrosine hydroxylase (Millipore AB152) and anti-MAP2 (Abcam 
AB5392). For gliosis, SN and ST sections were immunostained with either anti-IBA1 
(1:250; Wako 016-20001) or anti-GFAP (Dako Z0334) and anti-tyrosine hydroxylase 
(Abcam AB76442). SN tissue was also immunostained with anti-TH and anti-Nurr1 
(1:200; Santa Cruz SC991) for mean intensity measurements of Nurr1. All secondary 
antibodies used for IF were alexa flour 488, 555, and 647 (LifeTech, Carlsbad CA).  
Measurement of Gliosis and Immunofluorescence Imaging 
Quantitation of IBA-1+ and GFAP+ cells bodies was conducted on two sections of the 
SNpc and ST regions/per animal. Optical fractionator method employed was adjusted 
with counting frame size (150 X 150 μm) and frame spacing (for SN; 250 X 250 μm, for 
ST; 550 X 550 μm). Blind quantitation of cell bodies for relative number of glial cells per 
region was conducted on 40x z-stack images of IBA+ cells from the SNpc. Same IBA1+ 
cell images were also converted to a max projection, following a binary transformation 
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and then rendered to a skeletonized image in ImageJ, as previously described in Morrison 
and Filosa et al. 2013(Schneider et al., 2012; Morrison and Filosa, 2013). Images for 
quantitative measurements were all acquired with a Zeiss Axiovert 200M inverted 
fluorescent microscope equipped and a Hammatsu ORCA-ER-cooled charge coupled 
device camera using a 10x and 40x air objective (Hammatsu Pho-tonics, Hammatsu City, 
Japan).  High magnification representative images were generated with a Plan-
Apochromat 100X oil objective lens. High magnification images of three-dimensional 
IBA1+ cells were acquired with a 63X objective lens on a Zeiss LSM 510 laser-scanning 
confocal microscope, using Zen software (Oberkochen, Germany). Z-stack images of 
microglia were surfaced rendered in Imaris software (Bitplane; Zurich, Switzerland) for 
voxel view of morphology. Low magnification montage images of tissue sections were 
acquired with an air 10x-objective lens using a Hammatsu ORCA-Flash4.0 digital CMOS 
camera, ProScan III stage controller (Prior, Rockland, MA USA) and CellSens Dimension 
software (version 1.12, Olympus, Center Valley, PA, USA).  
Western blotting. 
Striatal tissue was homogenized and lysed in RIPA buffer with protease inhibitor for 
western blot analysis. Protein concentration was determined using a BCA protein assay 
kit (ThermoScientific, Pierce Rockford, Il). 30 µg of protein was loaded into a 
polyacrylamide 12% separating and 4% stacking gel. Anti-DAT (1:500; Millipore 
Ab1591P), anti-VMAT2 (1:750; gift from Dr. Gary Miller’s Laboratory, Emory University), 
anti-TH (1:1000; AB152), anti-Nurr1 (1:100; SC991), anti-GFAP (1:1000; Z0334) and anti-
Beta Actin (1:2000; Sigma A1978) were diluted in 5% milk/tris-buffered saline with tween 
(0.1%) blocking buffer. All western blots were imaged on a BioRad ChemiDoc MP imaging 
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system and raw TIFF files were analyzed for mean optical band density with ImageJ 
analysis software (Schneider et al., 2012).  
Pharmacokinetic Analysis of C-DIM12 and Determination of Catecholamine 
Content  
For PK analysis of C-DIM12, male C57/Bl6 mice (27-30g) were administered C-DIM12 
(25 mg/kg) dissolved in corn oil by intragastric gavage. Post administration, mice were 
euthanized at 0, 0.5, 1, 2, 4, 8, and 24 hours (N=4/per time point) by decapitation under 
isofluorane anesthesia. Midbrain tissue samples were rapidly dissected using a 1 mm 
brain block. Plasma samples were collected from trunk blood and centrifuged at 1,500 
rpm for 5 minutes. Frozen brain and plasma samples were then processed for liquid 
chromatography mass spectrometry (LC-MS) by the Pharmacology Core at Colorado 
State University as reported in previous studies from our group (De Miranda et al., 2013). 
Striatal samples from each experimental group were measured for dopamine and DOPAC 
by high performance liquid chromatography (HPLC) coupled with electrochemical 
detection. The Neurochemistry Core Laboratory at Vanderbilt University’s Center for 
Molecular Neuroscience Research group (Nashville, TN) processed all tissue samples 
from each experimental group with coded labeling for unbiased analysis. 
Computational Modeling 
Small molecule docking studies were conducted using Accelrys Discovery Studio 4.5 
(Accelrys Inc., San Diego, CA) and the crystal structure coordinates for the human Nurr1 
(NR4A2) ligand binding domain (PDB ID: 1OVL) (Wang, et al 2003, Nature 423: 555-560) 
were downloaded from the protein data bank (http://www.rcsb.org/pdb). The protein was 
prepared and subjected to energy minimization utilizing the conjugate gradient 
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minimization protocol with a CHARMm forcefield (Brooks et al., 2009) and the 
Generalized Born implicit solvent model with simple switching (GBSW) (Feig et al., 2004) 
that converged to an RMS gradient of < 0.01 kcal/mol. The Flexible Docking protocol 
(Koska et al., 2008), which allows flexibility in both the protein and the ligand during the 
docking calculations, was used to predict the binding of C-DIM12 in the regions of both 
the coactivator and ligand binding pockets of NR4A2. Predicted binding poses were 
energy minimized in situ using the CDOCKER protocol (G Wu et al., 2003) prior to final 
ranking of docked poses via consensus scoring combining the Jain (Jain et al. 1996), 
PLP2 (Parill et al. 1999), and Ludi3 (Böhm et al. 1994) scoring functions. Predicted 
binding energies were calculated using the distance-dependent dielectric model. 
Transfections and luciferase assays 
 
Neuron-like, PC12 cells were plated on 12-well plates at 2.5×105 per well in DMEM/F12 
supplemented with 2.5% charcoal-stripped FBS and were allowed to attach and settle for 
overnight. Luciferase plasmids (UASx5-Luc, NBREx3-Luc and NurREx3-Luc) and 
corresponding expression plasmids (GAL4-NR4A2 or FLAG-NR4A2) were co-transfected 
in cells at 10:1 ratio, i.e., 1000 ng Luc and 100 ng NR4A2 per well. Lipofectamine 2000 
reagent was used for transfection according to the manufacturer’s protocol and all 
plasmids have previously been described (Li et al, 2012). After 6 hr of transfection, cells 
were treated with medium (as above) containing either solvent (DMSO) or the indicated 
concentration of C-DIM12 for 18 hr. Cells were then lysed using a freeze-thaw protocol 
and cell extracts were used for luciferase assays. Luciferase activity values were 
normalized against corresponding protein concentrations determined in a Bradford assay. 
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Luciferase assays were run in triplicate for each determination and results are expressed 
as mean ± SD. 
RNA isolation and RT-qPCR array analysis 
Midbrain tissue samples from each experimental group were homogenized and lysed 
using Qiashredder columns along with on-column and in solution DNase treatment 
(Qiagen; Hilden, Germany). Samples were purified for RNA using an RNeasy kit, eluted 
with RNase-free water and concentrations were determined using a Nanodrop One 
spectrophotometer (ThermoScientifc; Waltham, MA). mRNA was reverse transcribed to 
cDNA with iScript (Biorad, Hercules, CA) reverse transcriptase enzyme for a total of 250 
ng and qPCR reactions were prepared in SYBRgreen mastermix (BioRad; Hercues, CA). 
Samples from each experimental group were amplified using RT2 profiler PCR arrays 
(Qiagen; Hilden, Germany) for NF-κB signaling pathway target genes (PAMM-025ZG-4) 
and Parkinson’s disease associated genes (Cat#: PAMM-124ZG-4) for a total analysis of 
168 genes. Both sets of 384-well pathway array plates were run according the 
manufacturer’s protocol on a Lightcycler 480 real time PCR instrument (Roche; Branford, 
CT, USA). Gene expression fold change was analyzed using the SAbiosciences software. 
Statistical Analysis 
Data was presented as the mean +/- SEM, unless noted otherwise. All experimental 
values from each mean were analyzed with a Grubb’s (α=0.05) test for exclusion of 
significant outliers. Differences between three experimental groups were analyzed with a 
one-way ANOVA followed by a Tukey post hoc multiple comparisons test. Two group 
comparisons for densitometry analysis was conducted with an unpaired student’s t-test 
followed by Welch’s correction. A two-way ANOVA was performed when incorporating 
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‘day’ as an experimental variable for behavioral tests.  Significance was identified as ++P 
< 0.01, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. All statistical analyses were 
conducted using Prism (version 6.0; Graph Pad Software, San Diego, CA). 
4.3 RESULTS 
C-DIM12 is highly concentrated in brain tissue 
We previously conducted neuroprotection studies with several C-DIM compounds 
known to activate NR4A1 or NR4A2, using daily oral dosing at 50 mg/kg (De Miranda et 
al. 2014). To determine whether a lower dose would have similar neuroprotective efficacy, 
we first performed a pharmacokinetic study with C-DIM12 (chemical structure in Fig 1A) 
at 25 mg/kg by administering this dose per oral and sampling plasma and brain 
concentrations at 0, 0.5, 1, 2, 4, 8 and 24 hrs.  Plasma and midbrain samples were 
analyzed by LC-MS analysis per our previously published methods (De Miranda 2013 et 
al.). As shown in Figure 1A-C, C-DIM12 reached a maximum concentration (Cmax) at 4 
hrs of 1120.0+/-404.7 ng/ml and 3622.5+/-1430.8ng/g in plasma and brain, respectively. 
The half-life was 249±23 min in plasma and 264±17 min in brain, approximately 15 
minutes longer in brain tissue compared to plasma (Fig.1C). Timing for Cmax and total 
drug clearance is consistent with the previous dosage of 10mg/kg (Fig 1A-B) (N=4 
animals/per time point). 
Daily Administration of C-DIM12 protects against loss of dopaminergic neurons 
during con-current neurotoxic challenge with MPTP/probenecid. 
Brain tissue was collected after 14 days of concurrent dosing with MPTPp and the 
presence or absence of C-DIM12 (25 mg/Kg), as depicted in dosing schematic in Figure 
2A. Immunofluorescence images were generated for number of TH+ cell bodies (red) in 
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the SNpc on tissue from Saline + corn oil (C.O.) (Fig. 2B), MPTPp + C.O. (Fig. 2F), and 
MPTPp + C-DIM12 (Fig. 2J) experimental groups, as depicted in representative images. 
The total number of neurons was determined by staining with the general neuronal 
marker, mitogen-associated protein, MAP2 (green) (Figure 2C, G, K). Based on unbiased 
3D-design based stereological quantitation of the number of TH+ neurons in the SNpc, 
mice treated with MPTPp+C.O. had a 63.75±4.27% loss of TH+ neurons, whereas mice 
treated with MPTPp+C-DIM12 had only a 35.28±8.46% loss of TH+ neurons (Fig. 2N). 
Similarly, loss of MAP2+ cells was 48.00±4.74% in the MPTP+C.O. treatment group, in 
contrast to only 25.50±7.92% loss of total neurons in mice lesioned with MPTPp in the 
presence of C-DIM12 compared to control (Fig 2O) (*P<0.05, **P<0.01,****P <0.0001; 
N=10 animals/group). TH+ fiber innervations of the striatum were also immunostained as 
depicted in representative images of Salinep+C.O. (Fig 2E), MPTPp+C.O.(Fig 2I) and 
MPTPp+C-DIM12 (Fig 2M). Density of TH+ fibers was measured by mean pixel intensity 
of the caudate putamen region and compared back to saline control (set at 100%). Mice 
treated with MPTPp+C.O. had 81.05±1.05% loss of TH+ terminals in the ST compared to 
only a 62.92±6.40% loss of TH+ fibers in mice treated with MPTPp+C-DIM12 (Fig 2P) (*P 
< 0.05; n=12 animals/per group). Thus, treatment with C-DIM12 reduced loss of TH+ 
fibers in the ST but did not completely protect against MPTPp-induced damage to 
innervating dopaminergic fibers projecting from the SNpc. 
Assessment of neurobehavioral deficits associated with PD and neurochemical 
analysis of the nigrostriatal system. 
Neurobehavioral function was assessed by open-field activity testing (OFT) on 
days 0, 7 and 14 during the 2-week study. Mice treated with MPTP+C.O. spent 
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significantly less time in the center of the chamber (dotted line represents baseline 
subtracted from Day 0) compared to controls, whereas the MPTP+C-DIM12 treatment 
group was not significantly different from control or the MPTPp+C.O. group at day 14 
(Fig. 3A). Quantitation of time spent along the margins of the chamber (a measure of 
anxiety) indicated that MPTP+C.O. treated mice spent significantly more time in the 
margin compared to saline controls. Mice treated with MPTPp+C-DIM12 were not 
significantly different from controls or the MPTPp+C.O. group at day 14 (Fig. 3B) (*P < 
0.05; N=19-25 animals/per group). Individual time traces and pseudocolored heat maps 
of activity across area over time (red=most time, blue=least time) plots from day 14 of 
OFT in each treatment group are represented in Figure 3C, demonstrating the trend 
toward decreased center time and increased margin time in MPTPp-treated mice that 
was prevented by concurrent treatment with C-DIM12. To assess locomotor function, we 
utilized a real-time video analysis system to determine stride length along a fixed track to 
measure alterations in gait related to changes in striatal dopamine. Representative 
images of illuminated paw print coordinates generated from video analysis are depicted 
in Fig. 3D. The overall rate of movement along the trackway was analyzed independently 
for left front (LF), right front (RF), left rear (LR) and right rear (RR) paws to identify 
changes in gait for each treatment group (Fig. 3E). An increased number of stop times 
and a correspondingly slower overall traverse rate along the trackway was noted in mice 
treated with MPTPp+C.O., which was largely restored to control levels at day 7 in mice 
treated with MPTPp+C-DIM12. Hind limb stride length analysis at day 7 also indicated a 
significantly shorter stride in the MPTPp+C.O. group and longer stride length in 
MPTPp+C-DIM12 group (*P < 0.05, **P < 0.01; N=6-12/animals/per group) (Fig 3F).  
 75 
MPTPp+C.O. vs. MPTPp+C-DIM12 groups were not significantly different at day 14 and 
the stride length of Salinep + C.O. treated animals was decreased, potentially due to 
either stress or habituation to the trackway by the conclusion of the treatment period. 
High-performance liquid chromatography (HPLC) was performed on ST tissue for 
measurement of dopamine (DA) neurotransmitter content and its metabolite, 3,4-
dihydroxyphenylacetic acid (DOPAC).  Significantly less DOPAC and DA were detected 
in MPTP+C.O. and MPTP+C-DIM12 compared to saline control (Fig 3G-H). Mice treated 
with MPTPp+C-DIM12 showed a trend towards protection against loss of DOPAC and 
DA compared to the MPTPp+C.O. group, but this was not statistically significant. The 
DOPAC/DA ratio was also higher in MPTPp+C.O. compared to control mice and the 
MPTPp+C-DIM12 group showed an intermediate effect that was not different from either 
control or the MPTPp+C.O. group (**P < 0.01, ***P < 0.001; N=9-10 animals/per group) 
(Fig 3I).  Proteins associated with the production and release of DA in ST tissue was also 
measured by western blot. Levels of TH were significantly depleted in both MPTPp+C.O. 
and MPTPp+C-DIM12 compared to saline control (set at 100%) but C-DIM12 treatment 
mitigated loss of TH compared to MPTP-only group (Fig 3J). Correspondingly, the 
amount of vesicular monoamine transporter 2 (VMAT2; P=0.1125), (Fig 3K) and 
dopamine transporter (DAT; *P < 0.05) (Fig 3L) were depleted in MPTPp+C.O. groups 
and higher in C-DIM12 treated animals (N=6-8 animals/per group).  
C-DIM12 suppresses microglial activation and preserves a ramified morphological 
phenotype in the substantia nigra. 
The relative number of microglia in the SN and ST were determined by 
immunostaining for ionized binding adaptor molecule (IBA-1; green), with counterstaining 
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for TH (red) to demarcate each region, as depicted in the representative images in Fig 
4A-C. An increased number of activated microglia compared to control was evident in 
MPTPp-treated SNpc tissue (Fig 4B-C). To quantitate these observations, stereological 
assessment of IBA-1+ cells was performed on SNpc and ST. In the SNpc, an increased 
number of IBA-1+ cells were counted in both MPTP-receiving mice, characterized by 
intense staining for IBA-1 and a change in morphology from a ramified phenotype to a 
more amoeboid shape. C-DIM12 treatment significantly suppressed the number of IBA+1 
cells in the SNpc compared to MPTP+C.O., however, in the ST the number of IBA-1+ was 
not significantly lower than in the MPTPp+C.O. group but also not significantly different 
from the control group (P=0.1162 for MPTPp + C.O. vs. MPTPp + C-DIM12, **P < 0.01, 
****P < 0.0001, N=10 animals/per group for SN and N=12 animals/group for ST) (Fig 4D, 
E). For analysis of a microglia morphological phenotype within the SNpc, the same 40X 
images used for IBA-1 counts were also rendered for skeletonization as depicted in the 
representative images in Fig 4F. Skeletonized images were quantitated for the number 
of branches/cell (Fig 4G), junction voxels/cell (Fig 4H), endpoint voxels/cell (Fig 4I) and 
average branch length/cell (Fig 4J). C-DIM12 increased the number and complexity of 
each morphological parameter, except average branch length/cell, which showed only a 
trend toward increase relative to the MPTPp-treated group (++P < 0.1), whereas all other 
parameters in the MPTPp+C-DIM12 group were increased comparably to the control 
group (**P < 0.01,***P < 0.001 ****P < 0.0001, respectively; N=6 animals/per group).The 
morphology of IBA-1+ cells within the SNpc was also characterized by high-resolution 
confocal microscopy to visualize three-dimensional morphology (Fig 4K, Supplemental 
Videos 1-3). Multiple optical z-planes were acquired and rendered in 3D using Imaris 
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Bitplane software to produce volumetric surface renderings of microglia from each 
treatment group. Microglia in the SNpc of MPTPp-treated mice displayed a loss of 
ramified cytoplasmic processes and a generally amoeboid shape, whereas mice treated 
with MPTPp+C-DIM12 had a cellular morphology more consistent with microglia from the 
control group. Amoeoboid-shaped microglia were also seen phagocytosing TH+ neurons 
in the SNpc in the MPTPp+C.O. group (see Supplemental Video 4).  
C-DIM12 suppresses astrocyte activation during progressive DA neuronal loss. 
Relative activation of astrocytes following MPTPp treatment was measured by 
quantitation of the intermediate filament, glial fibrillary acidic protein (GFAP), in cells in 
the SN and ST. Total levels of GFAP protein levels in the striatum were also analyzed by 
western immunoblotting. SN tissue was immunostained for GFAP (red) and TH (green) 
to delineate the pars compacta region for stereological counts, as depicted in high and 
low magnification representative images (Fig 5A-C).  A basal level of GFAP+ expressing 
cells within the substantia nigra pars reticulata (SNr) was evident in saline control animals 
(Fig 5A) and astrocyte proliferation noticeably increased within the SNpc upon treatment 
with MPTPp (Fig 5B). Based on stereological counts of GFAP+ expressing cell bodies, 
MPTPp+C.O. treated animals exhibited significantly more astrocytes within the SNpc 
compared to saline control. Mice that received MPTPp + C-DIM12 had significantly fewer 
GFAP+ cells within the SNpc compared to MPTP-only treated animals (Fig 5C,D). 
Similarly, C-DIM12 suppressed the number of GFAP+ cells within the ST comparable to 
saline control levels (N=9 animals/per group for SN, N=6 animals/per group for ST; *P < 
0.05, **P < 0.01, ****P < 0.0001) (Fig 5E). GFAP expression levels within the ST were 
also confirmed by western blot analysis, as depicted in Figure 4F. Based on optical 
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density measurements of GFAP protein, compared to control (saline set at 100%), C-
DIM12 significantly decreased total levels of striatal GFAP (*P < 0.05; N=4 animals/per 
group) (Fig 4G). 
C-DIM12 reverses MPTP-induced changes in gene expression related to PD and 
NF-κB signaling. 
To analyze patterns of gene expression in each experimental group, we isolated 
mRNA from midbrain tissue for real-time RT-PCR analysis of 168 genes in PD-associated 
and NF-κB-regulated gene arrays. Heat maps for PD-associated (Fig 6A) and NF-κB (Fig 
6B) gene arrays depict ontology dendrograms indicating that transcript expression in the 
MPTPp+C-DIM12 group clustered with the saline (control) group, whereas mRNA levels 
in the MPTPp+C.O. segregated independently, based on clustergram analysis.  Volcano 
plots for NF-κB regulated (Fig 6C,D) and PD-associated genes (Fig 6E,F) identified a 
number of genes upregulated in the MPTPp+C.O. group relative to control (Fig 6 C,D) 
that were downregulated in the MPTPp+C-DIM12 group (Fig 6D,F). Several unique 
transcripts identified in volcano plots that were significantly altered by MPTPp but not 
different from controls in the MPTPp+C-DIM12 group included the plasma membrane 
Ca2+ transporting atpase (Atp2b2) (Fig 6G), cell death regulator B cell 
leukemia/lymphoma 2 related protein Bcl2a1a (Fig 6H),  motif chemokine ligand Ccl5 
(RANTES) (Fig 6I), hypoxia-inducible factor prolyl hydroxylase 2 (Egln10) (Fig 6J), neural 
plasticity transcription factor early growth factor 1 (Egr1) (Fig 6K), synaptotagmin 1 (Syt1) 
(Fig 6L), tumor necrosis factor (ligand) superfamily, member 10 (Tnfs10) (Fig 6M) and 
TNF receptor associated factor 6 (Traf6) (Fig 6N) (*P < 0.05, **P < 0.01; N=4 animals/per 
group).   
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C-DIM12 maintains nuclear Nurr1 localization in DA neurons and prevents MPTPp-
induced Nurr1 protein expression changes in SNpc and ST. 
To visualize the subcellular localization of NR4A2/Nurr1 shuttling in DA neurons 
after treatment with MPTPp, we immunostained SNpc tissue for TH (green) and Nurr1 
(red) protein expression, as depicted in the representative high-magnification images in 
Figure 7A (white arrows depict subcellular localization). Nuclear Nurr1 in TH+ neurons 
was quantified for mean fluorescence intensity and indicated higher levels of nuclear 
Nurr1 in in DA neurons within the SNpc in mice treated with MPTPp+C-DIM12 compared 
to DA neurons in mice treated with MPTPp+C.O. (*P < 0.05, ****P < 0.0001; N=3 
animals/per group) (Fig 7B). qPCR analysis of mRNA isolated from SN tissue also 
demonstrates a trend for increased expression of Nurr1 mRNA following C-DIM12 
treatment (Fig 7C, P < 0.1081 compared to MPTPp +C.O.; N=4 animals/per group). 
mRNA expression data for the NR4A family member, Nur77 (NR4A1) display a 
2.67±0.79-fold induction with C-DIM12 (P=0.1154 compared to MPTPp + C.O.; N=4 
animals/per group) (Fig 7D). Additionally, total Nurr1 protein from ST tissue was analyzed 
by western blot and demonstrates a 39.5±4.6%depletion of Nurr1 with MPTP+C.O. that 
was prevented by treatment with C-DIM12 to 77.2±14.40% compared to control levels 
(Fig 7E-F). 
C-DIM12 activates Nurr1-dependent transactivation and modeling interactions of 
C-DIM12 with Nurr1.  
C-DIM12 also induced NR4A2-dependent transactivation in PC12 cells transfected 
with a GAL4-NR4A2 chimera (full length human NR4A2 fused to the yeast GAL4 DNA-
binding domain) and a luciferase reporter gene construct containing five GAL4 response 
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elements (UAS-Luc) (Fig 8A). In addition, PC12 cells were transfected with NBRE-Luc 
and NurRE-Luc constructs containing binding sites for NR4A2 monomer and homodimer, 
respectively (Li et al, 2012) (Fig 8B-C). C-DIM12 activated transactivation in PC12 cells 
in all three assay systems with the highest responses observed for the GAL4-
NR4A2/UAS-Luc assay (Fig 8A). To examine the potential for direct binding of C-DIM12 
to Nurr1, we performed computational-based small molecule docking studies to predict 
its possible binding orientation in either the coactivator binding site or the ligand-binding 
site. The modeling results in Figure 8D-F indicated that C-DIM12 was predicted to bind 
with high affinity to the co-activator binding site (binding energy: -73.3 kcal/mol), with the 
chlorobenzene ring buried into the hydrophobic region of the pocket, which includes 
Mse414, Ile587, and Leu591 and the indole moieties participating in hydrogen bond 
interactions with Glu415, pi-anion and pi-sigma interactions with Glu440, and pi-cation 
interactions with Arg418. The only substantive predicted interaction at the ligand binding 
site involved a pi-cation interaction between one of the indole moieties and Arg515 
(binding energy: -12.2Kcal/mol), with the balance consisting of comparatively weak 
hydrophobic interactions with Arg563, Cys563, and Leu570 (Fig 8G-I). 
4.4 DISCUSSION AND CONCLUSIONS 
Efficacy of small molecule therapeutics for neurodegenerative disease is 
dependent on the capacity to penetrate the blood brain barrier. We have previously 
demonstrated that selected C-DIM compounds have excellent structure-dependent 
bioavailability, with C-DIM12 having the greatest area under the curve (AUC) in brain 
compared to other p-phenyl substituted analogs when administered orally 50 mg/Kg daily 
(De Miranda et al., 2013). To assess brain/plasma distribution at the lower dose of 25 
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mg/kg used in the current study, we administered C-DIM12 to mice orally over a 24 hr 
period and observed ~3.5 times greater Cmax at 4 hours compared to our previous 
pharmacokinetic study that examined plasma and brain distribution at 10 mg/kg. At 25 
mg/Kg p.o., the AUC in brain was ~4.2 times higher in brain than in plasma, representing 
a brain:plasma AUC ratio indicative of highly favorable penetrance of the CNS, as 
indicated by the data in Figure 1. This dose-dependent increase in brain levels of C-
DIM12 confirms the utility of this analog for reaching the molecular target in brain as a 
pharmacological modulator of neuroinflammation.   
At the time of diagnosis, an individual with PD has already lost approximately 60% 
of dopaminergic neurons in the SNpc and 70% of striatal dopamine (Marsden, 1982; O 
Cooper et al., 2009). The subacute MPTPp mouse model used in this study conferred 
similar lesioning with approximately 63% loss of SNpc TH+ neurons, 52% loss of SNpc 
MAP2+ neurons and an 81% loss of DA terminals in the ST (Fig 2M-O). Based on 
stereological analysis of neuronal numbers after two weeks of exposure to MPTPp, 
concurrent treatment with C-DIM12 ameliorated neuronal loss to only 35% and 63% for 
DA cell bodies and terminals, respectively, compared to controls. However, C-DIM12 
provided less protection against loss of striatal DA, which is consistent with the use of 
MPTP as a potent toxicant damaging neuronal mitochondria in nerve terminals in 
projecting dopaminergic fibers in the striatum (Giovanni et al., 1994). The protective effect 
of C-DIM12 was consistently observed in MAP2+ neurons in the SNpc in addition to TH+ 
cells, demonstrating that neuroprotection was not confined to dopaminergic neurons only, 
but rather a general protective mechanism consistent with the anti-inflammatory activity 
of C-DIM12. 
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Subacute administration of MPTPp in C57/BL6 mice causes cognitive and 
locomotor dysfunction resembling that seen in PD (Goldberg et al., 2011; XH Wang et al., 
2012; De Miranda et al., 2014) Generally, anxiety-like, thigmotaxis behavior of mice is 
accompanied with reduced exploratory and spontaneous activity (Simon et al., 1994; 
George et al., 2008),  consistent with the trends we observed in open field activity assays 
(Fig 3A-C).  We also noted decreased hind limb stride length in MPTPp-treated mice that 
was prevented by co-treatment with C-DIM12 (Fig 4D,F), indicating protection against 
deprecations in striatal dopamine. However, this effect was not detected at day 14 (Fig 
D-F), possibly due to the characteristically severe loss of DA within the nigrostriatal 
system caused by MPTPp treatment that was partially prevented by C-DIM12 (Fig 3G-I). 
Yet, C-DIM12 preserved protein expression of TH within the striatum, as well as the 
synaptic and vesicular DA transporters, DAT and VMAT2 (P = 0.1125), respectively (Fig 
3J-L). The transporter proteins were induced at higher levels upon C-DIM12 treatment 
compared to TH, suggesting an imbalance of DA transport within the ST or due to 
vulnerability of TH to MPP+ induced oxidation. 
Animal studies suggest that microglial activation could be an etiologic factor in 
pathogenesis as well as a sequela of neurodegeneration due to MPTP exposure (PL 
McGeer and EG McGeer, 2008; Ramsey and Tansey, 2014). Regardless, microglial 
activation exacerbates DA neuronal loss, suggesting that suppressing inflammatory 
activation of microglia could be a viable therapeutic strategy for slowing the progression 
PD. Previous studies with the Nurr1 agonist, SA00025, showed that suppression of 
microglia activation and neuroinflammatory cytokine production was neuroprotective in 
the 6-hydroxydopamine (6-OHDA) rat model of PD (Smith et al., 2015). Similarly, we 
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demonstrated that C-DIM12 blocked neuroinflammatory gene expression in LPS-treated 
BV-2 microglial cells (De Miranda et al., 2014) and suppressed the relative number of 
IBA-1+ cells in the SNpc and ST following treatment with MPTPp in vivo (De Miranda et 
al. 2014). In the current study, microglial numbers were significantly reduced within the 
SNpc by concurrent treatment with C-DIM12, but only slightly in the ST (Fig 4A-E). 
Microglia within the SNpc were further examined to discriminate ramified, resting 
morphology from an amoeboid, activated-like cell type using three-dimensional IBA+ 
morphometric analysis (Fig 4F-K, Supplemental Videos 1-3). Based on the 
morphometry of skeletonized images, MPTPp+C.O. treatment reduced ramification and 
increased the number of phagocytic microglia surrounding dopamine neurons (Fig. 4K 
and Supplementary Video 4). C-DIM12 preserved a ramified morphology in SNpc 
microglia (Fig. 4G-K), indicating that inhibition of inflammatory activation directly 
correlated with preservation of dopaminergic soma. 
Increased astrocyte proliferation and hypertrophy surrounding DA neurons occurs 
at approximately 3-4 days after MPTP exposure in mice (Breidert et al., 2002; Hirsch and 
S Hunot, 2010). Although a certain level of astrogliosis may be neurotropic (Liddelow et 
al., 2017), severe activation leads to neuronal death(Carbone et al., 2008; Liddelow et 
al., 2017)In astrocyte cultures, by neurotoxin-induced nitric oxide synthetase (NOS2), C-
DIM compounds are potently anti-inflammatory and neuroprotective (Tjalkens et al., 2008; 
Carbone et al., 2008). Based on the gliosis quantitation of GFAP+ cells in both the SNpc 
and ST, concurrent C-DIM12 treatment suppressed gliosis in both regions (Fig 5A-E). 
Interestingly, there was greater reduction of striatal GFAP+ astrocytes than striatal IBA-1+ 
microglia (Fig 5E-G, 4E). This cell specific effect of C-DIM12 could be due to an 
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established deficit of striatal IBA-1+ cells by the end of MPTPp treatment regimen, or 
astrocyte activation persists as a  more chronically activated state in PD animal models 
(Hirsch and SP Hunot, 2009). Overall, C-DIM12 appears to modulate both glial cell types 
in MPTPp-induced models, suggesting C-DIM12’s regulatory role of inflammatory gene 
expression to be a promising neuroprotective mechanism. 
Neuroinflammatory gene expression mediated by NF-κB is up-regulated in PD 
post-mortem brain tissue (Hirsch and SP Hunot, 2009)). It is also essential for glial 
crosstalk signaling and has been demonstrated to be effected by multiple Nurr1 agonists 
in in vivo models (Kirkley et al., 2017;Smith et al., 2015; De Miranda et al., 2015). Based 
on heat map analysis of 168 genes from both qRT-arrays, C-DIM12 gene pattern 
expression was clustered similarly to Saline control levels compared to MPTP+C.O. 
treatment (Fig 6A-B). When comparing fold change levels from both gene arrays, NF-κB 
related genes were more prominently regulated by C-DIM12 than genes from the PD 
array (Fig 6C-F). This included Traf-6, Tnfsf10, CCl5, Bcl2a1a, and Egr1. Genes 
differentially regulated by C-DIM12 under the PD array were calcium homeostasis genes 
Atp2B2 and Syt1, as well as the redox sensing transcription factor Egnl1 (Fig 6G-N). 
These data indicate that C-DIM12-Nurr1 transcriptional activation may modulate death 
signaling regulated by NF-κB-dependent gene expression, whether or not these effects 
are from neurons, glia or both remain to be validated by future studies. 
Previous studies show that C-DIM12 induced NR4A2-dependent transactivation in 
pancreatic and bladder cancer cells (Li et al, 2012; Inamoto et al, 2008) and this response 
was consistently observed in neuronal-like PC12 cells (Fig. 8A-C). Additionally, in other 
work, we have observed C-DIM12 induced NR4A2-dependent transactivation in SY5Y 
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cells transfected NBRE-Luc and NurRE-Luc constructs (data not shown). C-DIM analogs 
have strong binding affinity to the ligand binding pockets of the NR4A family member, 
Nur77 (S-O Lee et al., 2014). X-ray crystal studies of the Nurr1 structure revealed that 
the classical ligand binding pocket is blocked by several bulky hydrophobic amino acid 
residues, suggesting that an alternative co-activator domain may allow ligand binding for 
transcriptional activation (Z Wang et al., 2003; Volakakis et al., 2006). Our computational 
modeling results predicted substantial greater binding affinity for C-DIM12 at the 
coactivator site (-73.3 kcal/mol) than to the ligand binding site (-12.2 Kcal/mol) (Fig 8E, 
H). Therefore, C-DIM12 interactions at the coactivator-binding likely modulates 
transcriptional activity. Nuclear import and export sequences (NLS/NES) mediate Nurr1 
shuttling from the nucleus to the cytosol during oxidative stress (García-Yagüe et al., 
2013).  We demonstrated that C-DIM12 maintains Nurr1 nuclear localization in DA 
neurons, which was consistently observed with post-lesion intervention as well (Fig 7A-
B) (De Miranda et al. 2014). Total levels of Nurr1 protein from ST were depleted about 
60% with MPTP+C.O. treatment and significantly restored to ~80% in C-DIM12 treated 
animals (Fig 7C, 7D). Furthermore, by qPCR analysis of Nurr1 expression we 
demonstrated C-DIM12 induces Nurr1 by ~3.5-fold times higher than both control and 
MPTP + C.O. (Fig 7E). There was also a ~2-fold induction of related NR4A member, 
Nur77 as well (Fig 7F). This is consistent to previous studies that confirm C-DIM12 has 
binding affinity to Nur77, albeit to a lesser extent than Nurr1 (S-O Lee et al., 2014). 
In conclusion, we demonstrated that C-DIM12 crosses the blood brain barrier, 
suppresses glial activation, protects against DA neuronal cell body loss, preserves DA 
terminals, improves neurobehavioral function and decreases NF-κB regulated 
 86 
neuroinflammatory gene expression in the MPTPp mouse model of PD by modulating 
transcriptional activity of Nurr1. Given these findings, we conclude that C-DIM12 is a 
functional Nurr1 ligand with distinct effects in neurons and glia that could represent a 








Figure 4.5.1 Pharmacokinetic analysis depicts high concentration of C-DIM12 in 
brain tissue. Plasma (A) and brain (B) samples were collected from mice at 24, 8, 4, 2, 
1, .5 and 0 hours after oral gavage of C-DIM12 (25mg/kg; black line, 10 mg/kg; grey line-
De Miranda et al. 2013) and analyzed for C-DIM12 concentration via LC-MS.  (C) Chart 
of AUC, t1/2 and Cmax depict a higher partitioning of C-DIM12 to brain tissue (n=4 




Figure 4.5.2 C-DIM12 protects DA neuron bodies/terminals from MPTP induced 
degradation. Concurrent dosing schematic with C-DIM12 and MPTPp treatments 
(A). 10X and 100X objective images of SN/ST tissue immunostained for TH (red) and 
MAP2 (green) treated with (B-E) Salinep + C.O., (F-I) MPTPp + C.O., and (J-M) MPTPp 
+ C-DIM12. (N) Stereological counts for TH+ and (O) MAP2+ cells bodies of the SNpc 
demonstrate significantly more neurons in MPTP +C-DIM12 treated group vs. 
MPTP+C.O. group. (P) TH immunoreactivity intensity levels also measured significantly 
more in C-DIM12 treated group (*P < 0.05, ** P < 0.01,****P < 0.0001, N=10-12 




Figure 4.5.3 Neurobehavioral deficits associated with PD are ameliorated and DA 
proteins are preserved with C-DIM12 treatment. Open-field test (OFT) was conducted 
on mice at 0, 7 and 14 days during study. (A) Change from day 0/per min OFT center 
time and (B) margin time was quantitated at day 7 and 14. (C) Trace and pseudo-colored 
time plots represent OFT mouse movement at day 14. (D) Representative image shows 
a real-time video gait analysis system used to detect paw coordinates for quantitative 
measurement. (E) Gait images depict distance vs. time graphs in animals in each group 
at day 7. (F) Graph displays stride length measured with RT-VGAS at day 7 and day 14. 
(G) High performance liquid chromatography (HPLC) was used for measurement of DA 
metabolite, DOPAC, (H) dopamine and (I) ratio of DOPAC/DA from each experimental 
group. Western blot analysis of striatal protein depicts levels of TH (J), VMAT2 (K), and 
DAT (L) (*P < 0.05, **P < 0.01, ****P < 0.0001, N=10-12 animals/per group for behavior, 




Figure 4.5.4 C-DIM12 suppresses microglia proliferation and maintains a ramified 
morphological phenotype. 10X and 100X objective representative images of TH (red) 
and microglia marker, IBA1 (green) in the substantia nigra are depicted for Salinep+C.O. 
(A), MPTPp+C.O. (B) and MPTPp +C-DIM12 (C). (D) Gliosis counts of the substantia 
nigra (SNpc) and (E) ST tissue were conducted for amount of IBA+ cells. To visualize 
microglia morphology changes of IBA+ cells in the SNpc, (F) multiple 40x-objective 
images were also transformed in ImageJ for skeletonization and quantitation of microglia 
(G) branches, (H) junctions, (I) endpoints, and (J) average branch length (++P < 0.1, *P 
<0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; N=12 animals/per group for counts, n=6 
animals/per group for skeletonization). (K) 64x-objective, 3D images of microglia in SNpc 
were surfaced rendered on channel for IBA1 in each experimental group (boxed cells 
from top images with IBA1/TH were selected; See Supplemental Videos 1-4). 
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Figure 4.5.5 Astrocyte activation is suppressed by C-DIM12.10x and 100x, objective 
images of SN tissue sections isolated from (A) Salinep + C.O., (B) MPTPp +C.O., and 
(C) MPTPp + C-DIM12 depict TH+ neurons (green), GFAP+ astrocytes (red). Stereological 
counts of GFAP+ cells in the (D) SNpc and (E) ST demonstrate significantly less astrocyte 
proliferation in C-DIM12 group. (F) Western blot of striatal protein has significantly less 





Figure 4.5.6 PD associated/NF-κB regulated gene expression is preserved in 
MPTPp + C-DIM12 mice. (A) Ontology dendrogram heat maps of 84 PD associated 
genes from SNpc RNA depicts a cluster grouping with MPTP+C-DIM12 and Saline 
treated groups. Notice NR4A2 (Nurr1) is lower in MPTP +C.O. treated group. (B) Heat 
map of 84 NF-κB regulated genes analyzed from SNpc RNA. Map depicts a cluster 
grouping to Saline control levels in MPTP+C-DIM12 treated tissue (red=increase, 
green=decrease). Volcano plots from PD (C-D) and NF-κB (E-F) arrays show fold 
changes for MPTP + C.O. and MPTPp + C-DIM12 groups compared back to Saline 
controls (red=min, green=max expression). Graphical display for Atp2b2 (G), Bcl2a1a 
(H), Ccl5 (I), Egln1 (J), Syt1 (G), Tnfsf10 (M) and Traf6 (N) depict significant gene fold 




Figure 4.5.7 Subcellular localization and expression of Nurr1 are modified by C-
DIM12 treatment in vivo (A) 100X objective images of TH+ neurons (green) show Nurr1 
(red) is sequestered to the nucleus with C-DIM12 treatment, white arrows depict nuclear 
localization. (B) Mean intensity of TH+ nuclear Nurr1 is significantly higher in C-DIM12 
group compared to MPTP + C.O. (*P <0.05, ****P <0.0001; N=4 animals/group). (C) 
Western blot of Nurr1 protein isolated from ST tissue show C-DIM12 prevents MPTPp-
induced protein changes, (D) as illustrated in quantitative measurement of mean optical 
density (control set to 100%; *P < 0.05,**P < 0.01,***P < 0.001, N=6-8 animals/group). 
qPCR data of mRNA isolated from SNpc for (E) Nurr1 and (F) Nur77 (NR4A1) expression 





Figure 4.5.8 C-DIM12-dependent transactivation of Nurr1 reporter constructs in 
neuronal cells and putative binding sites within the ligand binding domain of 
human NR4A2. Luciferase expression of PC12 cells co-transfected with UAS-Luc + 
GAL4-Nurr1 (A) NBRE-Luc + FLAG-Nurr1 (B) and NurRE-Luc + FLAG-Nurr1 (C) in the 
presence of 0-20 µM C-DIM12 (*P < 0.05; N=3/experiment). In silico modeling of the 
Nurr1 ligand binding domain displays putative binding sites for C-DIM12 at the co-
activator interface with a calculated binding energy of -73.3 Kcal/mol (D-F) and at the 






CELLULAR SELECTIVITY OF AAV SEROTYPES FOR GENE DELIVERY IN 





5.1 INTRODUCTION  
 
Adeno-associated viruses (AAVs) are the most commonly used vector for gene 
delivery to central nervous system (CNS). AAVs are small (20nm), non-pathogenic in 
humans and animals, contain a single-stranded DNA genome and are a member of the 
Parvoviridae family within the Dependovirus genus (Kotterman and Schaffer, 2014) (Daya 
and Berns, 2008). Serology of AAVs is an important functional characteristic for cell 
specific transduction efficiency within the CNS. AAV2 was the first serotype cloned into a 
bacterial plasmid and has since been used as a comparison to identify other serotypes. 
Each serotype has a different CNS transduction capacity and does not cross-react with 
naturally-occurring human AAV2-neutralizing antibodies (Samulski et al., 1982). Twelve 
serotypes (AAV1-12) have been tested thoroughly for their ability to transduce specific 
cell types and tissue and differentiated between capsid protein motifs that bind specific 
cell surface receptors for cell attachment [4]. For example, AAV1, AAV4, AAV5, AAV7 
(sialylated glycoproteins), AAV2/AAV3 (heparin sulfate proteoglycans), AAV9 (galactose) 
and AAV8 do not have a known primary receptor, although laminin is a potential co-
receptor for these viruses (Akache et al., 2006). More recently, a universal receptor, 
                                                        
2Reprinted with permission of PLOS ONE. All rights reserved. 
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KIAA0319 or AAVR, has been identified that mediates rapid endocytosis after cell binding 
and attachment for all AAV serotypes (Pillay et al., 2016). AAV hybrid serotypes or 
pseudo-serotypes have been created by viral engineering, which are constructed with 
integrated genome containing (cis-acting) inverted terminal repeats (ITR) of AAV2 and 
capsid genes of other serotypes for increased viral specificity and transduction (Choi et 
al., 2005).  Several studies display AAV serotype transduction differences in vitro and in 
vivo; dependent on cell type specificity, cell toxicity, viral delivery method, viral delivery 
timing, and AAV transgene expression stability over time (RL Klein et al., 1998; Royo et 
al., 2008; Howard et al., 2008; Chakrabarty et al., 2013; Aschauer, Kreuz, and Rumpel, 
2013a). However, some of these studies lack informative, transitional data incorporating 
both hybrid and wild type serotype differences found in neural cell culture preceding 
serotype comparisons in mouse brain.  
Neonatal intracerebroventricular (ICV) injection is a promising delivery technique 
for AAVs in mice that is minimally invasive and displays widespread tropism throughout 
the brain, as opposed to stereotactic injection procedures in adult mice, which are highly 
invasive and localize only to site of injection. Previous studies reported that when AAV2 
is injected directly into the cerebral lateral ventricles at birth, it can circulate through the 
subarachnoid space, disseminate through the ventricle ependymal cell lining and deliver 
viral vector throughout the CNS (Passini and Wolfe, 2001). Transgene expression 
following neonatal ICV injection can persist for at least 12 months, and there are regional 
differences in tropism amongst different AAV serotypes delivered by this method(J-Y Kim 
et al., 2013). Because of the reported variability in serotype-dependent regional tropism 
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amongst different studies, there remain questions as to which serotype is best suited to 
transduce neurons or astrocytes in specific regions of interest within the CNS by ICV. 
In the present study we therefore used multiple AAV serotypes expressing 
fluorescent GFP reporters to examine regional tropism and efficiency in transducing gene 
expression in primary neuron and astrocyte cultures and in vivo. AAVs were administered 
by ICV injection into neonatal P0 mice for delivery to the CNS. Tissue was collected at 3 
and 6 weeks post-ICV injection to compare AAV serotype stability in multiple regions of 
the brain. Previous investigations of AAV serotype differences have predominately 
focused on the localized expression after stereotaxic injection in adult mice for 
intervention in neurodegenerative disease models. Still, few studies have fully 
investigated the capacity of multiple ICV delivered AAVs serotypes to penetrate to deep 
ventral midbrain regions and transduce specific cell types (Chakrabarty et al., 2013; J-Y 
Kim et al., 2013; McLean et al., 2014). Using immunofluorescence and imaging, we report 
different patterns of cell specific AAV serotype tropism in cell culture and in multiple 
regions of mouse brain, including the substantia nigra (SN). Further testing was 
conducted with glial fibrillary acidic protein (GFAP) promoter-driven AAV using the optimal 
serotype to exclusively target astrocytes. These studies identified different AAV serotypes 
that preferentially transduced gene expression in astrocytes or neurons with surprising 
variability in regional tropism, suggesting several suitable serotypes for achieving gene 





5.2 MATERIALS AND METHODS 
AAV serotypes  
The following AAV serotypes tested were acquired from Vector BioLabs; AAV1(Cat# 
7002), AAV2/1(Cat# 7071), AAV2/DJ (Cat# 7078), AAV2/DJ8 (Cat# 7118), and 
AAV2/DJ9 (Cat# 7119) and astrocyte-specific, AAVDJ8-GFAP-mCherry-WPRE. AAV8 
and AAV9 were from Virovek.  All pseudo-serotypes incorporated ITRs of wildtype AAV2 
and mRNA stabilizing woodchuck hepatitis virus posttranscriptional regulator elements 
(WPRE). AAV2/1 had capsid protein of wildtype AAV1, AAVDJ was a synthetic serotype 
made from 8 wildtype serotypes, AAVDJ8 was AAVDJ modified to specific residues of 
AAV8, and AAVDJ9 was modified to specific residues of AAV9. Each pseudo-serotype 
also had a CMV/Chicken-beta-actin hybrid promoter and eGFP transgene. Wildtype 
AAV1 had a CMV promoter and an eGFP transgene. All Vector BioLabs serotypes were 
stored in a PBS/glycerol 5% stock at an initial concentration of 1X1013 GC/ml. Serotypes 
acquired from Virovek had a CMV promoter, a GFP reporter and a modified wildtype 
capsid. AAV8 was an initial concentration of 2.14X1013 GC/ml and AAV9 was at 
2.10X1013GC/ml, stored in a PBS/pluronic F-68 0.001% stock, before dilution to working 
concentration. All serotypes were made in aliquots to minimize freeze/thaw cycles and 
stored at -80°C. 
Use of animals 
Timed pregnant female C57BL/6 mice were obtained E16-E19 (Charles River aged 3-4 
months). P0 neonatal mice were ICV injected within ~12 hours post birth. Mice were 
housed in a 12hr-light/dark cycle and temperature-controlled room (maintained 22-24°C) 
with access to standard chow and water ad libitum. All animal procedures were conducted 
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in compliance with National Health Institute guidelines and approved by Colorado State 
University Institutional Animal and Use Committee. Neonatal ICV injections were 
conducted under heavy cyroanesthesia and adult terminal procedures were performed 
under isoflurane anesthesia.  
In vitro AAV transduction experiments and immunostaining 
Primary cortical neurons were isolated from P0 neonatal C57BL/6 mice, as previously 
described, and then seeded on Poly-D-Lysine (Sigma Cat# P6507-5mg) coated 12-mm 
coverslips at a density of 5.0X 104/well(W Li et al., 2015). For live cell fluorescent plate 
reading/imaging, neurons were seeded at 5X103/well in 96-well black-walled plates 
(Thermo Scientific, Waltham MA). Neuronal cultures were allowed to grow for 7 days prior 
to viral treatments. For mixed glial cell isolations, astrocytes were also isolated from P0 
neonatal C57BL/6 mice, as previously described (De Miranda, Popichak, Hammond, 
Jorgensen, et al., 2015). Mixed glia were seeded on FBS coated 12-mm coverslips at 
5.0X 104/well 24 hours prior to viral transductions. All AAV-GFP serotypes were diluted 
to 5X1010GC/ml in Neurobasal Medium (Life Technologies) for primary neurons or serum-
free MEM/EBSS (Hyclone) for astrocyte transductions. Native GFP fluorescence signal 
was monitored at 488nm emission/519nm each day on a Cytation3 Cell Imaging Multi-
Mode plate reader (BioTek Instruments, Winooski, VT). DIV 7 cells were washed with 
phosphate-buffered saline (1X PBS) and replaced growth medium with Fluorobrite DMEM 
(Life Technologies) for GFP and bright-field 20X objective imaging on plate reader, then 
fixed with ice cold methanol for 20 min at -20°. For mixed glia transduction experiments 
with AAVDJ8-GFAP-mCherry, a higher titer of 1.9X1011GC/ml was necessary for 
successful detection of mCherry expression and cells were fixed at DIV 11.. Both cell 
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types were immunostained for chicken polyclonal anti-GFP (1:500; AvesLabs Cat# 1020), 
rabbit polyclonal anti- mitogen associated protein (MAP2) (1:500; Abcam Cat# 32454) for 
neurons and mouse polyclonal anti-GFAP (1:500; Cell Signaling Cat# 3670S) for 
astrocytes and anti-mCherry (1:100; Abcam) for AAVDJ8-GFAP-mCherry transduced 
cultures. Secondary antibodies used were AlexaFluor donkey anti-rabbit 555, goat anti-
chicken 488, and donkey anti-mouse 555 (1:500; Life Technologies). All 12mm-coverslips 
were mounted on glass slides with VectaShield mounting medium containing 4′,6-
diamidino-2-phenylindole (DAPI; Vector, Burlingame, CA) and stored in 4°C until imaged.  
Neonatal Intracerebroventricular injections 
ICV injection procedures were closely adapted from several established protocols by Kim 
et al. 2013 & 2014 and Charkrabarty et al. 2013 (J-Y Kim et al., 2013; 2014). In brief, P0 
neonatal pups were induced with hypothermic anesthesia by placement on a cold 
aluminum plate in ice. Anesthesia was confirmed by neonatal color change from pink to 
purple, squeezing of paw and cessation of movement before injections. ICV injections 
were performed using a 10uL Hamilton micro syringe with a 32 G, 0.5”, 30° bevel RN 
needle. Ventricular injection sites were identified by 2/5 distance from lambda suture to 
eye and 3mm ventral from skin (marked on needle shaft). Working viral solutions were 
diluted in PBS at 1X1010GC/uL, and injected as a 2uL volume/hemisphere, equivalent 
2X1010GC/hemisphere. Injected pups were placed on warming pad and regained 
movement before returned to dam cage.  Juvenile weanlings were terminated at 3 weeks 




Histological Preparation of Tissue and Immunostaining 
AAV injected mice were terminated at 3/6 weeks under deep isoflurane anesthesia and 
decapitated for rapid brain dissection. Dissected brains were stored in 3% 
paraformaldehyde overnight and then stored in cacodlyate-PBS containing 15-30% 
sucrose at 4°C until processed for cryo-sectioning. Brains were then frozen in OCT and 
sectioned at 40µm thickness (coronal/sagittal) on microtome.  Free-floating brain regions 
of interest (ROI) were mounted on glass slides and imaged for AAV-GFP or stored in 
cryoprotectant at -20°C until immunostaining. Immunofluorescent tissue staining was 
conducted as previously described by Miller et al. (Miller et al., 2011), with the addition of 
antigen-retrieval by incubating tissue sections in 0.01 M sodium citrate buffer (pH 8.45) 
for 20 min prior to blocking.  Primary antibodies diluted in 0.1% triton-X containing tris-
base-saline (TBS) are rabbit polyclonal anti-MAP2 (1:500; Abcam Cat# 32454), rabbit 
polyclonal anti-S100β (1:100; Abcam Cat# ab41548), chicken polyclonal anti-GFP (1:500; 
AvesLabs Cat# 1020), and rabbit polyclonal anti-tyrosine hydroxylase (1:500; Millipore 
Cat#: AB152). Sections were stained for DAPI (Sigma) and mounted on glass coverslips 
in VectaShield mounting medium and stored at 4°C until imaging. 
CLARITY tissue-transmutation 
Passive clarification was conducted similarly to protocol established by Tomer et al. 2014 
(Tomer et al., 2014). In brief, brains were embedded in hydrogel (4% acrylamide/0.05% 
Bis-acrylamide) and sectioned at 400um thickness on a cryo-microtome. Sections were 
placed in clearing solution (4% sodium dodecyl sulfate/200mM boric acid, pH 8.5) for 7 
days at 37 °C and 35 rpm. Sections of clarified substantia nigra region were then selected 
for immunostaining. Clearing solution was removed by washing 3 times with TBS and 
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then sections were incubated for immunostaining with chicken polyclonal anti-tyrosine 
hydroxylase (1:200; Abcam Cat# ab76442), rabbit polyclonal anti-GFAP (1:200; DAKO 
Cat# Z0334), anti-GFP (1:200; AvesLabs) or anti-mCherry (1:200; Abcam Cat# 
ab167453). Antibodies were diluted in TBS at 37 °C and incubated with tissue sections 
with an orbital shaker at 35 rpm overnight and then at 4°C for 1 day afterward. Multiple 
washes were performed over 2 days at 37 °C (with orbital shaking at 35 rpm) and then 
cleared sections were placed in TBS containing goat anti-chicken AlexaFluor 647 (1:200; 
Life Technologies) and donkey anti-rabbit AlexaFluor 555 (1:200; Life Technologies) at 
37 °C overnight with orbital shaking (35 rpm). The next day, sections were washed 
several times with TBS and stored at 4°C until imaged. 
Imaging and Cell Counting 
Images of transduced primary cells and all quantitated AAV infected brain regions were 
acquired using a 20X air objective with a Zeiss Axiovert 200M inverted fluorescent 
microscope equipped and a Hammatsu ORCA-ER-cooled charge coupled device camera 
(Hammatsu Pho-tonics, Hammatsu City, Japan). For IF quantitation, multiple random, z-
stack images of approximately 30 μm dissector height for both hemispheres of all brain 
regions (in vivo quantitation) or a single 2D images (for in vitro quantitation) were acquired 
per coverslip/brain region and counted total %GFP cell/image field using Slidebook 
software (version 5.5, Intelligent Imaging Innovations, Denver CO). A background 
subtraction was performed for all IF in vivo images, prior to quantitation. Representative 
high-magnification images were acquired with a Zeiss Plan-Apochromat 100X oil 
objective lens. Representative 10X objective montage images of ROI were acquired with 
a BX51 microscope (Olympus, Center Valley, PA, USA) equipped with a Hammatsu 
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ORCA-Flash4.0 digital CMOS camera, ProScan III stage controller (Prior, Rockland, MA 
USA) and CellSens Dimension software (version 1.12, Olympus, Center Valley, PA, 
USA).  All bright field images of mock-injected brains were acquired with Olympus SZX12 
stereo-dissecting microscope. For enhanced CLARITY fluorescence imaging of AAVDJ8-
GFP, 40X oil objective montage images were acquired using a Fluoview 1200 scanning-
laser confocal microscope to penetrate ~80µm thickness of tissue (Olympus, Center 
Valley, PA USA). CLARITY fluorescent imaging of AAVDJ8-GFAP-mCherry was 
conducted on a Zeiss LSM 510 Laser-scanning confocal microscope to penetrate and 
capture ~180µm thickness of tissue. Both sets of CLARITY images were 3D-rendered in 
ImageJ analysis software (Schneider et al., 2012). Representative images of whole brain 
fluorescence were acquired with ChemiDoc MP imaging system (BioRad). Uninjected 
controls were imaged with each serotype for comparison of background fluorescence 
(Supplemental Fig. 3). 
Statistical Analysis 
All data are expressed as mean ± SEM. Grouped analyses was performed using a Two-
way ANOVA with Sidak’s post hoc test to compare biological replicate means between 
groups. For semi-quantitative representation of GFP+ cells/brain region as depicted in 
Table 1, cell counts were divided into quartiles as follows; +++£55.5 GFP+ cells/image 
field, ++£31.3 GFP+ cells/image field, +£11.6 GFP+ cells/image field and -£5.8 GFP+ 
cells/image field. Statistical significance was identified as *p <0.05, **p <0.01, ***p <0.001, 
****p <0.0001. All statistical analyses were conducted using Prism (version 6.0; Graph 




Comparison of multiple AAV serotypes in primary astrocyte and neuronal cultures. 
Several wildtype and hybrid serotypes carrying eGFP or GFP fluorescent reporters 
were compared for transduction efficiencies in astrocytes. Mixed glia cultures were 
transduced for 1 week with different serotypes and fixed for double immunofluorescent 
labeling for the astrocyte marker, GFAP (red) and GFP (green) (Fig. 1A, C, E, G, I, K, 
M). Astrocyte (GFP+GFAP+/GFAP) transduction efficiencies (Mean ± SEM; n=3-
7/serotype) were as follows: 4.785%±2.635 for AAV1, ~71%±7.79 for AAV2/1, 
33.17%±9.169 for AAVDJ, 58.49% ±11.43 for AAVDJ8, 46.64%±10.31 for AAV8, 
36.77%±4.749 for AAVDJ9, and 41.88%±11.49 for AAV9 (Fig. 1O). Similarly, primary 
cortical cultures were transduced for 1 week and fixed for double immunofluorescent 
labeling for the neuronal marker, MAP2 (red) and GFP (green) (Fig. 1B, D, F, H, J, L, N).  
Neuron (GFP+MAP2+/MAP2+; n=6-10/serotype) transduction efficiencies were 
quantitated as follows: 40.5%±11.9% for AAV1, 63.5±5.4% for AAV2/1, 49.1±5.0% for 
AAVDJ, 39.2±5.7% for AAVDJ8, 21.4±6.6% for AAV8, 49.6±7.1% for AAVDJ9, 49.2±8.7% 
for AAV9 (Fig. 1P). AAV-GFP fluorescence intensity was also monitored in neuronal 
cultures once per day for 1 week via live cell imaging using a fluorescence microtiter plate 
reader. AAV-GFP expression was noticeable at approximately 3 days post-infection and 
increased every day in vitro (DIV). AAV2/1 displayed a significantly higher fold-change in 
fluorescence intensity compared to all other serotypes at 6 DIV (1.733±0.117) and 7 DIV 




Intracerebroventricular injection of AAV constructs 
To administer several selected AAV serotypes to the murine CNS, ICV injections 
were conducted on P0 neonatal mice (Figure 2). Lateral ventricles were targeted for 
injection on both hemispheres as depicted in the schematic in Fig. 2A. Successful 
injection into ventricle space was confirmed by mock injection of trypan blue/PBS solution 
administered to neonatal P0 mouse brain for visualization of injection distribution and 
imaged on bright field stereo dissecting microscope, arrowheads indicate injection sites 
(Fig. 2B-C). Mock injected brains were incised along coronal and saggital planes to 
visualize sites of viral solution spread from the lateral ventricles (LV), third (3V), 
mesencephalic aqueduct (MA) and fourth ventricle (4V), arrowheads indicate ventricular 
spaces (Fig. 2D, Supplemental 1A-C). For in vivo AAV serotype characterizations, 
AAV2/1, AAVDJ8 and AAV9 were selected based on the capacity to efficiently transduce 
primary neural cultures and the noticeable distribution differences of other serotypes by 
ICV injection (Figure 1, Supplemental Figure 4B-F). Basic plasmid (pAAV) maps of 
each serotype are illustrated in Figure 2E. To monitor AAV tropism throughout the CNS, 
whole brains were ICV injected with AAV2/1 (Fig. 2F), AAVDJ8 (Fig. 2G) and AAV9 (Fig. 
2H) and dissected 3 weeks post-injection or imaging of intrinsic GFP expression. Lateral 
views of each whole brain are shown in the top image in pseudo color (Fig 2F-H). Medial 
intrinsic fluorescence is depicted in representative images of sagittal cross sections 
(bottom), along with serial coronal cross sections rostral to caudal on right of each panel, 




Quantitation of AAV2/1-GFP tropism at 3 and 6 weeks post-injection 
To determine degree of AAV2/1-GFP tropism in neurons and astrocytes from 
multiple brain regions at 3 and 6 weeks post ICV injections, anatomical regions including 
the olfactory bulb, striatum, motor cortex, hippocampus and cerebellum were 
immunostained for anti-NeuN (red, neuronal marker) and S100β  (purple, astrocytic 
marker) at 6 weeks post ICV (Fig 3A-E). Mitral cells of the granular layer were primarily 
transduced, with no observed astrocytes in the olfactory bulb (Fig 3A). AAV2/1 had 
modest penetration from ventricular space to striatal neurons, without any GFP+ 
astrocytes observed in the caudate putamen (Fig 3B). Most GFP+ cells in the primary 
motor cortex were in Layer 6a-6b, and fewer GFP+ pyramidal neurons of cortical layers 5 
and 2/3 (Fig 3C). Pyramidal layer neurons of CA1 hippocampus heavily expressed GFP, 
as well as some infected neurons in the molecular layer of the dentate gyrus (Fig 3D).  
Central lobules of the cerebellum had GFP+ Purkinje fiber neurons, no astrocytes were 
observed. Quantitative measurement of AAV2/1-GFP+ cells quantitated for each 
region/time point at 3 and 6 weeks are as follows:  47.5±11.7 and 37.7±17.5 in the 
olfactory bulb; 9.9+/-4.1 and 6.9+/-1.5 in the striatum; 38.2±10.3 and 20.7±6.7 in the 
cortex; 55.467±18.584 and 53.167±17.873 in the hippocampus; 21.8±12.3 and 2.9+/-1.6 
in the cerebellum (n=3/Time point) (Fig 3F).  
Quantitation of AAVDJ8-GFP tropism 3 and 6 weeks post injection 
The tropism of AAVDJ8-GFP in multiple brain regions at 3 and 6 weeks post ICV 
injections was also monitored in the olfactory bulb, striatum, motor cortex, hippocampus 
and cerebellum (Fig 4A-E). At 6 weeks post-ICV mitral layers of the olfactory bulb were 
heavily infected, including some observed AAVDJ8-GFP+ astrocytes (Fig 4A). Striatal 
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neurons and astrocytes of the caudate putamen were primarily infected in the dorsal 
region of the striatum (Fig 4B). High AAVDJ8-GFP infection was observed in all layers of 
the primary motor cortex, with robust signal in pyramidal neurons of layer 5 and astrocytes 
of multiform layer 6 (Fig 4C). AAVDJ8-GFP+ pyramidal neurons of CA1 were observed in 
the pyramidal layer and infected astrocytes were observed in the dorsal hippocampal 
layer and stratum oriens (Fig 4D).  Similar to AAV2/1, central lobules of the cerebellum 
GFP+ Purkinje fiber neurons were transduced but no GFP+ astrocytes were observed (Fig 
4E). AAVDJ8-GFP+ cells quantitated for each region/time point at 3 and 6 weeks are as 
follows: 24.7±6.3 and 29.0+/-2.8 in olfactory bulb; 10.9±1.6 and 12.0±2.1 in the striatum; 
51.7±15.5 and 38.3+/-4.7 in the cortex; 47.1+/-4.6 and 36.7±3.4 in the hippocampus; 
3.78±0.6 and 5.8±1.1 in the cerebellum (n=3/Time point) (Fig 4F).   
Quantitation of AAV9-GFP tropism 3 and 6 weeks post injection  
AAV9-GFP tropism was similarly monitored at 3 and 6 weeks post ICV injection. 
The olfactory bulb displayed comparable tropism to AAV2/1 with mainly infectivity in the 
mitral cells of the granular layer and no observed GFP+ astrocytes (Fig 5A). Minimum 
AAV9-GFP infection was present in the striatum, although infected neurons and 
astrocytes were identified within the caudate putamen region (Fig 5B). Both cell types 
were infected in the primary motor cortex, primarily neurons of layer 5 and astrocytes of 
layers 6a-b (Fig 5C). Neurons and astrocytes were minimally infected within the 
pyramidal layer of CA1 hippocampal region, and AAV9-GFP was noticeably expressed 
within the fiber tracts of the dentate gyrus (Fig 5D). Similar to AAV2/1 and AAVDJ8, 
Purkinje fiber neurons within the central lobules of the cerebellum were primarily infected, 
and no AAV9-GFP (+) astrocytes observed (Fig 5E). Transduction efficiencies of AAV9-
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GFP+ cells quantitated for each region/time point at 3 and 6 weeks are as follows: 9.6±4.2 
and 5.3±1.5 in the olfactory bulb; 8.4±3.0 and 1.7±0.8 in the striatum; 39.1±11.1 and 
6.4±3.3 in the cortex; 12.3±8.2 and 2.4±0.8 in the hippocampus; 11.3+/-2.7 and 5.9±2.8 
in the cerebellum (***p< 0.001; n=3/Time point) (Fig 5F). 
Analysis of AAV serotype-specific variation within the substantia nigra. 
 For further analysis/quantitation of the ventral midbrain region, specifically the 
substantia nigra (SN) was examined. Tissue sections were immunostained for dopamine 
neuron marker, tyrosine hydroxylase (TH), at 3 and 6 weeks post-ICV injection and 
quantitated for number of GFP+ cells. Representative IF images of AAV2/1, AAVDJ8 and 
AAV9 6 week SN tissue immunostained for dopamine neuron marker, tyrosine 
hydroxylase (TH) is depicted in Figure 6A-C. Transduced GFP+ cells quantitated in the 
SNpc at 3 and 6 weeks are as follows: 2.2±14.3 and 0.5±0.16 for AAV2/1; 8.0± 2.6 and 
13.8±2.1 for AAVDJ8; 15.1±5.3 and 5.8±1.8 for AAV9 (*p<0.05, n=3/serotype/time point) 
(Fig 6D). Number of dopaminergic neurons transduced/per image field in the SN pars 
compacta (SNpc) at 6-weeks were measured by counting GFP+/TH+ co-localizing cells 
(Fig 6E). Transduction efficiency of astrocytes was also quantitated by number of 
GFP+/S100β+ co-localizing cells.  AAVDJ8 transduction efficiency measured 56.4±7.5% 
S100β+/per image field cells and 14.9±7.6% and TH+ cells/per image field. AAV9 
transduced 22.3±1.0% S100β+ cells/per field and 45.5±2.8% TH+ cells/per image field 
(*p<0.05, n=3/serotype) (Fig 6E-G). Pearson’s co-localization coefficient was also 
calculated for both cell markers as follows: 0.57±0.06 (GFP+/S100β+) and 0.46±0.04 
(GFP+/TH+) for AAV9; 0.48±0.06 (GFP+/S100β+) and 0.54±0.05 (GFP+/TH+) for AAVDJ8  
(25-42 GFP+ cells/over n=3 animals/serotype; Supplemental Fig. 2A. Mean intensity of 
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GFP fluorescence was also measured for both cell types as accordingly:  295.1±75.5 
AU/per S100B+ cells and 309.6±65.8 AU/per TH+ cells for AAV9; 1207.0±142.2 AU/per 
S100B+ cells and 1157.0±105.9 AU/per TH+ cells for AAVDJ8 (25-42 GFP+ cells/over n=3 
animals/serotype; p<0.0001****; Supplemental Fig 2B-C). CLARITY tissue 
transmutation was performed on SN tissue to visualize AAVDJ8 transduction in 3D 
volumetric space. Clarified tissue was co-immunostained for TH (cyan), GFAP (red) and 
GFP (green), with expression of GFP primarily confined to astrocytes, noted by co-
localization of red and green fluorescence (yellow) (Fig 6H, Supplemental Video 1). 
AAVDJ8-GFAP-mCherry specifically targets astrocytes of SNpc 
 After determining the suitability of AAVDJ8 to transduce astrocytes within the 
SNpc, we used this serotype to express red fluorescent mCherry under the control of a 
truncated version of the astrocyte-specific gfap promoter (0.7kb) that is active and can be 
efficiently cloned into AAV (Fig. 7A).  Strong expression of AAVDJ8-GFAP-mCherry was 
observed in primary cortical astrocyte cultures at 83.2%±6.5 mCherry+/GFAP+ as 
depicted in representative images in Fig. 7B.  AAVDJ8-GFAP-mCherry was also tested 
in vivo by ICV to observe cell-specificity and tropism throughout the brain. By 3 weeks 
post-injection, high levels of mCherry expression were detected within cortical, 
hippocampal, thalamic and midbrain areas, as depicted in whole brain images of sagittal 
cross sections (Fig. 7C). To determine if there was similar penetrance to the SN as 
AAVDJ8-eGFP, we imaged immunostained SN tissue for TH, S100β and mCherry, shown 
in the representative images in Figure 7D. Images of tissue at 3 weeks post-injection 
were quantitated for the number of transduced astrocytes within the SN, indicating 80.3± 
6.3 mCherry+/S100β+ cells/image field. No TH+ neurons were found to express mCherry. 
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Mice injected with AAVDJ8-GFAP-mCherry were also aged for 6-weeks to determine the 
stability of expression with this vector. No significant difference was observed between 
time points; mCherry+cells/image field was quantitated at 7.2±2.3 and 8.8±1.9 at 3 and 6 
weeks respectively (n=3/time point; Fig. 7E). GFAP+-mCherry+ co-localization within the 
vicinity of dopaminergic neurons is visualized similar to AAVDJ8-GFP by a 3D volumetric 
view of the clarified SNpc tissue at ~4.5 times thicker (180µm) than typical tissue sections 
cut for cell quantitation (Fig. 7F; Supplemental Video 2). 
5.4 DISCUSSION AND CONCLUSIONS 
 AAV vectors are valuable tools for transduction of both mitotic and post-mitotic 
cells of the CNS. The high levels of tropism in multiple brain regions permit expression of 
a diverse array of transgenes suitable for mechanistic investigation of basic biological 
function as well as neurological disease. AAV serotype transduction differences have 
been highly studied for primary cell culture and for gene expression in vivo. However, 
there are few studies that provide a systematic approach for selection of AAV serotypes 
to achieve both in vitro and in vivo gene expression in murine neurons and astrocytes in 
a region-specific fashion. By use of multiple different AAV-GFP serotypes with CMV/CAG 
promoters, we demonstrate differences in infectivity and gene expression in primary 
astrocytes and neurons, as well as tropism in multiple regions of the brain, stability of 
AAV-GFP expression between 3-6 weeks post ICV injection and expression of AAV-GFP 
in ventral midbrain areas. In addition, we identified an AAV serotype to transduce 
astrocytes within the SNpc through evaluation of AAVDJ8-GFAP-mCherry.  
Serotype transduction differences have been previously reported in rat primary 
cortical neuronal cultures utilizing naturally occurring serotypes and engineered capsids. 
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Howard et al. found AAV1-CMV-GFP to have the highest expression of GFP compared 
to other naturally occurring serotypes in neuronal cultures (Howard et al., 2008; Royo et 
al., 2008). Accordingly, we screened both the naturally occurring AAV1-CMV-GFP 
serotype in comparison to engineered hybrid serotypes AAV2/1-CAG-eGFP, AAVDJ-
CAG-eGFP, AAV8-CMV-GFP, AAVDJ8-CAG-eGFP, AAV9-CMV-GFP and AAVDJ9-
CAG-eGFP to determine transduction efficiency in both MAP2+ and GFAP+ cells in 
culture. AAV2/1 transduced the most MAP2+ neurons and GFAP+ astrocytes in culture 
based on immunostaining. Additionally, according to daily measurements of GFP in 
cultured neurons, AAV2/1 was the most rapid and highest expressing serotype by DIV 7. 
Hence, AAV2/1 was the most efficient for transducing cells in vitro amongst the serotypes 
tested (Fig. 1). AAV2/1 has been utilized to target neurons for anti-inflammatory effects 
of dominant-negative chemokine CCL2 mutant, interleukin-10 (IL-10) in mouse models of 
Alzheimer’s Disease (AD) and brain-derived neurotrophic factor (BDNF) in rat models of 
Huntington’s Disease (Sadasivan et al., 2017) (Kiyota et al., 2012) (Connor et al., 2016). 
High transduction efficiency has been reported in regions of the basal ganglia in rat and 
non-human primate animal models by stereotaxic injection using AAV2/1 (McFarland et 
al., 2009) (Burger et al., 2004; Dodiya et al., 2009). In comparison to AAV1 sagittal cross-
sections, the patterns of transgene expression were drastically different with ICV delivery. 
AAV1 transduction was limited to the ependymal cells of the choroid plexus, whereas 
AAV2/1-GFP expression was observed throughout the brain (Supplementary Fig. 4C, 
Fig. 2C,).  Restriction of AAV1 to the ventricular epithelia when delivered via ICV is 
consistent with studies by JY Kim et al. 2013 and further supports our findings (J-Y Kim 
et al., 2013). These data suggest the ITR cis-acting elements of AAV2 and CAG promoter 
 112 
within pseudotype AAV2/1 are crucial for transduction efficiency in culture and penetration 
from ventricle to parenchymal space. With these findings, we selected AAV2/1 for further 
quantitative analysis in multiple brain regions.  
AAVDJ8 displayed promising results in glial cultures, comparable to AAV2/1 (Fig. 
1O). Wide distribution and higher levels of GFP expression were noticeable throughout 
the brain compared to AAV8 (Fig. 2D, Supplemental Fig. 4E). It was previously 
demonstrated that the AAVDJ8 pseudo-serotype produces ~10-fold higher titers than 
AAV2/1 and more efficiently drives expression of red fluorescent protein (RFP) in neurons 
of the rat amygdala (Holehonnur et al., 2014). Prior studies have also indicated that 
AAV2/8 is an effective vector for targeting neurons of the nigrostriatal system in 
neurodegenerative studies when administered via stereotaxic injection directly to the 
substantia nigra in rats (McFarland et al., 2009; 2014). Also, AAV8-based vectors have 
shown selective expression in astrocytes of the spinal cord, hippocampus, striatum and 
substantia nigra of adult rats when used with human GFAP promoter to drive transgene 
expression (Lawlor et al., 2009; K Li et al., 2014). Our findings with AAVDJ8-CAG-eGFP 
are consistent with these studies and support the use of the AAVDJ8 serotype to target 
neurons and astrocytes of specific brain regions. Furthermore, AAVDJ8 was a suitable 
serotype for GFAP-mCherry design to restrict transgene expression in astrocytes. 
AAV9 was chosen for further investigation based initially on the ability to transduce 
neurons in vitro and from reports that it can target multiple cell types in vivo(Foust et al., 
2008; Gray et al., 2011; Aschauer, Kreuz, and Rumpel, 2013a; McLean et al., 2014). 
AAV9 and AAVDJ9 had the same efficiency in primary neuronal cultures but AAV9 
transduced 5% more astrocyte than AAVDJ9 in culture (Fig. 1). AAVDJ9 did depict a high 
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level and wide distribution of transgene expression throughout most brain regions 
evaluated, yet had lower levels of penetrance to the ventral midbrain regions when 
compared to AAV9 (Supplemental Fig. 4F, Supplemental Fig. 5A-B). In previous 
studies, AAV9 has been used to target hippocampal neurons when delivered via 
stereotaxic injection in mice(Aschauer, Kreuz, and Rumpel, 2013b). However, it was also 
reported that AAV9 crosses the blood brain barrier when delivered intravascularly and 
targets neurons in neonatal mice but then expresses in astrocytes in adult mice (Foust et 
al., 2008). In contrast, Gray et al. asserted that AAV9 preferentially targets neurons in 
adult mice when utilizing the same delivery method and promoter/GFP reporter(Gray et 
al., 2011). Interestingly, AAV9 has been used to target TH+ neurons of the SNpc under 
control of the human synapsin (hSYN1) promoter to drive GFP expression after neonatal 
delivery via ICV(McLean et al., 2014). Based on these findings and our data, we selected 
AAV9 for further quantitative analysis in multiple brain regions. 
Since initial ICV studies, this method has been tested and optimized for timing of 
injection and serotype comparisons(J-Y Kim et al., 2013; 2014). It was found that when 
injecting at different time points (0-72hrs), AAV2/1 had broadest distribution throughout 
the brain at P0, whereas AAV2/8 and AAV2/9 transduced independently of the age at 
which they were injected (Chakrabarty et al., 2013). For the most efficient viral 
dissemination and consistency, we administered all AAV serotypes at P0. At 3-weeks 
post injection, AAV2/1 transduced the most cells of the olfactory bulb, hippocampus and 
cerebellum (Table 1). AAVDJ8-GFP+ cells were most prevalent in the striatum and cortex; 
and AAV9 transduced the most cells of the substantia nigra (Fig. 3F-5F, Table 1). Based 
on previous studies, ICV-delivered AAVs have been proven to be stable for up to 1-year 
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post injection(Passini et al., 2003; J-Y Kim et al., 2013). Interestingly, we noticed AAV-
GFP expression decreased in many of the regions examined infected at 6-week post 
injection. AAV9-GFP and AAV2/1-GFP lost expression in all brain regions at 6-weeks 
post-ICV, whereas AAVDJ8-GFP expression decreased only in the cortex and 
hippocampus.  The reduction in AAV transgene expression is consistent with other 
studies utilizing CMV-promoter based AAVs(McCown et al., 1996; RL Klein et al., 1998). 
Explanations for the observed loss of AAV transgene expression over time could be 
attributed to cell turnover within the given regions or that CMV promoters are prone to 
transcriptional inactivation by DNA methylation during viral latency (Royo et al., 2008). It 
was also reported that AAV transgene expression and persistence is improved when 
utilizing an endogenously expressed promoter-neuron-specific enolase (NSE)-containing 
construct compared to a CMV-containing construct (RL Klein et al., 1998).  
AAV2/1 had very minimal penetrance to the ventral midbrain area at both time 
points. AAVDJ8 was persistent in expression and AAV9 decreased from ~15 to ~6 
GFP+/image field in the SNpc. In support of our findings, previous studies reported ~46% 
of neurons in the SN were transduced with AAV9-hSyn-GFP at 6 weeks post ICV(McLean 
et al., 2014). Correspondingly, we quantitated ~45% TH+ neurons and ~22% S100β+ 
astrocytes/per field with AAV9 (Figure 6D,H). Also, AAV9 transduced more TH+ neurons 
than AAVDJ8, whereas AAVDJ8 transduced more astrocytes (Fig 6G). Co-localization 
(GFP +TH or S100B) and intensity values of GFP signal were also measured. As 
expected, AAVDJ8 had significantly higher GFP signal in both cell types due to the 
construct containing CAG promoter and eGFP, but Pearson’s colocalization coefficients 
were not significantly different between serotypes, indicating higher GFP signal did not 
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interfere with quantitative analysis (Supplemental Fig 2A). Based on morphological co-
localization studies, we noted a lack of co-localization of GFP with IBA1+ cells using any 
serotype (see Supplementary Figure 6A-B). This is consistent with other reports using 
these AAV vectors, which identified oligodendrocytes as an additional cell type 
transduced by these vectors rather than microglia (Lawlor et al., 2009; Chakrabarty et al., 
2013; Aschauer, Kreuz, and Rumpel, 2013a). Although the levels of AAV infectivity in the 
SNpc by ICV delivery were not as robust compared to the alternative SN stereotaxic 
injection method, there was evident penetration with AAV9 and AAVDJ8 within this region 
of the brain that suggests these two serotypes would be suitable for targeting specific 
cells of the SNpc via ICV administration (Fig 6H).  
Neuroinflammatory mechanisms that cause dopaminergic neuronal loss during PD 
progression are heavily mediated by astrocyte activation (De Miranda et al., 2014). Here, 
we report AAVDJ8 to be a stable serotype to transduce astrocytes of the SNpc by ICV at 
6 weeks (Fig. 6G-H). By use of enhanced CLARITY microscopy, AAVDJ8-eGFP 
expression can be visualized in brain tissue at ~2 times greater z-dimensions primarily in 
GFAP+ astrocytes in a 3D-volumetric view of the SN (Fig 6E, Supplemental Video 1). 
To further limit AAV transgene to astrocytes, we tested the use of truncated 681 bp 
human-gfap (gfaABC1D) promoter in AAVDJ8-GFAP-mCherry constructs by ICV delivery 
(Fig. 7A). The gfaABC1D promoter was previously designed to have two-fold greater 
activity than full-length (2.2kb) promoter and with much smaller size, ideal for the limited 
cloning capacity in AAV vectors(Y Lee et al., 2008). The full-length human-gfap was 
previously validated to transduce astrocytes with AAV2/1 striatal neonatal injections and 
selectivity of the 1.74 kb GFAP promoter has been tested with combined serotype 
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AAV2/5/7/8/9 by cortical injection.  More specifically, gfaABC1D promoter has been used 
with AAV9 via intramuscular delivery (Jonquieres et al., 2013; Meng et al., 2015; Vagner 
et al., 2016).  The data presented here are the first report that AAVDJ8-GFAP-mCherry 
efficiently and selectively expresses in cultured astrocytes and in the SNpc following 
neonatal ICV delivery in mice (Fig 7B, 7D). In culture, longer DIV incubation time and 
higher titer was required for robust mCherry expression, most likely because the GFAP 
promoter is weaker than CAG/CMV in culture. However, in vivo we noticed similar 
distribution patterns of AAVDJ8-GFAP-mCherry compared to AAVDJ8-eGFP in sagittal 
plane views (Fig. 7C, Fig 2G). There was also comparable number of mCherry+ 
cells/image field at 3-6 weeks to GFP+ cells/image field in the SN. AAVDJ8-eGFP had 
slightly higher number of transduced cells in this region at 6 weeks due to observed 
neurons transduced with this vector and no identified TH+/mCherry+ cells with AAVDJ8-
GFAP-mCherry (Fig 6D-G, Fig 7D-F). To fully visualize exclusive astrocyte-specific 
targeting of AAVDJ8-GFAP-mCherry we also conducted CLARITY immunofluorescent 
imaging, this time at ~4.5 times greater z-stack thickness than normal tissue samples for 
a better view of AAV penetrance within the SN (Fig 7F, Supplemental Video 2). Serotype 
differences in vivo were partially attributed to the ability to penetrate into the parenchymal 
space by ICV administration method, however there were differences in brain regions and 
cell specific transduction patterns compared to in vitro results. For example, AAV2/1 had 
the highest transduction efficiency in vitro, but did not virally express as well compared to 
AAV9/AAVDJ8 in the SNpc or was as stable in other regions compared to AAVDJ8 at 6-
weeks. The observed differences of serotype transduction efficacies in vitro compared to 
in vivo are a common issue when determining ideal serotypes for specific brain regions 
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and further supports the rationale to proceed past an initial in vitro assessment if the viral 
models are intended to be used in vivo(Hemphill et al., 2014). Lastly, with selection of the 
appropriate combination of serotype and promoter, targeting specific cell types within the 
SNpc can be accomplished for transgene expression for studies of biological mechanism 
or disease intervention.  
5.5 FUTURE DIRECTIONS AND PRELIMINARY DATA  
The previous data set described optimization of AAV serotype transductions into 
neurons and astrocytes. We therefore were interested in using the identified serotype for 
optimal astrocyte transduction (AAVDJ8-GFAP) to overexpress a transgene that would 
counter-regulate NFkB proinflammatory gene expression and potentially protect DA 
neurons from degeneration in mouse model of PD. Based on our previous results 
described in chapters 2-4, we decided to overexpress the coding sequence of Nurr1, 
specifically in astrocytes of the SN. The vector design for this approach used the 
previously validated backbone AAVDJ8-hGFAP-mCherry with a 2A-peptide linker 
sequence. During translation the 2A-peptide linker allows for a ribosomal skip after the 
last amino acid of the C-terminus end and release of the first fused protein, GFAP-
mCherry, along with most of the 2A peptide (~18 amino acids). The ribosome then 
translates the rest of the open reading frame (ORF), including 1 amino acid fused to the 
N-terminus (NTD) of the second downstream protein, Nurr1. In contrast to IRES 
sequences, the 2A-linker allows for an equimolecular proportion of both proteins, so 
mCherry fluorescent expression should directly correlate to Nurr1 transgene expression 
(de Felipe, 2004; Heinonen et al., 2014). The directionality of this ORF considered the 
location of Nurr1s’ proposed ligand binding domain located at the C-terminus, so mCherry 
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was placed upstream of the 2A-linker to carry the fused ~18 amino acids at the NTD (Fig 
8A).  
 We tested the newly designed AAV-Nurr1 in primary astrocyte cultures (method 
previously described earlier in this chapter). After a week of transduction, we collected 
mRNA and performed qPCR on Nurr1. AAV-Nurr1 induced Nurr1 mRNA ~1000 fold 
higher than AAV-mCherry empty control (Fig. 8B) (N=4/group; ***P < 0.001). Additionally, 
to visualize Nurr1 protein expression, we performed IF with anti-mCherry (red) and anti-
Nurr1 (green) after 1-week of transduction. The AAV-Nurr1 cultures noticeably expressed 
Nurr1 in the nucleus compared to less in AAV-empty (representation of 3 individual 
experiments) (Fig 8C). However, one issue that persisted was the lack of native mCherry 
expression with AAV-Nurr1 (data not shown). This required using anti-mCherry to 
visualize AAV transduced astrocytes and is a potential concern for future studies. 
 A pilot in vivo test was also performed to confirm AAV-Nurr1 efficacy in protecting 
DA neurons from MPTP-induced neurotoxicity. To specifically target the SN in adult mice, 
we tested stereotaxic injections using known coordinates (Oh et al., 2015). As depicted 
in Figure 9A we specifically targeted the left hemisphere with either AAV-Nurr1 or AAV-
mCherry empty control. After 5 days of recovery, the adult mice were challenged with an 
MPTP dosing regimen as previously described in chapter 2 with the absence of 
probenecid treatment (Fig 9B). Brain tissue was then collected for stereological 
assessment of TH+ neurons in both treatment groups. Figure 9C depicts localization of 
AAV-mCherry (red) in the left hemisphere surrounding TH+ neurons (blue). The SN was 
quantitated for total TH+ neurons using similar methods previously described in chapter 
2. Based on the preliminary results, there appears to be a neuroprotective trend with AAV-
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Nurr1 over AAV-mcherry empty control (Fig 9D). However, these data are only an N=2 
and require a larger cohort of mice to fully validate statistical power of this finding.  
In summary, these studies are ongoing and require additional experimentation to 
confirm efficacy of AAV-Nurr1 to slow neurodegeneration in mouse models of PD. 
Additionally, we are in the process of testing another vector without the inclusion of a T2A 
skipping sequence, due to the lack of native mCherry signal that is expressed in the vector 
described in Figure 8A. This will create a fusion protein of mCherry-Nurr1, which is 
currently being tested in vivo. Overall, using AAV technology to overexpress a desirable 
gene candidate could be a promising approach to controlling neuroinflammation regulated 







Fig 5.6.1 AAV2/1 is most efficient in primary neuron and astrocyte cultures. Primary 
neuron and astrocyte cultures transduced with multiple AAV serotypes for comparison by 
immunofluorescent analysis with astrocyte marker, GFAP (red; left) and neuronal marker 
MAP2 (red; right), GFP (green) and DAPI (cyan).  Representative images of virally 
transduced GFP reporter are depicted in 20X objective images of (A-B) AAV1, (C-D) 
AAV2/1, (E-F) AAVDJ, (G-H) AAVDJ8, (I-J) AAV8, (K-L) AAV9, (M-N) and AAVDJ9. 
Percent of GFP+ astrocytes (O) and (P) neurons were quantitated by co-localization with 
specific cell marker. (Q) Live cell fluorescence was measured in primary neuronal cultures 
by native GFP detection each day for 7 DIV (n=3-7/serotype; fixed astrocytes, n=6-
10/serotype; fixed neurons, n=6/serotype; live cell; representation of three separate 




Fig 5.6.2 Intracerebroventricular injection of multiple AAV serotypes in neonatal P0 
mice. (A) P0 neonatal mice were injected directly into the lateral ventricles for widespread 
viral solution as illustrated in cartoon schematic. (B) Mock injection of trypan blue/PBS 
solution was used to test successful target location at 2/5 from bregma suture and eye 
landmark. (C) Black arrows identify injection sites on dissected whole brain and (D) lateral 
ventricles (LV), 3rd ventricle (3V) and 4th ventricle (4V) on gross incised sagittal brain. (E) 
Plasmid AAV (pAAV) vector maps identify specific promoter/reporter elements of selected 
serotypes AAV2/1, AAVDJ8 and AAV9. Lateral plane view pseudo-colored whole brain 
native GFP fluorescence of (top), medial view of 10X objective montage images for 
sagittal cross sections (bottom) and rostral-caudal coronal cross sections (right) of (F) 
AAV2/1, (G) AAVDJ8, and (H) AAV9 injected brains at 3-weeks post injection 
(pseuodocoloring scale of fluorescence: white=highest, black=lowest; all images are 
representation of 3-4 animals/serotype).  
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Fig 5.6.3 Tropism of AAV2/1 in multiple brain regions at 3 and 6 weeks post 
injection. AAV2/1 6-week injected tissue of multiple brain regions were immunostained 
for total neuronal marker MAP2 (red), astrocyte marker S100β (purple) and GFP (green) 
as depicted in representative 10X montage (top) and 100X high magnification images 
(bottom) of the olfactory bulb (A), striatum (B), motor cortex (C), hippocampus (D) and 
cerebellum (E). Notice; red/green co-localize to yellow, green/purple co-localize to cyan. 
(F) Each region was quantitated for GFP+/per 20X objective image field at 3 and 6-weeks 





Fig 5.6.4 Tropism of AAVDJ8 in multiple brain regions at 3 and 6 weeks post 
injection. AAVDJ8 6-week injected tissue of multiple brain regions were immunostained 
for total neuronal marker MAP2 (red), astrocyte marker S100β (purple) and GFP (green) 
as depicted in representative 10X montage (top) and 100X high magnification images 
(bottom) of the olfactory bulb (A), striatum (B), motor cortex (C), hippocampus (D) and 
cerebellum (E). Notice; red/green co-localize to yellow, green/purple co-localize to cyan. 
(F) Each region was quantitated for GFP+/per 20X objective image field at 3 and 6-weeks 




Fig 5.6.5 Tropism of AAV9 in multiple brain regions at 3 and 6 weeks post injection. 
AAV9 6-week injected tissue of multiple brain regions were immunostained for total 
neuronal marker MAP2 (red), astrocyte marker S100β (purple) and GFP (green) as 
depicted in representative 10X montage (top) and 100X high magnification images 
(bottom) of the olfactory bulb (A), striatum (B), motor cortex (C), hippocampus (D) and 
cerebellum (E). Notice; red/green co-localize to yellow, green/purple co-localize to cyan. 
(F) Each region was quantitated for GFP+/per 20X objective image field at 3 and 6-weeks 




Fig 5.6.6 AAV9 and AAVDJ8 transduce DA neurons and astrocytes of the 
substantia nigra 10X objective representative images of SN from 6-week tissue 
immunostained for TH (cyan) to visualize viral GFP expression (native) in the SN pars 
compacta (white outline) and SN pars reticulata for AAV2/1 (A), AAVDJ8 (B), and AAV9 
(C) injected brains. (D) Total GFP+ cells/ 20X objective image field were quantitated for 
both 3 and 6-weeks post injection within the SN region (n=3/serotype; *p<0.05). (E) AAV9 
and (F) AAVDJ8 100X objective representative images immunostained for TH and S100β 
(red) within the SNpc. at 6-weeks post ICV. (G) % S100β-GFP+ and TH-GFP+ cells in the 
SNpc were quantitated/per 40X objective image field (n=3/serotype; p<0.05). (H) 
Representative, three dimensional (3D) 40X objective montage image of clarified SN 
tissue from a AAVDJ8–GFP infected brain, immunostained for TH (cyan), GFAP (red) 
and GFP (green) in XYZ and XZ volumetric planes. Video of 3D projection can be found 




Figure 5.6.7 AAVDJ8-GFAP-mCherry targets exclusively astrocytes in the 
Substantia Nigra. (A) Astrocyte-specific promoter, GFAP, was incorporated into suitable 
serotype AAVDJ8 to drive expression of fluorescent reporter, mCherry for targeting 
astrocytes, as depicted in plasmid AAV vector map. (B) Primary astrocyte cultures were 
transduced with AAVDJ8-GFAP-mCherry to confirm astrocyte transduction efficiency in 
vitro as depicted in representative 100X objective images of immunostaining for 
mCherry(red) and GFAP(green), 83.2%±6.5 GFAP+/mCherry+ quantitated . (C) mCherry 
(red) and S100β(green) immunofluorescence is visualized in 10X objective montage 
image of sagittal cross section from AAVDJ8-GFAP-mCherry 3-week infected brain. (D) 
AAVDJ8-GFAP-mCherry expression in 10X objective image of SN region immunostained 
for mCherry (red), S100β(green), and TH (cyan) from 3 week infected brain, 100X 
objective inset images represent colocalization of S100β+/mCherry+ cells. (E) AAVDJ8-
GFAP-mCherry expression levels were quantitated for mCherry+cells/20X objective 
image field at 3 and 6 weeks post ICV (n=3/serotype, groups were not significant). (F) 3D 
volumetric view in XYZ and XY planes for CLARITY immunofluorescent image stained 
for TH (cyan), GFAP (green) and mCherry (red) within the SNpc. AAVDJ8-GFAP-
mCherry infected astrocytes are exclusiveling co-localizing with GFAP+ cells within the 




Figure 5.6.8 AAVDJ8-hGFAP-mCherry-T2A-Nurr1 vector design and transduction 
test in vitro (A) Using AAVDJ8-GFAP to transduce astrocytes we incorporated a 
ribosomal skipping T2A sequence downstream of mCherry reporter for a 1:1 ratio of 
reporter and coding sequence of the murine Nurr1 gene. (B) By qPCR analysis we 
detected ~1000 fold increase of Nurr1 mRNA expression in primary astrocytes cultures 
transduced with AAV-Nurr1 compared to AAV-mCherry empty control (N=4/group; ***P < 
0.001). (C) IF images of anti-mCherry (red) and anti-Nurr1 (green) expression in AAV-






Figure 5.6.9. AAV-hGFAP-mCherry-T2A-Nurr1 injection test in vivo and challenge 
with MPTP (A) For adult stereotaxic injections, the left hemisphere was targeted for AAV 
administration into SN as depicted in coordinate map. (B) After stx. Injections mice were 
allowed to recover for 5 days following MPTP administration as depicted in treatment 
schematic. (C) 10x-objection montage image of injected shows anti-mCherry (red) 
expressed in vicinity of TH+ neurons (blue) of left hemisphere. (C) Preliminary 
stereological DA cell counts depict a neuroprotective trend with AAV-Nurr1 compared to 











Since current PD treatments only ameliorate symptoms, a new approach to halt 
irreversible damage to neurons is necessary for patient improvement. Many PD studies 
solely focus on function of the neuron during disease progression and perhaps limits 
discovery for treatment. As described in the dissertation, non-neuronal cells, astrocytes 
and microglia mediate a highly complex network of cellular communication, that should 
not be ignored. This process of communication by glia cells, known as neuroinflammation, 
can result in neurodegeneration, irrespective to the preceding state of the neuron. Thus, 
the studies described in Chapter 2-5, reflect cell-specific strategies for PD treatment by 
modifying only the astrocyte with a transgenic mouse model (Chapter 2), modifying solely 
the neuron in vitro (Chapter 3), targeting all cells in vivo (Chapter 4) or specifically 
targeting the astrocyte with a viral vector (Chapter 5). For a summation of each strategy, 
the following will detail each in reference to corresponding figures. 
Chapter 2 described a novel astrocyte-specific NF-kB knock-out mouse that 
revealed a highly neuroprotective mechanism which improved the neurological and 
pathological outcome of animals treated with both MPTPp and MnCl2 (Figure 1). 
Inhibition of NF-kB in astrocytes resulted in decreased reactivity of both glial cell types 
and astrocyte expression of complement protein C3, demonstrating suppression of a 
crucial innate immune response pathway. This resulted in a 92% protection of DA 
neurons against toxicity and apoptosis. The experimental approach in Figure 1. for 
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neuroinflammatory intervention is interesting, yet only demonstrative in a transgenic 
mouse model, not a translatable approach for PD. Additionally, concerns exist because 
keratinocytes also express GFAP which resulted in an off-target lesioning effect that 
occurred in ~30% of the KO animals, previously described by Kirkley et al 2017 as 
squamous cell carcinoma (Kirkley et al 2017). Therefore, another approach is necessary 
for solely modifying cells of the CNS which can be easily administered to humans. 
The second strategy for disease modification was detailed in chapters 3 and 4. 
Using the small molecular compound, C-DIM12, we demonstrated activation of the 
molecular target, Nurr1 to protect DA neurons in vitro and in vivo. Figure 2. depicts C-
DIM12 targeting all cells in the CNS that express Nurr1. In vivo, we showed that during 
co-current lesioning with MPTP, oral administration of C-DIM12 suppressed gliosis by 
counter-regulating NF-kB. Additionally, the effects of C-DIM12 in neurons can induce 
Nurr1 regulated DA’ergic genes, TH, VMAT2 and DAT. These effects on multiple cell 
types resulted in ~64% protection of DA neurons. Although, as previously mentioned, the 
expression of NF-kB in neurons has been proven beneficial for proper neuronal 
development and synaptogenesis (red text; Figure 2). This raises concern if synaptic 
health is compromised by counter-regulating neuronal NF-kB which remains to be tested 
in future studies.  
 Lastly, the final strategy for modulating neuroinflammation during the progression 
of PD could be a viral-mediated gene therapeutic approach. As described in chapter 5, 
AAVs have powerful capacity to deliver transgenes to both neurons and astrocytes. The 
future directions section of this chapter also discussed preliminary data using a 
recombinant AAV to overexpress Nurr1 specifically into astrocytes of the SN. As depicted 
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in Figure 3, the ongoing studies show that Nurr1 expression is increased in astrocytes 
and NF-kB activity is suppressed (data not shown). However, whether full suppression of 
glial activation and protection of DA neurons from degeneration with AAV-Nurr1 is still not 
known. Astrocyte-specific inhibition of NF-kB in the transgenic mouse model (Figure 1) 
provided more neuroprotection than the global suppression of NF-kB with C-DIM12 
(Figure 2). Potentially, a combinatorial effect with Nurr1 activating drugs, such as C-
DIM12, and AAV-Nurr1 could convey enhanced neuroprotection to DA neurons, rather 
than one monotherapy.  
In summation, the many intricacies that cause DA neuronal loss impel the 
tantalizing difficulties in experimental drug discovery. As neurodegeneration requires 
synergism from multiple causing factors as well as multiple cell types and pathways. 
Combinatorial effects of several drugs may be necessary to alleviate all possible 
contributors to PD pathology. Thus, the more innovative approaches we have for disease 
modification, the closer we will be to overcoming this debilitating disorder.  
  
 132 





Figure 6.1.1 Astrocyte-specific modulation with transgenic mouse model (detailed 
in chapter 2). 
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Figure 6.1.3 Astrocyte-specific modulation with AAV-Nurr1 (detailed in chapter 5; 
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